Sitemap
Genmab strikes deal with German biotech companyNovo Ventures invests millions in Bavarian Nordic rival UCPH spin-out to develop the future's obesity medicine with Novo NordiskBavarian and other RSV companies navigating uncharted territoryDanish company prepares to take the psoriasis market by storm – seeks FDA approvalNovo Nordisk develops new mechanical insulin pill with star researchers from MITBavarian will use own money to start RSV trials, but is still seeking a partnerMIT researcher behind mechanical insulin pills prepared for new Novo partnershipsAmerican senators behind over-the-counter hearing aid law demand answers from the FDA: When will the sales guidelines be ready?Leo Pharma looks towards billion-dollar market after phase III successSale of hearing aids in the US exceeds 4 million devices for the first timeEnochian Biosciences has a market cap of $238 million, but researchers doubt the company: "There is no scientific documentation to base their claim on"New CEO backs Leo Pharma's transformation: "It is definitely the right strategy"Leo gambles on partner’s skin cancer drug even though option agreement is not yet settledLeo Pharma boss on newly purchased drug: "It is a very cleverly designed antibody"Biogen hopes for breakthrough at Danish Medicines Council after new price drop: "We have taken significant action"EU advocates general says Lundbeck's DKK 700 million fine is justifiedLeo Pharma makes new push for older treatment with brand new trial conceptBiogen shocked by Danish medicines council doubt over SpinrazaNovo Nordisk bets on innovative insulin: "Many doctors said we were crazy"MC2 prepares for US launch by the end of the yearLeo Pharma wants to be first in US with hand eczema treatmentOwner foundation to sell Leo Pharma stakeLeo Pharma to cut up to 650 positionsLeo Pharma poised to market new drug every 2-3 yearsLeo Pharma poised to post DKK billion figure into San Francisco drug: "We're waiting for the trial results"Novo Nordisk to suppliers: Switch to green transport or lose us as a customerFDA plans new sales channel for hearing aids in autumnColoplast CEO: "It's important for me we don't turn into a company, where it only works if we invented it"ALK launches tablet vaccine for tree pollen allergy The life science industry has a sexism problem – and no one knows the scaleColoplast executive: We've had sexism cases, and they've been handled with zero toleranceEli Lilly executive on crucial tirzepatide data: "It is a very exciting time"Eli Lilly prepares obesity efforts with future hope – goes down same path as Novo NordiskNovo Nordisk unsure about chance of reaching upper growth target: "This would require significant changes"Hungarian factory initiative brings Coloplast one step closer to sustainability goalsColoplast CEO on expectations: "There are many swing factors"Novo Nordisk acquires collaborative partner for USD 1.8bnALK CEO after upgrade: "In spite of Covid-19, ALK is on a roll – I'm really proud"Researchers behind Alzheimer's study: GLP-1 drugs show great promisePandemic kicked off ALK's digitization processStartup aims for tailwind after Alzheimer's study involving Novo drugVaccine researcher lays head on the block: "If Pfizer's Covid-19 vaccine works, so will ours"Covid-19 creates uncertainty for Zealand Pharma drug against short bowel syndromeALK gains millions from webshop – may reach the size of the firm's core marketBavarian on lacking coronavirus vaccine funding: Sponsors prioritize speed over qualityIrishwoman takes over EMA Executive Director positionAmbu ready for price war on market for single-use devicesDanish-Swedish diabetes company goes on the stock exchange in 2021GN Hearing lost ground at US VA – and so did DemantFormer Widex CEO on chairman prospects: I can deliver in every areaNovo Nordisk cuts 450 positions in the USMajor medtech supplier teams up with Copenhagen-based startupUS senators behind over-the-counter hearing aid sales legislation: Get started on sales guidelines!Moderna reveals price of coronavirus vaccineNovo Nordisk and Biomarin make peace in strife over employees and confidentialityHearing aid giants position themselves within US sales channel using new productsPhilips has grown stronger from the pandemic: This has been an organizational stress testGalecto fetches former CEO from Aimmune for board Genmab ditches drug candidateBiogen taps Danish biotech firm for collaboration on novel Lupus treatmentEU plans for better access to low-cost generics and biosimilars in new pharmaceutical strategySonova-owned hearing company plummets on top and bottom lines – survives at the mercy of ownerNovo breathes life into Alzheimer's speculations after executive huntDemant launches new flagship productColoplast CEO: I can calmly declare that the best times are ahead of usIncyte expands in Scandinavia and plans to more than double its employeesNovo Nordisk loses court case against Sanofi over Danish press statementDanish Business Authority's decision causes Lundbeck to downgrade guidanceExperiences from Covid-19 will create success for Demant's virtual product launchJanssen turns to Danish startup for pill to replace the need to inject drugsGenmab: Janssen applies for approval for lung cancer drug in the USOrphazyme opens US headquarters in Chicago and appoints executivesNew CEO gets rid of a number of Ambu executivesNovo Nordisk submits obesity drug for FDA approvalMillion-dollar investment leads AGC Biologics to start new staff hunt – needs up to 300 new employeesNovo Nordisk completes acquisition of Emisphere TechnologiesNovo Nordisk withdraws press statement – had misleading marketingEli Lilly candidate shows weight loss at 11 percent in phase III trialFormer Novo Nordisk employee plans to revolutionize market for insulin pensCoronavirus vaccines are lucrative businessSonova receives FDA approval for new technologyInvestcorp buys Danish Sanos GroupDemant turns up outlook after better-than-expected salesNovo after crucial data from competitor: Welcomes drug R&DAmbu CEO: "We need an innovative speed that's hard to compete with"Orphazyme board on CEO changes: She had an old-fashioned management styleMedia: Europe aims for vaccine approval on Dec. 23Zealand Pharma disappoints with diabetes drug in phase IIIAmbu lands new single-use endoscope contract with US GPONovo Nordisk to start phase III trial with tablet for Alzheimer'sNovo Nordisk files for EU approval for obesity treatmentNovo Holdings and CEO Kutay on the hunt for billion kroner investmentY-mabs closes deals in China and Europe for the firm's two drugs against pediatric cancerNovo Nordisk places stakes on Alzheimer's treatment: hunts for success on the pharmaceutical industry's boulevard of broken dreamsBavarian Nordic secures second part of smallpox vaccine order from the USDrugmakers agree to halve prices to secure access to ChinaThe Lundbeck Foundation's new strategy: CEO wants to buy more firms like Lundbeck, ALK and FalckHemophilia firm from former Novo employee secures millions from Novo SeedsBavarian Nordic defies new failure and maintains efforts in cancer areaBiotech stocks ready for more Covid-19 results in first quarterSanofi is battle-ready: "We welcome competition, not least from our great colleagues at Leo Pharma"EU to help vaccine manufacturers expand productionNovo Nordisk applies for label extension for diabetes treatmentAscendis submits FDA application to start cancer trialEU to help vaccine manufacturers expand productionBavarian Nordic will supply smallpox vaccines to three European countriesGenmab initiates phase III trial with drug against cervical cancerNovo Nordisk selects first drug candidate in Dicerna collaborationPfizer readies to compete against Ascendis and Novo Nordisk: Submits weekly growth hormone to FDAWidex family secures power over WS AudiologyEli Lilly skyrockets following positive Alzheimer's dataCalm Novo Nordisk following Brexit: We had five years to prepare"After finding out half a million tests were far from enough, we had to work out how to produce five million"WSA puts new man in charge of US brandNovo CEO Lars Fruergaard Jørgensen hopes for Eli Lilly's future successColoplast CEO urged to take action: Release the billions!Novo ceases payments to US politiciansAfter decades Novo Nordisk approaches historic milestone for obesity marketLeo Pharma goes head to head with Janssen in new psoriasis trialUS hospital sales of Novo Nordisk's hemophilia drug dropped in DecemberEuropean Medicines Agency: Leaked documents have been manipulatedNovo Nordisk seeks extended approval for diabetes drug in the USGermany to start registering single-use scopes – Ambu to take advantageAmbu surpasses Q1 expectations and hits significant milestoneAmbu to raise USD 212m in new capitalAmbu will use pandemic to kick in door to new marketsWS Audiology books new billion-kroner deficit – lost EUR 243m during virus yearExpert committee recommends new Novo Nordisk growth hormone for EU approvalWS Audiology loses USD 600m across two years – still withholds net profit guidanceGN Hearing introduces new product family in lowest price rangeBavarian Nordic is ready to produce Covid-19 vaccines for other companiesFrance says Europe vaccine strategy safer than U.K.’sColoplast surpasses guidance and sets out to launch share buyback programEU chief says she was responsible for gaffe over vaccine exportsMads Krogsgaard Thomsen resigns from Novo NordiskNovo Nordisk expects 5-9 percent sales growth in 2021Vaccine disputes may harm pharmaceutical industry's reputationNovo Nordisk CEO: Strategy remains constant after Krogsgaard's departureColoplast CEO on buying spree: "Something has to happen"Novo Nordisk's CFO expects US growth boost this yearLundbeck beats forecasts considerably in Q4Lundbeck plans for carbon neutrality by 2050EU poised to beat cancerLundbeck on new climate plan: aims for carbon neutrality long before 2050Ambu expands US contracts with single-use endoscopesNovo Nordisk kicks off phase III trial program for new insulin hope EU cancer plan applaudedLundbeck: acquisitions must be well consideredSanofi's eczema drug is four-time blockbusterSanofi's diabetes business affected by Q4 falling prices and Covid-19EU president recognizes responsibility and failures in vaccine purchaseNovo Nordisk CEO: Semaglutide could create serious obesity treatment market Demant report looks to future following two horrifying fiscal yearsPost-pandemic healthcare trends will turn, says SEB's new biotech portfolio lead Coloplast considers increasing tax payment transparency after criticismALK has decent growth forecast in sightDemant plans to grow 23-27 percent after two awful yearsDemant to boost transparency on differing business developmentsDemant forecasts better 2021 than pre-corona and hacker attackAnalyst: Demant's guidance reflects improved market conditionsEli Lilly CFO leaves after "exhibiting poor judgment"ALK winds up with Q4 deficit despite record-breaking revenueLundbeck gets top marks for engaging suppliers in climate effortsDemant CEO's wages barely changed in Covid-stricken yearFood allergy venture to boost ALK's growthPharmaceutical company makes commitments to EU antitrust chiefGenmab and Seagen submit cancer drug application to US FDAGN Hearing expects 2021 comeback after tough yearPoliticians want their hands on pharmaceutical companies' vaccine patentsLundbeck CEO's pay cut in half in 2020In spite of Covid-19 lock-downs and sent-home employees, GN have held on to R&D effortsTeva plans to take over major chunk of migraine marketEMA clarifies: No Russian application for vaccine approvalGN Hearing got DKK 103m in state support in 2020 – and laid off a few employeesALK invested DKK 1bn in US breakthrough: "It didn't pan out the way we'd hoped"Retail stakes proved costly for Demant during first coronavirus lockdownOlympus' endoscope sales retreatAmbu CEO on stream of launches: "Won't be easy, but we're building an ecosystem"Analyst: Eli Lilly considers Alzheimer's submission after phase IIEMA starts rolling review of Curevac vaccine against Covid-19Danish PM is willing to finance vaccine productionBiotech firm raises USD 80m for pharmaceutically treating hearing lossNovo Nordisk increases transparency on tax paymentsLundbeck hunts for new success drugs in niche diseasesLundbeck's hopes have high costs: "You won't see us reaching that level in the future"Europe prepares a mutant Covid vaccine plan to fight the crisisAlmirall acquires rights to new psoriasis drug in EuropeOlympus looks into patient injuries from duodenoscopesMillions of vaccines waiting in warehousesEMA starts safety-related review of obesity drugNovo Nordisk CEO on his legacy: What I spend most of my time onEli Lilly's Tirzepatide shows reductions in blood sugar levels and weightAnalyst: New Eli Lilly drug doesn't throw Novo Nordisk's Ozempic curveballGenmab-developed sclerosis treatment beats competition in small injector pen studyLeo Pharma finds new head of UK and Ireland marketsExperts: Mandatory release of patents highly unlikelyFerring divests testosterone drug in new dealRoche to embrace new technologies early onCochlear states that its momentum has improvedGlobal antimicrobial fund expands with USD 140m and CEOUS biotech to submit new psoriasis treatment to the FDA in summerFlourishing trade activity in life science industryGenerics companies get green light for Lundbeck drugAlmirall predicts positive 2021 development of psoriasis productAnalyst emphasizes 2021 guidance in Genmab fiscal reportGenmab appoints chief medical officerNovo Holdings buys Canadian life science companyFormer utility boss nominated for new Novo Nordisk board memberWSA gets Google Country Director for boardAlmirall closes gap in product portfolio through commercialization agreement with MC2Commentator views former Ørsted CEO as potential Novo Nordisk chairmanGenmab to take at least one new product to phase III in 2021Genmab CEO: Arbitration might be concluded in 2021Novo's dark forecasts have been disproved: "We're stronger in the US than we've been in many years"MC2 Therapeutics aims to lead psoriasis marketEU leaders want to secure vaccine productionFormer FDA top dog joins board of Parkinson's firmGenmab's CEO pulls in DKK 37.3m salary – has shares worth DKK 1.6bnNovo Nordisk plans to invest DKK 500m in expanding tablet production facilitiesGenmab CEO: Three products may turn into five this yearHorizon Therapeutics to make blockbuster out of Genmab drug in 2021Coloplast CEO: Digital Denmark has proven worth during Covid-19Astrazeneca's CEO and colleagues grilled at EU HearingNovo Nordisk Pharmatech lands record profits in 2020 Biomarin awaits crucial approvals and flat growth in 2021Novo Nordisk appoints new head of drug discoveryTop news from MedWatch this weekOrphazyme recruits new CEONovo Nordisk Pharmatech to open new sales office in USFinance analyst: Novo's sales from obesity drugs may grow earlier than anticipatedPfizer may present new growth hormone in 2022Boehringer Ingelheim inks third collab in four years with Danish biotech companyBoard on new Orphazyme CEO: He has the management style we wantOrphazyme: Anticipated product approval to secure transformational yearGenmab and Lundbeck implement sustainability goals in executive incentive programsFraudsters offer EU vaccinesFinancial analyst raises share price target for Lundbeck due to Rexulti potential Orphazyme CFO: 2021 will be the decisive yearDanish PM open towards the idea of establishing vaccine factoryAmbassador views Teva CEO as important player in potential vaccine allianceNovo Nordisk lines up for May Alzheimer's trialGlobal investment firm KKR buys Danish biotech firm share for USD 100mFujifilm starts expanding Danish production facilityDenmark and Israel have discussed vaccine collab for almost a yearThe EMA starts rolling review of Russian vaccineEli Lilly surpasses Novo's golden diabetes drugAnalyst: Lilly doesn't overshadow semaglutide in spite of strong dataNovo Nordisk chair foresees pressure on pharmaceutical industryDenmark, Israel and Austria to look into the possibility of a joint vaccine productionNovo Nordisk chairman on top wages: "It's a hard balance to strike"EU Commission initiates formal investigation of TevaTop news from MedWatch this weekBavarian Nordic presents new preclinical data for Covid-19 vaccineFinance analyst: Eli Lilly deals hard blow to Novo Nordisk with new dataNovo Nordisk chairman: We must make heaps of strong leaders for ourselves – and for other companiesAnalyst views clinical results as central to Bavarian Nordic's external financingBavarian Nordic still hopes to find financing for Covid-19 vaccineBavarian eases up on categorical statements on Covid-19 vaccine financingDanish government hesitant to rein in EU health response even though industry calls for itBiomarin's previously rejected hemophilia drug gets special status at the FDANovo Nordisk hires former Director General of DMABavarian Nordic sells discount shares to help fund Covid-19 vaccineFund chief to kickstart fundamental changes in antibiotics marketGN gave off shares to Demant in VA sales channelNovo Nordisk tests grand acquisition in phase III trialUK denies EU allegation that vaccine exports have been bannedBavarian Nordic on new capital raising round: Covid-19 was the decisive factorMedia: EU is major vaccine exporter in spite of supply problemsDenmark suspends Astrazeneca vaccinationsWS Audiology balances out male-dominated top management with new coworkerZealand Pharma CEO before possible approval: We can take major leapAscendis powers ahead on capital spendingNovo Nordisk chairman on lacking diversity: "I haven't done enough"Lundbeck wants Merck EVP as board memberTop news from MedWatch this weekBavarian Nordic's 2021 will be full of developmentEMA starts rolling review for Eli Lilly's Covid-19 treatmentNovo Nordisk EVP: "When you're the little brother you're still part of the family. This is important to remember"Cochlear gets US clearance for new implant – first to have streaming for both Android and IphoneThe Novo Nordisk Foundation discusses Danish vaccine production with governmentNovo Nordisk has three biopharma blockbusters on the wayMore attacks on Lundbeck's big sellerFollowing recalls and delays, Novo Nordisk kicks off smart insulin pen launchJefferies valuates Bavarian Nordic's Covid-19 projectGalecto ditches high doses in phase II trialNovo Nordisk Foundation chair warns against new state-funded vaccine productionLundbeck poaches CSO from US biotech firmEMA: We're firmly convinced of the benefits of the Astrazeneca vaccineGlooko raises just under DKK 190m in financing round with Novo Nordisk as major investorNovo Holdings appoints new head of responsible investmentsBioporto CEO holds Covid-19 test at arm's length: "Could be everything or nothing"Former Novo employee alleges sexual harassment, discrimination: success meant flirting with bossNew Lundbeck exec to get firm's next research leg startedGN chair sees divisional collaborations as advantageNovo Nordisk and Gilead expand partnership Vaccines seen protecting against Brazil strain in Oxford studyNovo Holdings beats records in 2020 and earns DKK 29bnMoment of truth for Coloplast's US ventureNovo increases fatty liver efforts: "We've seen some highly convincing data"EU and US to zoom in on pharmaceutical industry mergersTop news from MedWatch this weekCanada orders more smallpox vaccines from Bavarian NordicCovid-19 created many attractive opportunities for Novo Holdings in 2020Leo Pharma struggles with lawsuit in the USVaccines hope takes Bavarian Nordic's share price to more than 300 DKKZealand Pharma gets approval for low blood sugar treatmentFDA refuses to file Novo Nordisk applicationNordic Capital posts millions of euros in Leo Pharma – gets owner's share at under 25 percentLeo Pharma elaborates on 2030 strategy after new capital injectionZealand Pharma sends rescue pen on the market in late JuneLeo Pharma failed on the top line yet succeeded on profit in 2020On 24 occasions employees warned Lundbeck management of foul playLeo Pharma's board now has one person lessTrust in Astrazeneca vaccine is dropping in EuropeEU vaccine rules may disrupt global supply, including to alliesCompetition authority interferes with Takeda's deal with Danish OrifarmEU Court of Justice turns down Lundbeck appeal – fine still standsNovo Holdings has worked large Convatec investment for four years: "Things don't happen overnight"Lundbeck disappointed over verdict – fine paid in 2013Danish bank: Lost appeal case paves way for new compensation claims against LundbeckVirtual Novo Nordisk AGM: Headed for 2025 goal, but pandemic caused fragile public financial situationBavarian Nordic's CBO quitsEU chief: Astrazeneca must adhere to EU contract to exportNovo Nordisk Pharmatech finds new CEO – choice falls on board memberTop news from MedWatch this weekCHMP recommends Novo Nordisk's Saxenda for adolescentsOrphazyme fails trial in muscle wasting disease Democrats want insulin producers investigatedTrial with Danish coronavirus therapy is prioritized in the UKColoplast gets crucial US deal for ostomy productAnalyst on US Coloplast contract: Important contract – volumes will probably increaseOrphazyme CFO on failed trial: "Highly disappointing and highly surprising"Novartis gets approval for Genmab drug against multiple sclerosis in EuropeNew Pharmatech CEO expects larger external sales – but this won't weaken relationship with Novo NordiskCEO after US contract: "For the first time ever, Coloplast has equal access to the market"Orphazyme share recovers somewhat after diveGenmab chief on sclerosis drug launch: Novartis prioritizes usFDA approves new larger production setup for Genmab drugOrifarm got Covid-19 discount on Takeda purchases: "The timing was in our favor"GN intensifies goal: Plans to have at least 25 percent female leaders by 2025Astrazeneca fully understands Danish vaccine pause: "It's about maintaining trust in the vaccines"When the world shut down, Roche went all-in and carried on its research programsOne in two Danes would opt out of Astrazeneca vaccineFDA investigates infection rates for endoscope use – Olympus and Karl Storz recur in reportsBavarian receives USD 28m order from JanssenHearing aid CEO predicts big rebound after virus year and massive costs shutting down subsidiaryAnalyst: Ebola order has positive signal value for Bavarian's investorsDanish Covid-19 therapy shows promise in phase I trialM&A advisors: "We've never seen such investor interest in this service before"Genmab drug becomes more accessible in the USHearing aid company fetches million dollar figure in capital raising roundEMA sticks to the recommendation of Astrazeneca's covid-vaccineNovo Nordisk tests own mobile app in phase III trial with insulin hopeLundbeck drug hope moves closer to moment of truthDanish Health Authority awaits Danish study results before giving verdict on AstrazenecaEli Lilly has to wait a while longer for FDA verdictKesimpta's complicated developmental path has shaped Genmab's approach to partnershipsZealand Pharma will soon launch first drugNovo puts million-dollar figure towards television commercialsFrance wants to mix vaccines – Denmark considers the sameTop news from MedWatch this weekFDA grants new Genmab drug priority review status New Orphazyme CEO has great ambitions: Wants to create new GenmabAuthorities are closely monitoring blood clot cases following vaccinesAnalyst: Genmab's progress with the FDA sends a positive signalGN lost market shares from veterans in March – againNovo Ventures company plans to fetch USD 127.5m on the US stock exchangeLundbeck carries on Rexulti study after new analysisOrphazyme investor following muscle wasting disappointment: "Now everything has to run smoothly in 2021"Analyst: Genmab share price may doubleLundbeck executive remains confident about Alzheimer's drug after new analysisBoehringer Ingelheim and partner launches stage II trials for NASH and obesityPension fund criticizes Genmab salary packagesGN Hearing maintains guidance – still predicts 25 percent growth for 2021Danish authorities: Astrazeneca vaccine to be discontinued in DenmarkInvestors demand tax transparency from GN Store NordGenmab CEO on possible settlement in dispute with Janssen: "I have no comment"Astrazeneca on vaccine skepticism: "Many forget it's a non-profit project"Here is why the Danish Health Authority stopped using the Astrazaneca vaccineWHO: Denmark considers sharing Astrazeneca vaccine with developing countriesGilead scores new FDA approval for drug obtained in billion-dollar purchaseWS Audiology is the no. 1 applicant for patents within hearing aid industryDanish government makes vaccine production a priority in new life science strategyMorgan Stanley: 12 new product launches will pave the way for AmbuEU likely to decline new vaccine deals with Astrazeneca and J&JTop news from MedWatch this weekHealth organizations see danger in Denmark’s decision to stop using Astrazeneca vaccineRoche publishes new sclerosis data to keep Novartis at bay ALK gains important approval on difficult US marketSydbank: Expanded ALK approval is good newsDenmark discusses vaccine swap with other countriesWS Audiology plans to list subsidiaryJanssen receives new approval for Darzalex in CanadaAlnylam is at the new frontier of medicines: "It will have the same impact on the industry as antibodies"Janssen had better Darzalex sales than expected in Q1EU politicians plan to focus on Europe's obesity problemVerathon gets European approval for single-use productRoche reports slightly better sales than predicted in Q1FDA requires more data from Y-mabsAnalyst: Listed subsidiary may pave the way for WSA and take chunk out of massive debtNovo Nordisk initiates trial with obesity-treating tabletNovo Nordisk wants obesity tablet to have same effect as injectionEU prepares to file lawsuit against AstrazenecaLundbeck drug shows significantly improved functioning in major depressive disorderFDA postpones plan for new hearing aid sales channel – againAnalysts lose confidence in Biogen Alzheimer's approvalEU Commission denies report on Astrazeneca lawsuitCHMP recommends Leo Pharma's tralokinumab for approval in atopic dermatitisLeo Pharma executive on EU progress: This is a huge milestone for usEU won't take up option to buy more Astrazeneca vaccinesUS authorities investigate new death following J&J vaccinationTop news from MedWatch this weekCHMP recommends eight medicines for approvalGN Hearing kicks off trial with self-fitting hearing aidEU expects new portal for clinical trials will be ready in early 2022Sanofi hits bullseye in phase III trial of treatment for RSVEU initiates lawsuit against Astrazeneca for breach of contractMSD sets carbon neutrality goalLundbeck eyes major breakthrough for brain diseasesÖssur advances in all areas after Covid-19-affected yearEli Lilly lowers guidance for 2021Bavarian Nordic may start producing covid-19 vaccines next yearNovartis chief sees remote-work hybrid persisting after pandemicY-mabs files for EU approval for pediatric cancer drugSanofi's diabetes business shrinks againSanofi's Dupixent sales grow 45 percent in Q1Boston Scientific had better results in Q1 than predictedEli Lilly on tirzepatide data: Surpasses our expectationsPfizer buys Amplyx Pharmaceuticals from LundbeckfondenBavarian Nordic on vaccine candidate: Preclinical data indicates broad protectionCancer firm Adcendo raises EUR 51mDanish government will allow gradual vaccine production in DenmarkTop news from MedWatch this weekFDA issues complete response letter to Leo Pharma's tralokinumab Pfizer and Biontech request to expand authorization for vaccine for adolescentsLundbeck backs Trintellix with new dataBiomarin gets ready for launch in second half-year of 2021Olympus launches line of single-use scopesAnalyst predicts that covid-19 will still affect DemantAnalyst: Novo Nordisk's year may start with zero growthDemant raises financial guidance for 2021New top product and Philips range have won market shares for DemantWSA ready to launch new Signia product platformAnalysts to home in on expenses in Genmab's Wednesday fiscal reportFrench reforms and US vaccinations benefit Demant in corona-struck timesALK's Q1 better than predicted on top and bottom lineNovo Nordisk beats expectations – upgrades outlookAGC Biologics will produce chronic gout treatment for Horizon TherapeuticsChinese authorities have approved Novo Nordisk's OzempicNovo Nordisk CEO on disappointing Rybelsus sales: Influenced by lockdownALK powers ahead on crucial market following new regulations for prescribing medicineDifficult conditions in the UK and postponed operations expected to affect Q2 for ColoplastGN Hearing's top line took a dive in Q1 – firm maintains 2021 guidanceGenmab spent more than DKK 1 billion in Q1Novo Nordisk expands obesity business in spite of obstaclesWSA raises guidance in first-ever public H1 reportColoplast raises EBIT margin guidanceGN flagship product gets off to a bad start with war veterans: "It is an unfortunate cocktail"Genmab is going through a growth spurt and expands on three continentsLeo Pharma's board chair steps down US exercises option for Bavarian Nordic smallpox vaccineWSA feels a change in the wind: Sees benefits of transparency after 65 yearsGenmab CEO on legal fight with Janssen: Standing up straight and fighting for what's morally and ethically rightEU splits on vaccine patent waivers to cast doubt on US planOrphazyme CEO disappointed with failed ALS trial – pins hope on other disease areaTop news from MedWatch this weekOlympus targets carbon neutrality by 2030Novo Nordisk recalls medicine samples following Texas power outagesEU countries are in no hurry to waive vaccine patentsLundbeck: Pandemic and currency woes have led to setbacksCovid-19 costs Coloplast USD 33m in extended court casesSwiss hearing aid giant makes EUR 200m acquisition – poised for new US sales channelLundbeck loses top-line terrain but surpasses expectationsAlmirall starts the year with solid growthEU readies new lawsuit against Astrazeneca over vaccinesGN executive does not envy sister firm's booming successAnalyst believes in continued progress for AmbuLundbeck bets on four core products during hard yearAmbu gets US approval for new productAmbu fails to live up to revenue forecastsElectronics firm presents long-awaited hearing solutionAnalyst on new Bose hearing aid: "Won't disrupt Danish manufacturers"Tough competition forces innovation at AmbuZealand Pharma CEO: "A very busy time for us"Stock market unease causes listing of WSA subsidiary to be postponedNovo Nordisk's semaglutide shows improved mental and physical wellbeing as obesity treatmentALK awaits crucial adrenaline data in 2021 and plans to submit FDA application in less than three yearsSix companies show interest in vaccine production in DenmarkTop news from MedWatch this weekLife science executives: We can feel the lack of traveling salespeoplePrivate equity firm Gilde eyes growing potential in ScandinaviaNovo Nordisk working on new digital solution for treating patients with insulinAstellas enters into strategic collaboration with Kyoto UniversityWSA wants Widex products back in US sales channelWSA exec quits – internal candidate takes overNovo drug ziltivekimab meets primary endpoint in inflammatory biomarker trialSonova affected by fluctuating currencies in 2020/2021Leo Pharma starts phase III hand eczema trialALK expands digital venture with US partnershipSwiss hearing aid giant comes out on top after covid-19 crisisNovo Holdings takes the lead in investment in new Asian companyXellia pays steep price for factory delaysTeva CEO on decimated share price: "It's rational enough from a market point of view"Swiss take steps to guarantee supplies of EU medical productsUS health authority reprimands large pharmaceutical firms after disagreement on drug discountsNovo Nordisk looks into repurposing millions of used insulin pensBiomarin presents new five-year data for hemophilia gene therapyEli Lilly plans to submit tirzepatide application at the end of the yearLundbeck to push transport sector in greener directionAnalyst: New study confirms that Eli Lilly's tirzepatide is a good productY-mabs enters into partnership with Uruguayan firm to launch cancer drugs in South AmericaNovo Holdings co-leads Swiss funding roundBiotech firm gets Chinese patent on plant substance cocktail for diabetes, obesity and fatty liver preventionGoogle app will help detect skin ailmentsAudientes builds up momentum and prepares for Q3 launchNovo Nordisk to issue Euro medium term notes worth up to EUR 5bnColoplast starts new colostomy leakage trialTop news from MedWatch this weekEMA gives positive opinion on Genmab's Darzalex in combination treatmentGenmab partner gets approval for lung cancer drug from Duobody platformNovo Nordisk prepares to launch diabetes tablet in IndiaColoplast recalls urology productEli Lilly sues HHS in strife over discounted drugsBoston Scientific gets CE marking for single-use bronchoscopeNovo Nordisk launches smart insulin pen in DenmarkGlobal tax agreement could prompt Novo Nordisk to take tax payments elsewhereNovo Holdings contributes to USD 540m investment in US health platformIO Biotech puts down roots in USA and hires new CSOEU demands Astrazeneca court order to supply vaccine dosesNew regulation means stricter requirements for medtech firmsBavarian Nordic maintains guidance for 2021Pentax obtains EU approval for single-use scopeDarzalex performs well in Janssen's rare disease studyBavarian Nordic partners up with Dynavax on hepatitis B vaccineNew sales agreement is another piece of Bavarian Nordic's commercial puzzleNovo Holdings completes third investment in Asia in one monthNovo Nordisk successfully prices Euro medium term notes worth EUR 1.3bnNovo Nordisk risks insulin shock on Chinese marketTravel restrictions bite Bavarian as rabies vaccine sales plungeCarb-X investment gives Snipr Biome validation before going to clinicTop news from MedWatch this weekAscendis increases expenses shortly before moment of truthNovo Nordisk resubmits higher-dosage Ozempic application to the FDALundbeck CEO Deborah Dunsire wants to prioritize mental health in the wake of covid-19FDA approves migraine pill as preventative treatment Nordic politicians encouraged to place antibiotic resistance higher on the agenda316 European residents experienced blood clots following hotly debated vaccineNovo Nordisk enters collaboration with Heartseed on cell-based treatmentMicrobiome venture can start production in Denmark and SwitzerlandStallergenes gets European approval for dust mite allergy tabletAnalysts: Stallergenes' approval may expand the market for allergy tabletsPentax forms Chinese partnership for single-use scopesNew partnership may pave the way for first Novo Nordisk stem cell treatmentFDA approval of semaglutide could help Novo Nordisk access unexploited obesity marketEU deal forces large firms to share tax informationNovo Holdings and Healthcap launch new biotech firmAnother Genmab drug from Janssen receives breakthrough therapy designationGN and Demant lose VA market shares againBoehringer Ingelheim and Zealand Pharma's Nash candidate fast tracked by FDAGenmab to collaborate with Californian biotech company on three drugsOrphazyme's hour of reckoning approaches: "Its existence is threatened if it gets a clear no"Bavarian Nordic hunts for best covid-19 vaccine production setup – may drop current manufacturerAnalyst: Pentax partnership might lead Ambu to new marketGN launches Jabra hearing aid at CostcoLack of news leaves Lundbeck high and dryGN CEO: Jabra's strong brand is perfect for CostcoEU’s trade response to pandemic stops short of vaccine IP waiverDenmark sends 358,000 surplus vaccines to KenyaDrugmakers in China take aim at pharma’s lucrative cancer fightersAudientes CEO: We have the perfect product for the future OTC channelG7 ministers: Global tax agreement in sightTop news from MedWatch this weekFDA approves Novo Nordisk's semaglutide as obesity treatmentNovo Nordisk EVP: Semaglutide can double obesity business in few yearsDemant and GN ramp up investments – with money to spareWHO gives further support to Bavarian Nordic and Johnson & Johnson's Ebola vaccineLaunch of obesity drug will be Novo Nordisk's fastest everFate of Biogen’s stock rides on Alzheimer’s drug decisionObesity drug has no competitors on unexploited market, says Novo NordiskBiogen passes FDA test for Alzheimer's medicineWS Audiology joins Science Based Targets initiativeBiogen's US Alzheimer's drug may also come to EuropeFDA heavily criticized by independent institute over Biogen approvalThree global giants consider vaccine production in DenmarkNovo Nordisk enters into collaboration with Danish crispr firm SniprBogus drugs and medical equipment abound in EuropePfizer gives Danish PM cold shoulder: rejects idea of starting vaccine production in DenmarkDementia professor on new Biogen approval: The first small step towards new developmentsHearing company enters into first partnership in big venture in IndiaDanish companies: A minimum tax rate has advantagesBiogen to start shipping new Alzheimer's drug in two weeksTeva and Eli Lilly scrap over migraine drug rightsWHO: Europe is far from safe from covid-19Biontech plans to produce mRNA vaccines in AfricaNewly established firm puts down roots in DenmarkFDA advisors quit after approval of Alzheimer's medicineAnalyst calls Orphazyme's 300 percent value jump "strange and noteworthy"Orphazyme CEO on trading explosion: "We have no idea what is going on"Top news from MedWatch this weekEquity trader on Orphazyme surprise: "It's a bit like Gamestop all over again"Bavarian Nordic to supply UK with monkeypox vaccinesFDA extends review period for Ascendis Pharma's first drugOrphazyme launches investigation into dramatic and mysterious share price roller coasterIncyte's atopical dermatitis cream delayedOlympus gets new Regional Managing Director for the NordicsJanssen publicizes more Darzalex data Novo Holdings acquires diagnostics company for USD 564mNovo Holdings plans to enter ChinaFDA agrees to meeting with Enochian over HIV therapySage Therapeutics depression drug disappointsDemant won major market shares at VA in MayFormer Emisphere investors sue following sale to Novo NordiskAnalyst: Demant's Oticon More generates strong VA figuresEMA to be beefed up for future crisesLarge shareholder sells some Orphazyme shares shortly before vital FDA ruling, general partner denies connectionNovo Nordisk enters into research collaboration with Lumen BioscienceOlympus hires former Ambu CEOSonova gains two new board membersBiogen partner calls for global Alzheimer's effortOlympus on former Ambu CEO's advisory role: "He will be a big asset"Novo Holdings hot on diagnostics: This is the key to unlocking two of the largest healthcare issuesUtility Therapeutics prepares FDA applicationBavarian Nordic: Vaccine production almost came to DenmarkMore disappointment for Orphazyme as FDA rejects Niemann Pick C applicationOrphazyme cuts guidance following FDA setbackTop Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"EMA hesitates over flunking Curevac vaccine despite missed targetUS OTC hearing aid channel back on Department of Health agendaOrphazyme CEO silent on potential firings in wake of FDA rejectionTop news from MedWatch this weekNovo Nordisk CEO's pay sets itself apart on especially one pointEU and Astrazeneca each declare lawsuit victoryOrphazyme not seeking fresh capital despite reduced cash position FDA approves new Ambu productSeries of setbacks have not caused Orphazyme CEO to consider departingColoplast sees potential in RussiaBavarian Nordic CEO frustrated with lack of reply on financial support for vaccine candidateLeo Pharma's new drug for atopic dermatitis receives EU approvalRoche's digital health venture boosted by pandemicNovo Nordisk expands collaboration with US app companyFinancial analyst: Novo Nordisk's obesity treatment could triple marketEMA continues to review link between myocarditis and coronavirus vaccinationLeo Pharma starts study of eczema tablet for nettle rashJanssen gets expanded authorization for Genmab's Darzalex in EUBiogen criticized in the US over price of new Alzheimer's drugLeo Pharma receives UK approval for AdtralzaGoldman Sachs reduces share in Orphazyme and drops below 5 percent boundaryUS dermatology top boss moves to Danish biotech firmY-mabs delayed again in the USAmgen gets Japanese authorization for migraine drugNovo Holdings sees golden opportunity in dialysis company, contributes to USD 245m investmentOticon Medical gets FDA approval for cochlear implantLilly gets sought-after FDA designation for Alzheimer's candidateZealand Pharma sends blood sugar drug to US marketStallergenes Greer production back to full capacity after years of limited activityOticon president satisfied with FDA approval: "A huge milestone"Pharmacosmos launches cell therapy market offensiveAustralian firm acquires Denmark's largest cannabis companyECDC wants to bring forward second jab to tame variantCHMP recommends eight new drugs for approval – one cancer drug rejectedTop news from MedWatch this weekOrphazyme to get rid of two thirds of employeesFDA recommends single-use bronchoscopesSanofi reveals detailed timeframe for RSV candidateAmbu gets recommendation from FDA, analyst doubts effectOticon Medical General Manager after US FDA approval: It's a competitive situationNovo Nordisk wants to innovate in new ways to find curesVifor Pharma gets new CEOTwo main factors behind Sanofi's dialog with Danish authoritiesSanofi to establish mRNA vaccine center with 400 employees AGC Biologics contacted minister over Danish vaccine collaboration before PM announcementEli Lilly welcomes competition for cheap insulin in USNovo Nordisk's analog insulin will be sold cheaply in WalmartNovo Nordisk sticks to cautious obesity sales goalWSA raises ESG ambitionsZealand Pharma President of US Operations on first launch: Timing was our most important goal Novo Nordisk closes deal on technology platformFerring appoints Lars Rebien Sørensen as new chairmanEQT and owner family divest Fertin Pharma to Philip Morris International for DKK 5.1bnLeo Pharma appoints former Novo Nordisk CFO as new chairman of the boardEMA second-in-command retires after 25 years at the organizationAmbu downgrades due to covid-19 and logistical challengesNew chairman to prepare Leo Pharma for IPO with new launches and financial disciplineConflicts of interest have kept Lars Rebien Sørensen away from pharmaceutical boards – until now130 countries enter into tax reform agreementTop news from MedWatch this weekNew Coloplast Senior Vice President: MDR will guide our innovation focus in the futureBank bemused by Ambu downgradeOrphazyme investors snatched up profits before FDA failureAmbu brings plans for Mexico factory forwardBioNTech/Pfizer vaccine is less effective against Delta variantLeo Pharma to collaborate with US biotech companyLundbeck hands over former Alzheimer's candidate to privately-owned biotech companyMC2 and Almirall clear crucial obstacle to psoriasis treatment in EuropeAlmirall opens submissions for new dermatology partnershipsBoehringer and Eli Lilly meet primary endpoints in heart failure treatment studiesAmplifon expands Chinese presence in new joint ventureNovo Nordisk Pharmatech closes distribution agreement for Russia and CIS countriesAscendis moves forward with phase III drugNovo Holdings invests huge sums in the USAlmirall partner MC2 on the verge of EU victory after ten years of hard workNovo Nordisk veteran takes up CMO position at Danish-Swedish biotech companySales of Biohaven's migraine tablet exceed expectationsSanofi pays up to USD 1bn for new multiple myeloma therapyBrazilian success: SynAct Pharma scores positive results with therapy for covid-19WSA buys US retail chainFDA changes prescribing information for new Alzheimer's drugBiden starts new offensive to bring down medicine prices New Biden order criticizing hearing aid expense causes falling share pricesTop news from MedWatch this weekAnalyst: Biden attack on pharmaceutical industry seems symbolicEMA currently sees no need for Covid booster jabPharma giants see huge potential in new "super technology" for fighting a wide range of diseasesNovo Nordisk buys treatment candidate for rare disease for up to USD 1.2bnUS sees global tax agreement as beneficial for allAmplifon buys Bay Audio for DKK 2.6bnJanssen gets FDA approval for new Darzalex combination Experts: The world needs more than just mRNA vaccinesHearing industry challenger applauds Biden's price battleResearchers trick malaria parasites with new vaccineNovo Nordisk, Sanofi and Eli Lilly face court in US over insulin pricesDane overcomes Tokyo culture shock to run Lundbeck's most successful launchEli Lilly acquires biotech firm in new insulin ventureBillionaire Moderna founder and world's most cited engineer sees "pretty unlimited" potential in mRNAGenmab surpasses 1,000 employeesPharmacosmos' revenue grows by USD 16m despite corona challengesCovid vaccine makers target bottlenecks to speed up productionEli Lilly allies itself with Alzheimer's institute in phase III dementia drug trialsGN Hearing shrinks again and Denmant's growth proves short-lived on VA channelWith launches on the way in the US and EU, MC2 turns attention to the rest of its pipelineSales of Novo Nordisk's Victoza drop in USTop news from MedWatch this weekEli Lilly and Incyte's eczema treatment delayed at FDA – againPharmacosmos predicts record financial year after launches in US and ChinaPfizer executive: "It is hugely important that the world prepares itself for potential future pandemics"MC2 Therapeutics launches psoriasis cream in USSaniona borrows USD 10m for clinical studiesNovo Nordisk bets on RNA in several business areasDenmark's largest companies report huge expansions to legal departmentsEMA starts continual assessment of Sanofi's corona vaccineLeo Pharma brings in old friends and new blood for eczema treatment launchSclerosis drug developed by Genmab brings in USD 66m to Novartis during Q2Darzalex sales exceed expectations in second quarterAnalyst: Genmab may upgrade financial guidance based on Darzalex sales figuresHemab raises USD 55m for treatment of rare bleeding disordersÖssur key market sales normalize during second quarterEMA pays respects after sudden death of Research and Innovation leaderBiogen upgrades financial guidance after exceeding expectations in Q2Over half of all adults in the EU are now fully vaccinated against covid-19Lundbeck to trial migraine drug in young peopleRoche's hemophilia treatment well on the way to triple blockbuster status Top news from MedWatch this weekCHMP recommends two new drugs for approval and rejects oneCHMP recommends Moderna covid-19 vaccine for approval in 12-17-year-oldsSweden phases out AstraZeneca's covid-19 vaccineAllarity keeps streamlining pipeline – sells cancer drug for USD 18mFDA gives Saniona candidate priority statusPfizer and Biontech expand study of vaccines for childrenNordic Capital in talks to buy healthtech firm InovalonBiontech plans to examine mRNA technology for malaria vaccinesBoston Scientific reports significant growth in endoscopy business – grows 54 percentAstrazeneca shot shows no increased clot risk after two dosesGN Hearing top exec stops after 17 years – replacement found within own ranksPharma industry is discretely working against a global tax agreementPfizer upgrades guidance for sales of covid-19 vaccineInvestors: Novo Nordisk's obesity efforts will lead to growthSanofi upgrades 2021 guidance after sales of Dupixent and diabetes products increaseFDA makes historic ruling on biosimilar insulinSmith & Nephew revenue better than expected, but operating result disappointsBiomarin prepares for European approval of Ascendis competitorAmplifon doubles Q2 sales and upgrades 2021 guidance Takeda surpasses analyst forecasts in Q1Danish State Serum Institute launches world's largest investigation of late effects from covid-19ALK closes largest deal in 10 years – gets DKK 90m for partnership in China on adrenaline autoinjectorNovo Nordisk's Wegovy sells like hot cakes in the US – increases productionPfizer and Moderna raise prices for coronavirus vaccinesDanish scientists raise alarm after discovering link between Bayer drug and brain cancerPfizer launches phase III trial with RSV candidate in SeptemberAnders Dyhr Toft waves goodbye to Novo Nordisk after 18 years to become the CMO of Synact: "It's going to be more DIY-based"Eli Lilly specifies guidance for this year's revenueEU approves upscaling of Moderna vaccine in US production facilitiesLead-up to Novo Nordisk report: Growth-heavy quarter with GLP-1 focus aheadMedia: Pfizer's covid-19 vaccine will soon get full approval in the USDenmark has shipped half a million vaccines to Ukraine Novo Nordisk upgrades guidance for the rest of the yearBank analyst on Novo Nordisk report: Impressive quarter, to say the leastNovo Nordisk's new obesity drug hits 8,000-prescription mark in few weeks: Comparing with Saxenda, it took around four yearsOlympus upgrades guidance following better-than-expected reportALK nominates former Sanofi executive for board membershipOrphazyme postpones financial reportNovo Nordisk plans to test cholesterol-lowering oral solution in phase II trialTop news from MedWatch this weekUS authority increases subsidies for single-use duodenoscopes – which benefits both Ambu and Boston ScientificMajor US bank shoots way above Novo Nordisk's own goals: New obesity drug will sell for almost USD 3.5bn in 2025.Lundbeck closes RNA deal worth USD 109m with US biotech firmAstellas shakes structure of R&D division Bavarian Nordic: Covid-19 vaccine beats Pfizer's on several parameters Bavarian Nordic CEO notes progress in vaccine funding talks with Danish government ALK upgrades guidance following convincing sales and savingsJefferies fears renewed pressure on Novo Nordisk's growthLundbeck breathes life into stranded molecule to treat new diseasesAnalyst predicts progress in Demant's H1ALK increases sales in Q2, but operating result decreasesGN Hearing and Demant lose market shares in VAAnalysts predict possible 2021 guidance upgrade from DemantFDA approves single-use bronchoscope from Boston ScientificPostponed clinical trials affect ALK finances – central phase III trials have been delayedDemant closes Q2 ahead of guidance, upgrades both revenue and earnings Genmab's successful CEO dismisses retirement plans Genmab: Janssen dispute cost DKK 146m in H1Boehringer Ingelheim and Gubra send obesity drug candidate to clinical trial Demant CEO: Ketchup effect could lead to above-average growth in 2022 and 2023Demant benefits from French reform more than projectedALK acquires drug against swimmer's ear from now former US partnerBiogen's Alzheimer's drug denied support by Veteran Affairs Bose expands to whole US with new direct-to-consumer hearing aidZealand Pharma CEO: Zegalogue launch continues as planned Genmab considers vaccine requirement for staff Novo Nordisk plugs hemorrhage with lucrative Biopharm unit restored to growthEli Lilly scores positive phase III results with new eczema treatmentAmbu overture: Weakened demand and bottlenecks burden quarter Ambu's Q3 ended better than expectedAnalyst forecasts YoY quarterly growth for Coloplast following virus year Ambu joins green climate initiative Lundbeck report could trigger upgrade despite headwindCovid-19 pins geographic needles in Ambu's core business – CEO hopes for stabilization aheadAmbu launches new duodenoscope in four weeksLundbeck upgrades annual earnings guidance, cuts revenue outlook Capacity problems accelerated Ambu's construction of world's largest endoscope plant Eli Lilly in big reshuffle: Sets up new units for neuroscience and immunology New trial shows top-selling Lundbeck drug not beating placebo for borderline Coloplast notes advance for all four units, adjusts annual guidance Covid-stricken US still causing Lundbeck problemsGN Hearing disappoints despite high Q2 growth – maintains annual guidance Coloplast seeks more US catheter acquisitions: "We want increased coverage" Eli Lilly's diabetes drug approved to treat heart failure Lundbeck partner soon to seek approval for new Abilify Maintena version Unvaccinated staff not welcome at Novo Nordisk's US HQ New GN device to open giant market for mild hearing loss Novo Nordisk expects to cover demand for obesity drug in 2022Coloplast drops prior skepticism, agrees to divulge national tax informationGN Hearing eyes opportunities for new product in coming US sales channelLundbeck CEO on most controversial drug approval in recent memory: Will bring new innovationXellia's delayed factory now up and running Bavarian Nordic initiates phase II trial for Covid-19 vaccine Coloplast sets climate goals for executive bonus programColoplast CEO struggling to find good acquisition candidateEU approves Danish plan to put EUR 108m behind Bavarian Nordic's Covid-19 vaccineBavarian Nordic CEO sees massive sales potential for Covid-19 vaccine after securing state aidAGC Biologics breaks ground on USD 190m Danish factoryDelayed Danish state Covid vaccine to be trialled on humans in 2022Danish Medicines Council rejects Johnson & Johnson's psoriasis medicine: "Worse than existing standard treatment"Medtronic reports good start to fiscal yearBavarian Nordic releases more specific guidance - downgrades expectationsWS Audiology revenue and operating result increase significantlyWS Audiology continues to prioritize Signia on Veterans Affairs channelVertex spends billions on CRISPR technology in search of diabetes cureWS Audiology: Quarterly reports will improve transparencyFDA approves Ascendis' weekly growth hormoneNovo Nordisk after US delivery issues: New obesity drug launch set for H2 next year Bavarian Nordic: State gains from vaccine support capped by contractLundbeck introduces vaccine requirement for US staff Ascendis aiming to become market leaderWS Audiology reports massive growth in Europe compared to pre-pandemic levelsNew factory takes AGC Danmark to another level within the corporationAscendis ready for new hires after FDA approvalTop news from MedWatch this weekNew study provides good results for Eli Lilly and BoehringerSanofi gets positive results for eczema treatment – this time in young childrenSonion changes CEO for second time in two yearsSonion chair blames pandemic for CEO exitUK denies approval for Genmab's Darzalex comboPfizer goes head to head with Sanofi's multi-blockbuster with new study dataOrphazyme expects to lay off 100 employees this yearLeo Pharma swims against US tide by allowing unvaccinated staffOrphazyme may face class action suit from US investorsNo room for more mistakes at LundbeckBavarian Nordic reports promising results for RSV vaccine in phase II trialBavarian Nordic: RSV efforts could be "key to the promised land"Ascendis Pharma aims for USD 400m from share issueMost US employers say vaccine mandates are possible by end of yearPentax rejects Ambu's claims of head startLundbeck starts new study of tablet version of drugInvestment bank: Bavarian Nordic's RSV data reduces risk associated with important assetSobi co-founder thinks acquisition is likely after USD 8bn bid Pfizer begins phase III trial for vaccine against RSVBank skeptical about Novo Nordisk share price – requires USD 40bn a year in obesity drug salesZealand Pharma Chief Medical Officer sells shares worth USD 650,000Analysts upgrade share price targets for Bavarian after run of good newsTop news from MedWatch this weekAstrazeneca and EU settle missing vaccines caseDespite recent successes, Bavarian remains second-most shorted stock on Nasdaq CopenhagenDemant on the hunt for employees: "Even high-level people are on the phone"WS Audiology brings in VP of accounting and head of communicationsDanish government cancels vaccine production tenderBiogen takes second royalties victory in blow for Forward PharmaFujifilm's factory in Denmark generates USD 430m revenueDanish government wants to spend USD 160m on permanent research and development tax deductionEMA begins assessment of Pfizer booster application Ambu leadership under scrutiny for communication styleColoplast opens new factory in Costa RicaAscendis ready with clinical trial of another cancer drug Investors worry about Lundbeck's future, analysts remain optimisticHorizon begins phase four clinical trial of Genmab drugBavarian increases capital of USD 8.9m from selling sharesLundbeck to measure brain with microscopic camera in new partnershipColoplast axed traditional budgeting process: "It wasn't promoting growth"Sanofi's big dermatology hope fails in phase IIIAnalyst thinks RSV vaccine market could reach over USD 10bnEli Lilly and Boehringer Ingelheim's Jardiance against heart failure achieves breakthrough designation from FDANovo Nordisk's new VP of digital health to focus on internal and external innovationFormer Lundbeck CEO: Voicing public opinions isn't always prudentSwedish diabetes company raises USD 17.5m for phase III trialSanofi opines on Danish government's Bavarian contract: Single supplier would be a mistakeEli Lilly to raise millions for green initiatives Top news from MedWatch this weekDenmark sells 500,000 surplus vaccines to New ZealandNo needles in sight as Novo succeeds with new capsule technologyLundbeck CEO joins board of directors at Syros PharmaceuticalsABG hires equity analyst to cover hearing health and pharmaceutical companiesNovo Holdings sets sights on more acquisitions in hot bioindustry sectorSnipr Biome to collaborate with US cancer hospitalItalian hearing aid retailer disappoints with growth prognosisGalecto begins third phase II trialInvestment bank raises guidance for Novo Nordisk after "impressive" Wegovy launchY-mabs receives priority review status for cancer drug in ChinaOlympus survives malware attack without data lossEU to present plans for new emergency health authority on ThursdayItalian hearing aid retailer expects first OTC products in 2022Leo Pharma will not use acquisition option after candidate disappoints in phase III trialAmbu changes stance, mandates vaccines for US workers Sonova says surge of Delta cases in US hasn't affected hearing aid marketNovo Nordisk Foundation grants USD 46m to new genomics research center in BostonNovo Nordisk starts crucial trial of obesity tabletWS Audiology makes headway in green conversion of Singapore headquartersIO Biotech begins phase III trial with partner MSDNew data a boost for Johnson & Johnson and Bavarian Nordic's Ebola vaccineJefferies downgrades Genmab recommendation due to lack of short-term catalystsSnipr Biome and US cancer hospital target gut microbes in attempt to eradicate immune therapy side effectsSonova enters strategic alliance with French biotech company to treat hearing lossDemant CEO: It will take a long time to meet pent-up demandLundbeck Foundation buys stake in asset managerNew EU health authority to respond rapidly to future health threatsWS Audiology still chewing over listing of online hearing companyOticon: Covid-19 led to debates about product launchesEU Commission ends Danish HERA dreams – but could provide new opportunities for the pharmaceutical industryCEO at WSA: No clarity on EQT exit plans yetCHMP recommends nine new drugs, rejects oneNovo Holdings considers sale of Xellia PharmaceuticalsBayer collaborates with Gubra to unleash peptide potentialFDA pauses Swedish diabetes company's phase III trial plansGenmab presents "encouraging" data for cervical cancer candidateCEO at GN Hearing: Properly regulated OTC sales channel could make a differenceRoche brings new general manager to Denmark from Swiss headquartersDemant increases Veterans Affairs market share slightlyFDA gives accelerated approval to Genmab and Seagen's cervical cancer drugDanish Medicines Council refuses to approve wider usage of Biogen's muscle wasting disease treatment despite yet another price cutBritt Meelby Jensen was labeled "the biotech queen": "Unfortunately, I think it demonstrates how there are still few female top executives in Denmark"Pharmacosmos settles legal dispute with ViforAnalyst: New Genmab approval shows portfolio potential New Johnson & Johnson data show high booster shot effectivenessBank sees increasing likelihood of third Novo Nordisk upgradeEli Lilly strikes deal with EU over Covid-19 antibody treatmentAnalyst: GN should sell Hearing and bet on AudioSwedish diabetes company gets domestic green light to begin phase III trialNew Genmab/Seagen drug will cost up to USD 120,000Incyte gets green light for new eczema cream – and a warningNovo Nordisk prepares phase III trial of potential blockbuster drugAmbu gets EU approval for bronchoscopeGN rejects notion of selling Hearing division, againAmbu on EU bronchoscope approval: Makes us the most wide-ranging and dominant player on the marketEU Commision working on solution for IVDR bottlenecksNovo Nordisk turns up the heat on inlicensed Genmab drug with phase III preparationsNovo Nordisk Pharmatech makes first sales agreement in MexicoGE acquires BK Medical for USD 1.45bnSenators fear inadequate OTC regulation could harm hearing device usersNovo Nordisk creates new RNA and gene therapy unitFunding deal between Bavarian Nordic and Ministry of Health approved by Danish parliamentTop news from MedWatch this weekBK Medical will retain independence after GE acquisitionUS government threatens Novo Nordisk with fine for discount program violationsNovo Nordisk settles case of market manipulation, will pay USD 100mDemant expects medium to long-term revenue growth of 7-10 percentLundbeck hopes long-term Covid-19 effects will boost Trintellix EQT wants to stay in WS Audiology for "several years"FDA postpones decision for Pfizer's weekly growth hormone treatmentNovo Nordisk strikes deal with French Biocorp to develop add-on device for insulin penDemant joins green initiative, seeks to reduce emissions by 50 percent in 2030Union Therapeutics strikes million-dollar deal with Chinese partnerAnalyst: Chinese reforms will impact sales and earnings at Novo NordiskRoche: The US and Asia outsprint Europe in life science sectorNovo Nordisk has begun phase III trial with antibody Analyst: Eli Lilly price drop is a sign of competitive US insulin market Sanofi pivots toward boosters after Covid vaccine delaysEU countries to boost research with cautious transparencyEMA starts evaluation of Moderna's booster applicationEisai and Biogen begin application process for second Alzheimer's drugFDA approves Abbvie's preventative migraine tabletAmbu heir: "We're in it for the long haul, but I would be lying if I said I don't keep track of the share price. I check in daily"Leo Pharma expands digital trial partnership, hopes to reduce costs by 25 percentIqvia wins tender to provide laboratory system for Danish National Genome CenterEMA ramps up measures to reduce animal testingJanssen begins phase III trial of RSV vaccine for older patientsRoche dismisses Novo Nordisk as potential threat on lucrative hemophilia marketColoplast recalls urology productsEli Lilly presents positive data from tirzepatide sub-studiesLeo Pharma expects new FDA ruling for eczema treatment tralokinumab in early 2022Lundbeck wins patent case against six generic medicine producersDiagnostics giant cemented its leading role during the pandemicNovo Holdings silent on newly created company with million-dollar backingTop news from MedWatch this weekJanssen is foreign company of the year in DenmarkNovo Nordisk Foundation to boost pandemic preventionLeo Pharma expands its arsenal of arguments for Adtralza with new long-term dataEMA appoints new head of international affairsJanssen presents positive results from phase II RSV vaccine trialNobel Prize goes to US scientists for discoveries of temperature and touch receptorsInternational CEO praises Danish testing efforts for "thinking more strategically and long-term than other places"EMA approves Pfizer and Moderna Covid-19 booster shotsNovo Nordisk Foundation CEO surprised by mRNA Nobel Prize snubGN downgrades expectations for GN Hearing significantlyGN Hearing to transform activities with new head of research and developmentOrphazyme to discuss NPC rejection with FDA in mid-OctoberAnalyst surprised by GN downgrade: Significantly bigger than expectedOrphazyme no longer expects EMA decision this yearGN Hearing restructures after research and development letdownAmbu downgrades financial expectationsAmbu CEO predicts short-term shipping challenges for Core businessABG Analyst expects significant costs increase at ColoplastWHO adds Novo Nordisk insulin to essential medicine listsAnalyst on Ambu downgrade: Doesn't change investment caseWeight loss as new diabetes target could boost sales of Novo Nordisk's obesity drugAudientes gets off to a flying start with Indian preordersBoston Scientific acquires company for USD 1.75bnNew unit to bring Novo Nordisk closer to goal of using RNA and gene therapies across all treatment areasWHO recommends world's first malaria vaccine for childrenLundbeck shuts down in India Despite downgrades and stock decline, Ambu chair maintains trust in leadershipAmcham welcomes new chairwoman from Siemens HealthineersTakeda's new CEO in Denmark wants to hire more peopleNew biotech Roxiant to tackle age-related diseasesNovo Nordisk hires Queen Latifah for US marketing offensiveEllab acquires British lab companyAmbu wants electric car fleet by 2030Central EU committee makes case for faster EU drug approval processTop news from MedWatch this weekFour firms received USD 840m for running rapid Covid-19 tests in DenmarkGlobal corporate-tax overhaul advances as 136 nations sign onEU pharma strategy could allow for shorter drug patentsLundbeck silent on shutdown of Indian operationsRhovac hires investment bank to generate interest in lead candidateDanish Covid-19 treatment approved for human trialsCopenhagen Medical hires profile from Novo Nordisk FoundationLundbeck CEO expects foundation backing for large acquisitionsNovo Nordisk hopes to stabilize Wegovy supply in early 2022Life science investor adjusts organization to stay on top of its gameGlobal challenges ahead for Ambu's dreams of electric fleetFormer Shire CEO shakes up Galderma as IPO decision loomsRhovac is open to all sale and partnership opportunitiesChief scientific officer at Johnson & Johnson set to retire this yearNovo Nordisk to spend more on acquisitions and external innovationLundbeck CEO considers stepping up marketing of VyeptiEU Commission earmarks EUR 725m to secure critical production capacityStockholm wants to become leading life science regionLife science firms warm up before Tour de France starts in DenmarkWSA group CFO resigns – interim replacement appointedApple investigating Airpods as hearing health solutionAnalyst: Potential Apple product could target GN's market segmentBank predicts double blockbuster status for Novo obesity drug next yearDemant recalls cochlear implants – will cost up to EUR 13.4m in 2021, with more consequences for 2022 Lundbeck acquires phase I-ready candidate from South Korean firmEuropean health ministers welcome EU Commission's HERA Leo Pharma chairman: "In the long term, we will probably have fewer employees"Demant CEO on implant recall and sales halt: "This is very serious"New Lundbeck candidate to kick off R&D divisionFormer FDA head to make comeback under Biden, media reportsMedicon Valley chair says Swedish growth ambitions will improve Danish life scienceDenmark donates 250,000 Covid-19 vaccines to RwandaLundbeck's schizophrenia treatment for teenagers receives FDA priority review statusNovo Nordisk has picked second RNA drug candidate for USD 358m collaborationColoplast heir reaps record USD 780m profits on personal investmentsAscendis launches growth hormone Skytrofa in the US CHMP recommends six new drugsTop news from MedWatch this weekCHMP gives positive opinion on Genmab partner's lung cancer drugUnique ownership structure makes CFO position at WSA appealing and challengingBiogen stumbles in crucial ALS studyAustralian hearing aid firm starts clinical trial of affordable hearing product – will seek FDA approval in 2022French biotech firm surprises analysts with corona vaccine dataIO Biotech prepares for IPO in the USSonova acquisition to drag out into 2022Novartis subsidiary Sandoz's antibiotics efforts bear fruit during pandemicConde-Knape makes the future of pharmaceuticals possible at Novo NordiskSaniona clears obstacle ahead of new trialGenmab sales of Darzalex exceed expectations in Q3Vertex has initial success in new diabetes projectAnalyst: Darzalex sales figures could result in Genmab upgradeAnalysts say Darzalex sales prognosis could be too cautiousFDA proposes regulation for OTC hearing aids after string of delaysAnalyst on FDA proposal: Ball is in hearing aid industry's courtRoche soars in Q3, carried by Covid-19 test demandDiabetes company brings European phase III trial forward as US troubles continueBiogen Q3 results better than expected, updrades guidanceHearing aid manufacturers unconcerned about potential OTC disruptionsBiogen to apply for approval for antidepressant in 2022Audientes accelerates preparations for US market entry after OTC market newsLundbeck Foundation wants stronger biotech businesses in Denmark, but this doesn't rule out international growthGN and Demant slightly increase Veteran Affairs foothold Audientes fulfills 2021 resolution to make third Indian partnershipEMA to investigate Covid-19 treatmentLeo Pharma strongly criticizes Danish Medicines CouncilWhile others divest, Sandoz expands: "Antibiotics are the backbone of modern medicine"Sofinnova raises EUR 472m for life science fundNew Sanofi study is yet another win for blockbuster drugUS court orders Eli Lilly to pay royalties on diabetes drugsDiabetes firm Vtv Therapeutics announces new CEOTop news from MedWatch this weekResearchers find reported HPV vaccine side effects could have been due to everyday infectionsChemical leak at Novo Nordisk causes road blocksDanish regions launch ultrasound scanner tenderUnion Therapeutics starts phase II trial of nasal spray for Covid-19 patientsLeo Pharma's eczema drug for adolescents meets phase III trial targetsNovo Nordisk chemical leak under control – production unaffectedMSD provides blockbuster drug free of charge for Evaxion's combination trialLundbeck chairman demands change: "We can't live with this"Novartis beats expectations for third quarterColoplast could win big on Polish reimbursement changesDelta variant outbreaks in the US affect Össur salesAnalyst: Novartis's Kesimpta sales exceeded expectationsCloud computing saves money and cuts carbon emissions at Novo NordiskEli Lilly upgrades earnings per share guidanceSeveral positive elements in Eli Lilly Q3 report, says analystStallergenes Greer enters partnership to develop device and appInvestors' focus will be on GN Hearing's downgrade, says analyst ahead of Q3 reportUS-based obesity firm hires former Novo VPAmplifon tops sales expectationsBoston Scientific boosts endoscope sales by 11 percentDeborah Dunsire after three years at Lundbeck: "We're coming up to an inflection point in neuroscience"Bristol Myers Squibb reports double-digit growth in Q3Sanofi upgrades 2021 guidance once again – Dupixent drives growthGN launches hands-free calling for Resound One users using Apple devicesTakeda boosts sales of Lundbeck-developed drug in H1 2021Biomarin is still expecting an EMA decision on hemophilia drug in H1 2022Biomarin: Interest in new dwarfism drug for children exceeds expectationsGitte Aabo nominated for Danish leadership awardFew weeks after downgrade: GN Hearing maintains guidanceDelayed GN Hearing device sent for FDA evaluationConvatec upgrades 2021 sales forecastGN CEO on job security: "It's a board decision"WSA acquires majority of Chinese online retailerEMA gains more power to monitor medicinesAnalyst ahead of Coloplast full-year report: Focus will be 2021/22 guidanceNovo Nordisk upgrades guidanceGN Hearing's CEO regards new OTC regulation positivelyAnalyst: Unexpected Novo upgrade "demonstrates positive development"Covid-19 impact lasting longer than expected on some markets, says GN Hearing CEOLundbeck presents positive results from migraine drug trialColoplast expects organic growth of 7 percent next yearOrphazyme after FDA meeting: New phase II/III trial won't be necessaryColoplast has increased investment in company behind vapor therapyCEO wants to make Bavarian Nordic one of the world's largest vaccine companiesDemant upgrades financial guidance again despite October's implant issuesDeborah Dunsire is breaking an old pattern: The definition of madness is doing the same thing over and over, expecting a different outcomeColoplast's urology business takes growth leap after Covid-19 diveNovo CEO: The pandemic has increased the value of collaborations and dealsZealand Pharma sends obesity candidate to clinicSeasoned Lundbeck researcher poached by up-and-coming biotech firm to lead R&DDemant wins market shares: "We are a far bigger business now than before Covid-19"Novo's obesity business and Chinese challenges will be examined closely, says analystNovo Nordisk Q3 profit surpasses USD 1.8bnNovo Nordisk's biopharm arm recedes in Q3Year-to-date obesity drug sales at Novo Nordisk surpass all of 2020Coloplast prepares big study of main asset from million-dollar acquisitionObesity drug submitted for approval in Japan, Novo Nordisk reportsSemaglutide fails in phase II trial within fatty liver diseaseChinese authorities approve seasoned Novo Nordisk combination treatmentNovo Nordisk CEO encouraged by Saxenda's role in obesity business growthRoche gifts blockbuster cancer drug to Galecto for new clinical partnership trialHorizon's Genmab drug gets blockbuster status FDA fast tracks former Leo Pharma eczema candidateDiscontent with GN Hearing CEO Gitte Aabo is growing, reports mediaGN ramps up climate efforts and joins Science Based Targets initiativeNew study reveals "enormous medical value" of Lundbeck's new migraine drug compared to generics, Head of R&D saysLeo Pharma loses US region CEO – interim replacement found in current CFORaising ambitions at Novo Nordisk an obvious move, says CEOOrphazyme prepares for USD 50m capital hunt after nightmare yearGenmab upgrades financial guidance againFormer Leo Pharma candidate heads into big study as FDA fast-tracks assessmentOlympus upgrades after Covid-19 recoveryAnalyst: All of the building blocks for Genmab's upgrade were in placeColoplast CEO looks forward to pivotal launchLundbeck ready to take Genmab antibody to phase IIZealand Pharma enters US partnership over pump systemWegovy weight loss results "very encouraging," says Novo EVPNovo Nordisk waves goodbye to VP in charge of device developmentColoplast CEO wants to increase US market share to global levelColoplast acquires Atos Medical for USD 2.5bnNovo EVP says new data shows Wegovy stands out in obesity crowdAnalyst says acquisition strengthens Coloplast's core competenciesSwiss media reports of defective Sonova cochlear implantsColoplast's USD 2.5bn acquisition is its biggest everAfter historic acquisition, Coloplast CEO takes stock: "Building up capacity will take a while"Analyst will focus on Ambu's new financial guidance after preliminary Q4 figures1000 Coloplast employees to give Atos flying start in ChinaAmbu's expectations for the new financial year disappoint analystsAnalysts predict results in upper end of Lundbeck's expectations ahead of financial reportAmbu prepares wide-ranging launch of improved single-use duodenoscope Missed targets cut salaries in half for top Ambu execsAmbu plagued by transportation troubles in disappointing year – CEO has a card up his sleeveAnalyst: Duodenoscope study is a ray of sunshine on a cloudy day for AmbuAmbu has replaced its duodenoscopes the world over: "We have the product of choice"Sales of migraine drug exceed expectations at Lundbeck during third quarterNovo Nordisk objects to proposed reimbursement change for its fast-acting insulin in DenmarkLundbeck lets 300 employees go: "We are on a constant hunt to make our organization as effective as possible"Express Scripts to cover psoriasis cream from MC2 TherapeuticsNew trial of Genmab substance is symptomatic of Deborah Dunsire's LundbeckDoctors are diagnosing more patients as US market normalizes, says Lundbeck CEOAnalyst: Undramatic Lundbeck report shows fine growth for key productsNovo Nordisk to introduce vaccine mandate at US facilities from Dec. 8Genmab increases income in Q3 and maintains upgraded full-year guidanceALK upgrades guidance after positive Q3 reportGenmab CEO says lower operating costs are a fleeting phenomenon Dropping two drug candidates puts Genmab in a better position, says CEOFocus will be on vaccine sales and pipeline news when Bavarian Nordic report is released, says bankGenmab is considering Covid-19 testing mandate for employees – if guidelines allowGlobal supply issues have ALK thinking creatively Ascendis Pharma doubles sales expenses ahead of product launchPfizer acquires commercial rights to Biohaven migraine drug outside the USZealand Pharma downgrades after disappointing Zegalogue salesNovo Nordisk within touching distance of European obesity market as CHMP recommends approvalEuropean interest in Wegovy expected to match US demand, says EVP at Novo NordiskBavarian Nordic CEO receives "extraordinary" retention bonusPositive CHMP opinion paves way for Lundbeck's Vyepti in EuropeCovid-19 has potentially cost Bavarian Nordic EUR 100mCHMP recommends higher dose of Novo Nordisk's OzempicNovo Nordisk creates AI division to help novel drug developmentCHMP vouches for Ascendis Pharma's growth hormone for childrenCHMP approves 11 new drugs, rejects oneEli Lilly and Boehringer drug gets head start at FDASonova beats expectations, lands USD 1.74bn revenueLeo Pharma refinances loans and links costs to sustainability targetsLundbeck begins phase II trial of antibody for migraine prevention Danish politicians furious over "deeply provocative" Bavarian bonusALK CEO on peanut allergy competitors: "They might have been the first, but that does not necessarily mean they are the best"ALK still has two horses in adrenaline raceBiotech company closes heavily oversubscribed financing roundAudientes enters into fourth Indian partnership – now spans 90 retail locationsSingle-use scopes take center stage at Ambu as core business areas recedeLeo Pharma starts phase II trial of Korean tabletAnalyst predicts blockbuster potential for Biomarin's growth hormoneALK execs sell shares worth USD 4mZealand Pharma CEO undeterred by lower than expected Zegalogue salesGE to capitalize on increasing demand for diagnosticsSiemens Healthineers upgrades mid-term guidanceCEO of Pila Pharma increases share holding to over a thirdImpact of China's drug policy will be visible soon, says JefferiesColumn: The EU must up its game to retain pharma strengthBiogen's Alzheimer's drug Aduhelm faces EU rejectionPharmacosmos sees big potential in million-dollar acquisitionEMA begins review of Novavax's Covid-19 vaccineInternational antibiotics resistance organization ICARS gains independenceGN Hearing's devices approved in the EU, granted CE markingNovo Nordisk acquires Dicerna for USD 3.3bnNew EU directive to require enormous cybersecurity investmentsLikely EU rejection of Biogen's Alzheimer's drug comes as no surprise, says dementia researcherHuge acquisition scores Novo Nordisk an FDA-ready treatmentNovo Nordisk will take Dicerna's technology to the next level, says EVPEli Lilly reaps rewards of Novo acquisitionJanssen sees USD 12bn sales potential in Genmab-developed drugsAscendis presents data from phase II trial of rare hormone disease treatmentCompetitors turned collaborators: Dicerna acquisition sends Novo Nordisk into the arms of rivals Eli Lilly and Boehringer IngelheimBiogen's EU setback highlights importance of research, says Alzheimer's organizationAmbu's new duodenoscope reaches over 98 percent success rateBiomarin's dwarfism drug receives FDA approvalEMA allows emergency use of MSD's Covid-19 capsule treatmentAnalyst: Positive results from Ambu's Duodeno 1.5 reflected in Ambu sharesSonova loses Veterans Affairs market sharesZealand Pharma reports positive data from phase Ib trialLundbeck Foundation portfolio company acquired for USD 230mRaw materials price spikes will prove costly for the life science industryGrass allergy sufferers wanted for Lundbeck phase I antibody studyNovo Nordisk Foundation's CEO warns antibiotic resistance will be world's second-biggest killerAnthony Mancini will help Genmab take its next stepsJoe Biden hopes to end "outrageous" insulin pricesAmbu introduces corona passport requirement in DenmarkNykode Therapeutics CEO after another million-dollar deal: We have no competitorsNovo Nordisk's reimbursement appeal goes unheard, Sanofi insulin deemed equivalentDicerna CEO explains how a desire to expand collaborations turned into a potential acquisitionAnalyst on Novo stock: The risk of disappointments is bigger than the chance of surprisesEargo faces delisting if it fails to provide Q3 reportEuropean pharma strategy report approved with huge majority Dicerna expects to continue collaborating with Novo's rivals after potential acquisitionNovo Nordisk Pharmatech and Novozymes enter into enzyme partnershipDicerna pushed up price and contacted other suitors before making deal with Novo NordiskDanish tax authority wins million-dollar legal dispute – Supreme Court case may followEMA recommends Covid-19 vaccination for children as young as 5Novo Nordisk is making progress toward stabilizing Wegovy supplyNovo Nordisk gets obesity drug approved in CanadaNovo Nordisk's sales growth will be negatively impacted in 2022Analyst: Novo Nordisk's estimated sales growth decrease not as big as expectedWHO calls in experts to assess new Covid-19 variantProfessor says vaccines can easily be modeled after new Covid-19 variantsTop news from MedWatch this weekFunding deal secures Denmark first batches of Bavarian Nordic's Covid-19 vaccinePharmaceutical giants prepare for battle with new corona variantMSD Covid-19 treatment less effective than first thoughtColumn: The EU pharma strategy must become more ambitiousNovo Holdings board member steps down after less than two years in roleAmbu board member sells 5,000 sharesBavarian Nordic: We can adapt our vaccine if necessaryLundbeck appoints new chief commercial officerNew plan for insulin reimbursement concerns Danish diabetes associationDenmark has the cheapest generic medicines in Europe, study findsPresident and CEO of Leo Pharma to resignEU countries approve new powers for disease prevention agencyEU drugs agency can clear Omicron shot in 4 months if neededColoplast starts testing sensor-based product for ostomy leakageLeo Pharma looks for CEO with capital markets experience ahead of IPOGenmab pipeline hype makes investment bank uneasyHeadhunter calls outgoing Leo Pharma CEO a "flop"European reference laboratory network to ensure better data across the regionDanish Medicines Council could be a roadblock for sclerosis drug KesimptaPresident of the European Commission puts mandatory vaccination on the table"Real world" patient data documents the long-term effects of ALK vaccinesContact with consumers will secure continued growth in China, says SonovaCSL eyeing acquisition candidate in Vifor PharmaY-mabs CEO has big ambitions: Wants to create the Tesla of biotechAGC's Japanese and Danish factories to produce German biotech firm's drug candidateEMA begins rolling review of another Covid-19 vaccineFDA approves another Darzalex combination treatmentA.P. Moller Holding set to acquire UnilabsNovo Nordisk wins big on strong US dollarBillion-dollar acquisition of Sobi failsLundbeck has great expectations for new antibody: "This could be the new generation of migraine drugs"Astra sinks Advent's USD 7.6bn buyout of biotech SobiTop news from MedWatch this weekPhase II study confirms efficacy of Bavarian Nordic's Covid-19 vaccineLeo Pharma sells development program, becomes shareholder of Swedish biotech buyerBavarian plans to send RSV vaccine to phase III, prepares equity raiseA.P. Moller Holding rejects future life science investments despite record-breaking purchaseAmbu wins single-use endoscope contract with US healthcare service giantBavarian Nordic EVP on Covid-19 vaccine: "We couldn't have wished for better data"Lundbeck Head of R&D denies allergy aspirationsAudientes enters fifth partnership in India, extends reach into populous rural areasBavarian Nordic finds buyers for accelerated share offeringIO Biotech expands collaboration with MSD – begins phase II trialNovo's acquisition has legal ramifications: Dicerna sued by shareholdersSonova to sell Australian-developed hearing aidsLundbeck's chief financial officer to exit before May 2022EU Council recommends extending deadline for implementing new cybersecurity law Lundbeck's CEO: Departing CFO is not defecting to competitorGN chair promises delayed product launches in H1 2022Lundbeck's former head of North America appointed CEO of Capsida BiotherapeuticsGN chair puts no blame on GN Hearing's CEO Gitte AaboLundbeck's CFO of 14 years to join VeluxGN Hearing loses Veterans Affairs market shares in NovemberUS-based biotech firm fires two-thirds of employees, focuses on diabetesDicerna on Novo's billion-dollar acquisition: Alleged wrongdoing has no hold in realityScandalized hearing firm Eargo fires one fourth of employeesWSA lost EUR 81.9m during 2021Orphazyme makes changes to board of directorsColoplast's new country-by-country tax report reveals enormous national differencesAlmost three years after the merger of Widex and Sivantos, WSA enters a new phaseBig Bavarian Nordic shareholder on pivotal projects: "We're in a completely unique position"EMA: Omicron cases appear "mostly mild"Novozymes closes majority stake acquisition of SynergiaSynact Pharma intensifies partnership discussionsBavarian Nordic's spending on factory expansion exceeds USD 150mUS trade agency extends deadline of Novo Nordisk's historic acquisition Copenhagen lands top three spot in global pharmaceutical rankingEli Lilly enters into strategic partnership on metabolic diseases with Regor TherapeuticsNovo Nordisk invests USD 2.6bn in new manufacturing facilitiesColoplast moves important production to country on tax haven watch listGenmab partner receives conditional EU approval for cancer drugContinued growth expectations behind Novo Nordisk's biggest ever manufacturing investmentEli Lilly enters into USD 300m research partnership with Foghorn Therapeutics Questions about Demant's future remain as 2022 nearsGN Hearing acquires US-based online marketing platform for USD 94.8mNGO slams "hypocritical" Coloplast for keeping Costa Rica accounts secretLeo Pharma begins phase IIb study of oral atopic dermatitis drugAnalyst says GN Hearing's acquisition will build bridges and bring in customers Novo still expecting EU Wegovy approval around the New YearGN Hearing left 9 percent ownership in Lively's hands to ensure work motivationZealand Pharma enters USD 200m financing agreement Novo CEO is on the hunt for future growth: "The pressure is bigger than ever"Genmab raises USD 2.4m from employee warrant exerciseGE Healthcare partners up with Minerva on precision medicineZealand Pharma may use acquisition option to beef up commercial muscle, CEO saysEli Lilly upgrades revenue and earnings per share expectationsCEO of Novo Nordisk on potential successors: "I've only just begun"MEP seeks to add Bavarian Nordic to vaccine contract court caseZealand Pharma ends recruitment for phase III study of glepaglutideDicerna CEO fears insider trading crackdown, withdraws own shares from Novo Nordisk offerEli Lilly submits tirzepatide for approval in US and EUDenmark allows unapproved pill for at-risk Covid-19 patients in line with EMA adviceDanish life science exports nearly tripled in 12 years: "We have yet to reach our goal"Novo CEO on US obesity drug demand: "It was the perfect storm"Nykode Therapeutics proposes chair of Zealand Pharma to lead own boardNovo Nordisk Foundation grants EUR 300m to new research centerDoctors doubt effect of new Covid-19 tablet EMA provides guidelines for another unauthorized Covid-19 tabletBiogen's Aduhelm rejected by EMA committeeCHMP approves 13 new drugsUS manufacturer cannot supply Wegovy injector pen syringesDemant identifies cochlear implant fault, plans market return in late 2022Novo Nordisk on problems at contract manufacturer: "They need time"Biogen slashes price of controversial Alzheimer's drugCompanies celebrate new stem cell center as an alliance and recruitment catalystNovo Nordisk must stay ready to increase Wegovy sales, says CFONovo Seeds invests in Dutch biotech firm with NASH focus againFDA expands indication for Amgen psoriasis drugLundbeck broadens phase III trial of Vyepti in childrenLundbeck finds new head of clinical developmentAmbu recalls resuscitation product Roche General Manager talks teamwork, international networking and Danish neighborsGradual IVDR implementation backed by EUFDA rejects Takeda/Shire candidateDanish firm launches cryotherapy venture in US following FDA approvalPension companies push for Coloplast's secret Costa Rica tax reportWSA appoints new CFOBiogen's Alzheimer's drug blocked in JapanBavarian's biggest competitors have a landmark 2022 aheadKaro Pharma acquires Reckitt's dermatology brand E4Analytics firm predicts global psoriasis market to grow twofold by 2030Big investments in Danish life science industry make 2021 historic year for raising capitalEditor in chief blasts Facebook following censure of Pfizer-critical articleHigh growth at low margins is better than the reverse, says Novo Nordisk CEODenmark defends controversial Covid-19 pillFDA approves Leo Pharma's tralokinumab after rejection 8 months agoLeo Pharma's US sales organization waited 8 months on approval: "It has had an economic impact"Novo Nordisk closes Dicerna acquisition dealNovo Nordisk predicts period of "different" growth when semaglutide patents expireAnalyst: Novo Nordisk was expected to complete acquisition – despite issues Nykode initiates clinical study of "pan-variant" Covid-19 vaccine Director at Lundbeck: "Some whistleblowers write in a way that makes it completely impossible to investigate anything at all"Allarity considers partnerships for the potential launch of cancer drugJanssen applies for FDA approval for Genmab drugAudientes strengthens leadership team with industry veteranSanofi loses bid to revive Lantus Solostar insulin-pen patentsThis year's most read stories from MedWatchDrug commercialization company Medical Knowledge Group acquired by Novo HoldingsAscendis Pharma extends trial of growth hormone in adults EQT reinforces long-term nature of WS Audiology investmentNovo Holdings acquisition highlights growing pharma commercialization service market, says managing partnerWS Audiology acquires Brazilian distributorAnalyst to focus on Bavarian Nordic, Novo Nordisk and Lundbeck in 2022Former Lundbeck venture advisors start new biotech fund"Bad luck" delayed Leo Pharma's prize candidate for eight monthsNovo Holdings acquires US contract manufacturer in second billion-dollar deal in two daysUnion Therapeutics recruits first psoriasis patient for phase IIb studyGenmab buys ADC technology license from SynaffixA.P. Moller Holding invests USD 50.8m in Blue Ocean Robotics2curex finds partner for Polish launchFDA fast-tracks Abbvie's lung cancer drugBiotech boss overjoyed by new life science fund: "The more the merrier"Former Alnylam CEO appointed new chair of HemabNovo Nordisk trains sights on Roche with "aggressive" hemophilia drug developmentSet-in-stone criteria will reduce risk for new biotech fundPharmacosmos investigates anemia treatment in new patient groupAmbu launches two new endoscope cartsNovo Nordisk expects lack of Wegovy doses to continue until H2 2022Novo Nordisk expands research collaboration to develop hemophilia drugFDA approves Lundbeck's schizophrenia treatment for teenagersColoplast disappoints pension firm: "The outcome doesn't please the company, the investors or the employees"Amgen combines Danish and Norwegian unitsChildren's pain relief company wants former Genmab boss on boardFormer Symphogen colleagues reunited in Norwegian biotech companyTop news from MedWatch this weekNovo Nordisk CEO spies new pharmaceutical sales modelPension firm: Coloplast's secret tax report could cost skilled employees Catalent behind Novo Nordisk's supply issues, says mediaBiomarin's hemophilia drug meets all endpoints in phase III studyAmgen to free up time and capacity with new Danish-Norwegian management teamEstron's CEO steps down – hunt for replacement has begunEuropean Biomedical Alliance appoints Danish presidentSnipr Biome to send first candidate to clinicGates Foundation awards women's health grant to life science incubator firm – new CIO hiredDanish notified body expected approved in 2023Olympus designates three focus areas for its endoscopy businessBiogen's Alzheimer's drug loses subsidies in the USDementia professor "humbled, proud and honored" to take on Biomedical Alliance's president roleAudientes starts 2022 with another Indian partnershipNovo Holdings participates in USD 100m financing round of Chinese contractorBioinnovation Institute wants to boost women's health research: "It hasn't been prestigious enough"EU Commission to consider medtech industry's recruitment challengesBioinnovation Institute reaches DKK 1bn milestoneNovo Group employees raise USD 3.5m to fight Covid-19Lawyer leaves Novo Nordisk, joins LundbeckEli Lilly considers copying Novo Nordisk's semaglutide branding strategyDemant gets FDA green light for new bone-anchored hearing solutionLeo Pharma and Astrazeneca keep future plans tight for tralokinumabAscendis Pharma's growth hormone formally approved in the EUSonova acquires US-based hearing aid provider for USD 310mGenmab CEO hopes for verdict in Johnson & Johnson arbitration soonNovo Holdings lets billions of dollars flow, bets big on Chinese and US acquisitionsAscendis to investigate new indications following EU approval17 notified bodies have filed for IVDR designationTen EMA initiatives will strengthen clinical research in EuropeTop news from MedWatch this weekNovo Nordisk settles securities lawsuit in DenmarkSnipr Biome chose clinical debut in CRISPR-ready USAAn end to lawsuit is positive for Novo Nordisk, says analystLeo Pharma closely followed by Pfizer and Abbvie with FDA atopic eczema approvalsAnalyst: GN price drop is an obvious opportunity to buyStallergenes bets big on personalized allergy treatment, enters another research collaborationNovo Holdings participates in USD 150m financing round of digital health companyBioinnovation Institute ramps up ambitions, wants twice as many companies under its wingLeo Pharma and Roche want to strengthen clinical research in DenmarkColoplast chair on transparent tax payments: "Experiences aren't especially good"Sonova wins Veterans Affairs market shares in DecemberOrphazyme upgrades after careful spending yearBavarian Nordic brings in chief operating officer from GSK VaccinesNovo Nordisk partners with Swiss biotech firm on obesity – zebrafish to unlock new drugsGN enters partnership to detect cognitive impairment in people with hearing lossLayoffs and restructuring will prepare Leo Pharma for IPOWSA merges with its independent retailerLeo Pharma ends Boston betHearing aid industry association responds to FDA's proposed OTC regulationOverwhelming majority passes new EMA powersSwedish bank slashes Novo Nordisk price target ahead of 2022 outlookDanish bank expects slow start to 2022 for Coloplast, lowers price targetLeo Pharma's Boston boss exits companyZealand Pharma finds all patients for phase III studyNovo Nordisk launches oral semaglutide in IndiaColoplast initiates trial of ostomy leakage product Audientes ships first hearing aid batch to IndiaDanish bank cuts Genmab price target, retains "buy" recommendationHearing firms urge FDA to increase OTC safety requirementsTop news from MedWatch this weekAnalyst suggests Coloplast could utilize currency fluctuations in potential upgradeNovo Nordisk spotlights star diabetes drugs in massive TV ad campaignsLundbeck receives grant from Michael J. Fox Foundation in hunt for Parkinson's testFDA rejects Pfizer's weekly growth hormoneSymphogen turns year-long deficits into first profitable year following Servier acquisitionLundbeck's migraine drug approved in EUNew CCO at crisis-hit Lundbeck: "2022 will be a growth year for Lundbeck in all regions"Demant's surgical division loses president of 13 yearsColoplast upgrades growth expectations following acquisitionGenmab: Darzalex sales in line with expectationsHearing aid market in US grew by 37 percent in 2021FDA fast-tracks Snipr Biome's primary candidateAs raw material and energy prices rise, so do Coloplast's costs Orphazyme seeks shareholder support in future capital raiseAnalyst on Coloplast: Very good financial report was helped by favorable currency ratesDanish bank changes Coloplast recommendation to "buy"Snipr Biome CEO delighted over FDA fast-track statusPatients are returning in Europe, but China and US lag behind, says Coloplast's CEOBavarian Nordic and other vaccine companies suffer as Covid-19 restrictions ease: "You might ask whether the ship has sailed"Amnesty warns Danish firms at Dubai health event: ”Do your due diligence”Starkey calls out President Biden: Hearing aids aren't consumer electronicsAllergy Therapeutics cleared by FDA to start testing peanut allergy vaccine Danish researchers working on vaccine for multiple cancersCHMP recommends approval of Pfizer's Covid-19 pillDanish Medicines Council recommends Genmab-developed sclerosis drugTen firms win second joint Nordic medicine tenderLeo Pharma files for marketing approval of tralokinumab in JapanNew EU portal for clinical trials launches on MondayCHMP approves seven new drugsTop news from MedWatch this weekEli Lilly to build USD 1bn factory in North CarolinaNovo Nordisk and Eli Lilly ramped up lobbying efforts when US legislators targeted insulin pricesBavarian aims for universal Covid-19 boosterDanish bank eyes uncertainties for Demant in 2022Eli Lilly prepares for FDA rejection of eczema treatmentDanish chamber of commerce says notified body should be followed up by reference labBritt Meelby Jensen steps down as CEO of Atos Medical Leo Pharma poaches Orphazyme CEOProduction issues could put a damper on Novo Nordisk's 2022Novo Nordisk to expand insulin pen recycling campaign to more countriesÖssur driven by growth in EMEA and APAC regions in Q4AJ Vaccines brings in former Lundbeck exec as new CEOAll eyes on Novo's new outlook on eve of 2021 reportNovo Nordisk had a record-breaking 2021 profit, but has reined in expectations for 2022Novo Nordisk aims higher than analysts in 2022 outlookObesity business grows at Novo Nordisk despite Wegovy woesNovartis increases sales of Genmab-developed sclerosis drugDisappointing phase I results halt Novo's Dutch acquisitionBiopharma sales slightly lower than expected at Novo NordiskNovo Nordisk plans to submit weekly growth hormone for approval in H1Novo Nordisk invests billions of dollars in post-semaglutide futureNovo CEO: Obesity goal within touching distance well before 2025 deadlineNovo CEO calls Wegovy problems "a perfect storm," will not move production in-houseLeo Pharma sells app firmNovo Nordisk spies great hemophilia opportunities with partner GenmabNovo Nordisk stops development of new insulin product Novo Nordisk ready to go toe to toe with AscendisEli Lilly's Trulicity beats growth expectationsBoston Scientific's endoscope business grows by over 20 percentEli Lilly under pressure as Alzheimer's application delayedLeo Innovation Lab says sale of spinoff is "stamp of approval"Ambu's Ascope Gastro and Abox 2 approved by FDANovo development exec: ”I’m looking at a rich pipeline across all therapy areas"Sanofi sees higher earnings as blockbuster skin drug soarsLeo Pharma introduces bonus program for employeesNovo CEO eyes cheap biotech market: "Of course the price matters, but there are other factors, too"Olympus increases endoscopy sales, monitors supply chain issuesTop news from MedWatch this weekAbbvie to submit first Genmab collaboration candidate in 2022Genetic researchers map different migraine types in hunt for new treatmentNovo Nordisk execs sell out after receiving sharesDemant unveils parts of full-year report by mistakeGN Hearing expands flagship portfolio with new product Janssen submits Genmab-developed drug for EMA approval Demant's 2022 growth prognosis to take center stage in full-year report after accidental releaseLogistics and comparisons will bring growth down for Ambu, analyst saysAnalyst ahead of ALK report: Focus will be on 2022 prognosis Demant reports record operating resultAmbu beats expectations but sees considerable setbacks compared to last yearALK predicts 8–12 percent revenue growth in 2022Bank says Demant prognosis probably affected by component shortagesCEO of GN Hearing: R&D is back under control after restructuringEMA updates Spinraza's product summary, gives Biogen hope in DenmarkDemant sees window of opportunity as millions lack hearing aids due to Covid-19Ambu's CEO remains confident of job security despite run of bad newsGN announces US launch of hybrid hearing aid built for OTC salesLundbeck eyes progress in 2022, disappoints compared to consensusAnalyst on Ambu report: Mixed results but still thumbs-downGN Hearing: We are uniquely positioned in the OTC channelALK maintains China bet despite geopolitical unrestDemant and Sonova take Veterans Affairs market shares in JanuaryNew product will positively impact sales prognosis, says CEO at GN HearingNovo Nordisk could lose millions on discount dispute in USLundbeck's Northera took massive dive in 2021GN Hearing will grow by 5–10 percent in 2022WS Audiology's revenue grows by 10 percent in Q1Deborah Dunsire aims for 10 European Vyepti launches this yearMajority owner: Lundbeck's new share structure could double acquisition powerWS Audiology looks to new OTC market – but won't disclose plansGN Hearing will prepare for continued logistical issues with million-dollar injectionDeborah Dunsire beats Novo Nordisk CEO in salary comparisonOrphazyme plans to resubmit FDA application in H2CEO of WSA: Broad product portfolio behind Q1 growthComponent shortages impact WSAGN Hearing CEO takes pay cut due to downgrade and launch problems HERA launches first work plan with millions in R&D financingLeo Pharma to test tralokinumab with new device in phase III studyTop news from MedWatch this weekLundbeck preps for war against generic drugmakers in USBavarian Nordic receives special designation from FDAEli Lilly warms up for summer launch with long-term success goalUpcoming hearing aid will be GN Hearing's last under Resound One brandFrom zero to hero – the rise of Novo Nordisk's best-selling drugALK bets on well-known tablet technology to treat peanut allergyBlackrock increases Novo Nordisk holding to over 5 percent Novo Nordisk sues Teva over generic drug developmentZealand Pharma finishes phase III enrollmentBavarian Nordic on FDA special status: A huge validationLong-standing GN board member steps downAnalyst ahead of Genmab report: Focus will be on Darzalex prognosis Denmark responds after Covid-19 numbers used in scare tacticOrphazyme gets investor backing for fundraising roundUS Senate confirms Biden's FDA candidateHearing firm Med-El launches historic first implant for younger children Blow for Eli Lilly as research institute deems diabetes candidate no better than competitionDanish scientists first in Europe to use new clinical trial databaseDanish cases drop, defying critics of early end to Covid curbsNovo's antibiotic fund participates in financing round of infectious diseases firm Genmab raises 2022 sales outlook to top USD 1.6bnGenmab CEO: Tivdak launch has provided important experience for future treatmentsOrphazyme elects new board member Genmab CEO hopes arbitration uncertainties will ease off soon Prominent investors criticize Lundbeck's share structure splitGenmab CFO targets 39-percent recurring revenue growth in 2022 Employee growth to continue as Genmab offices specialize across the globeLeo Pharma poaches Novo Nordisk VP to lead US divisionGenmab CEO lands USD 6.8m salary in 2021Moderna plans to open office in DenmarkGenmab CEO expects more legal twists in futureGlaxosmithkline halts RSV trial after safety recommendation Orifarm ramps up growth plans following USD 703m acquisition Novo Nordisk participates in USD 57m financing round at strategic partnerAlmirall launches MC2 Therapeutics-developed psoriasis cream in EuropeGenmab CEO eyes big opportunities in global biotech downswingColoplast starts share buyback programFDA rejects Allarity's cancer candidate, demands more dataChairman intends to retire from Almirall in MayFinnish investor looks for Nordic investors in its new life science & health fundAlmirall's psoriasis drug drives 2021 growth ahead of duller 2022 outlookNovo Nordisk proposes new vice chair and board memberLeo Pharma owner: "You can’t go public without a growth outlook or an interesting pipeline"Leo Pharma to terminate up to 150 R&D jobsALK proposes to split shares into 20Novo Holdings appoints new CFOMedia changes Lundbeck recommendation to "buy"Smith & Nephew releases full-year report, appoints new CEOHovione enters partnership with Zerion Pharma Sunstone participates in EUR 39m financing round of Targed BiopharmaALK CEO misses bonus target for fifth year in a rowModerna initiates phase III study of RSV vaccineOrphazyme to give oral explanation as EMA committee decision nearsMillion-dollar investment from Eir Ventures will bring Swedish cancer company to clinicBavarian unconcerned by Moderna RSV advance: ”It's completely as expected"Novo Nordisk enters 8-year long partnership with sustainable aviation fuel firmOrphazyme predicts EU rejection after meeting with CHMPAbbvie seeks to add major depressive disorder to drug labelNovo Nordisk slams Danish Medicines Council's methodology: Has flaws and shortcomingsOrphazyme stock plummets following bad news from CHMPNovo Nordisk restores enough Wegovy supply to meet prescriptions in US Biomarin projects 2022 Voxzogo sales of USD 115m Orphazyme deputy chair thinks layoffs could be option after EU disappointmentNovo Nordisk expects drugs excluded from sanctions against RussiaOrphazyme board member on expected EMA rejection: "The next few days will be hell"Janssen puzzled by Denmark's refusal of antidepressant nasal sprayRussian invasion of Ukraine could impact over 200 clinical studiesBrokerage firm slashes Orphazyme price target by 77 percentLundbeck maps pandemic mental health impact on US residentsCHMP approves 13 new drugsTop news from MedWatch this weekAdditional phase II data backs up Bavarian Nordic's Covid-19 vaccineOrphazyme CFO to take up CEO mantle ahead of timeWidex families on future WSA co-owners: Danish investors preferred to public listingAnalyst: Bavarian Nordic has an attractive Covid-19 vaccine candidateAudientes gets green light to sell self-fitting hearing aid in IndiaAscendis Pharma initiates clinical trial of dwarfism drugBavarian Nordic's vaccine has potential to last longer than competition, says CEO Coloplast senior vice president leaves for new roleCanon acquires Danish x-ray company NRTFuture of Novo Nordisk, Lundbeck and Ascendis Pharma trials in Ukraine remains unclearLundbeck donates USD 1.5m to Danish Red Cross for emergency relief in UkraineSonova completes Alpaca Audiology acquisitionThree years after merger, WS Audiology is stronger than everGenmab appoints two new executivesAbbvie takes over Novo Holdings portfolio company Biden wants to cut costs of prescription drugs in the USGN suspends all trading with RussiaAnalyst: Biden's insulin message won't negatively impact Novo NordiskDemant breaks off all trading with Russia after GN boycott, WSA says supplying Russia "impossible"Sonova has finished acquiring Sennheiser's consumer divisionLundbeck will supply Russia with medicine for as long as sanctions allow
GN Hearing's boycott decision was a "principled stance"Pfizer's RSV candidate receives FDA special statusNovo Nordisk donates two months' worth of insulin to UkraineAnalyst: Focus on Bavarian Nordic's 2022 outlook, orders and costs in upcoming reportWegovy update on Novo Nordisk's capital markets day agendaFounder steps down from CEO role at Beta BionicsNovo Nordisk aims for three new Dicerna drug candidates a yearNovo Nordisk CEO: "We are very encouraged by growth momentum"Sonova will continue trading with RussiaAscendis continued big investments into 2021, driving operating deficit upNovo Nordisk's first phase III data for weekly insulin to be released in few monthsOrphazyme postpones 2021 annual reportNovo expects GLP-1 products to drive diabetes business growth Novo Nordisk more than doubles 2025 obesity sales goalBavarian Nordic expects revenue setback in 2022Demant buys 20 percent of Chinese firm, eyes full purchase laterChinese dispensation allows ALK to file for registrationCEO of ALK on Chinese waiver: ”Some of the best news ALK has had in years"Novo Nordisk launches smart insulin pens in the UKNew EMA powers have come into forceRussian invasion of Ukraine could have multimillion-dollar impact on Novo NordiskLeo Pharma can switch away from gas within 72 hours if neededVaccine acquisitions could pave the way for Bavarian Nordic's 2025 ambitionsUS transformation has been successful, says Novo Nordisk's country headBavarian is still open for contract production – but in-house projects come firstNovo Nordisk to focus on patient outreach, prescribing doctors and subsidies to reach obesity goalsNovo Nordisk's gilded stock yields almost USD 59bn over 20 yearsNovo Nordisk initiates patent suit to stop Ozempic copiesSmall molecules to lead Leo Pharma to greatnessConvatec expects up to 5.5 percent growth in 2022Two years after criticism: Ambu and Leo's efforts to bring more women into leadership have mixed resultsGenmab receives orphan drug designation from FDASanctions expert: Sonova's sales in Russia are still permittedSanofi and Sobi's hemophilia drug meets phase III primary endpoint Leo Pharma finds new medical director at BayerNovo CFO: Obesity market is difficult to predictPharmaceutical firms prepare for potential Russian gas haltMerck Denmark joins Novo Nordisk's injection pen recycling campaignNovo expands research collaboration with US universitiesColoplast doesn't expect impact from potential Russian gas haltAdvanced Bionics loses patent infringement suit Novo Nordisk spotlights future innovations within diabetes as insulin sales recedeLeo Pharma's board still struggles with skewed gender ratio Bavarian Nordic brings in CEO of Innovation Fund DenmarkNetwork of seven women aims to put gender equality on the life science agendaDemant expands executive board to four membersOrphazyme seeks court protection during restructuringZealand Pharma reports higher costs in 2021Orphazyme gets requested observation status CEO of WSA: "Multi channel is the future"Russian firms now allowed to violate patents from "unfriendly" countriesOrphazyme stock in free fall after in-court restructuring requestTop news from MedWatch this weekAscendis Pharma reports promising phase III dataAnalyst: Zealand Pharma pipeline will be crucialNo replacement nominated for outgoing Bavarian board memberRussian ambassador to Denmark: Takeover of foreign firms is an optionEU agrees on approach to gender equality directiveNovo Nordisk grants Taiwanese firm access to smart pen data Genmab nominates Eli Lilly veteran as board memberWHO urges Ukrainian labs to destroy pathogens as war rages onNovo Nordisk Foundation teams up with Gates Foundation: "It isn't a question of if another pandemic hits, it is a question of when"Sanofi and Blackstone enter multimillion-euro partnership on bone marrow cancer drugAmbu brings in new CFO from RocheT&W Holding's historical result due to tailwinds on the financial marketsBiogen and Eisai change agreements on Alzheimer's drugMSD stops prostate cancer trial Lack of IT specialists could hamper life science growthGilde Healthcare closes oversubscribed fundEli Lilly halts new studies and exports of some medicines to RussiaNovo Holdings participates in series B round at Belgian cancer firmSnipr Biome expands executive management teamBiogen lays out long-awaited Alzheimer’s data in obscure journalVice chair and board member leave Leo PharmaLeo Pharma disappoints as deficit surpasses USD 720m Roche tops ranking of pharmaceutical industry's 2021 R&D budgetsWS Audiology halts IPO plans for subsidiaryLeo Pharma executives receive huge bonuses despite multi-million dollar deficitEMA management board elects new chairDelayed US approval will hit Leo Pharma at full strength this yearLeo Pharma will retain thrombosis business despite goal to focus on dermatologyAnalysts sow doubts about Ambu's projections Orphazyme to convene creditors for meeting on company restructuringAmplifon lands all-time high revenue, projects positive 2022Top news from MedWatch this weekGN and Demant lost ground with veterans in FebruaryBavarian Nordic enters license agreement with Nuance Pharma on RSV candidateNovo Nordisk creates new unit to ramp up use of artificial intelligence and digital tools in researchLundbeck parks Alzheimer's drug hope as there is no evidence it worksBavarian Nordic could be first on the RSV market in ChinaBoehringer Ingelheim and Saniona schizophrenia partnership advances to next stageNovo Nordisk winds down clinical activities in RussiaAnalyst: Bavarian Nordic RSV partnership could be first of manyBavarian Nordic hunting for RSV partners: "If the firm is too small, we might as well consider launching ourselves"Orphazyme files for delisting in USNovo Nordisk recruits 500 people for Alzheimer's trial Orphazyme withdraws marketing application ahead of final voteSwedish biotech firm gets green light to take diabetes candidate to clinical phaseHeavy-handed Covid-19 approach in China causes problems for hearing aid firmsThe Lundbeck Foundation delivers record-breaking resultAmbu and Coloplast unaffected by Covid-19 lockdowns in China – for nowMedia: Lack of buyers' interest in Novo Holdings-owned Xellia Pharmaceuticals Lundbeck faces criticism over new share structureLundbeck has halted studies in Russia, continues to supply medicine Lundbeck chair on shareholder criticism: Share split benefits everyoneColoplast study demonstrates significant improvements with Provox LifeGN Hearing wants an EBITA margin of over 20 percent in 2024Leo Pharma has applied for expanded approval for eczema treatment in EUAnalyst: Obesity market could surpass USD 70bn by 2030Ascendis Pharma to raise capital with convertible notesColumn: This is how the Danish Medicines Council should strengthen its application processNovo Nordisk settles patent infringement lawsuit with NovartisNovo CEO condemns invasion of Ukraine – but keeps Russian factory runningNew vice chair elected to Novo Nordisk boardAudientes predicts top sales of USD 4m in 2022, plans capital raise Novo Nordisk chair believes in globalization despite international tensionsAscendis veteran leaves chair role at Swedish biotech firm Another win for Pfizer as RSV vaccine receives FDA special statusWS Audiology and GN settle false advertising case in US CHMP approves 5 new drugs in MarchTop news from MedWatch this weekDemant to release quarterly figures from May onwards Danish Medicines Council releases recommendations – mixed bag for Sanofi and BMSNovo Nordisk's acquisition journey is driven by price pressure and a hunger for innovationGN denies involvement in false advertising caseNovo Holdings beats record as value of assets exceeds EUR 90bnJapan approves iron deficiency drug from PharmacosmosPotential success could be head-scratcher for Novo Nordisk chairNovo Nordisk gets 2.0 mg Ozempic dose approved in USIGM Biosciences and Sanofi enter deal with USD 6bn potentialFDA requests 34-percent budget increaseSanofi gets first ever approval within Niemann-Pick as Japan green-lights drugCEO van de Winkel wants long tenure at GenmabOrphazyme gets another annual report extension approvedSanofi lifts sales potential of blockbuster drug to USD 14.5bnNew FDA requirements could provide opportunities for Genmab, CEO saysNovo Holdings eyes opportunities as biotech bubble burstsLundbeck enters licensing agreement for antidepressant in IndiaWorld's biggest audiologist conference to focus on OTC sales channelOrphazyme CEO stays silent in run-up to creditor meetingZealand Pharma appoints head of R&D as CEORestructuring gives embattled Orphazyme three paths to survival US legal appeal rejected in win for Novo NordiskGenmab CEO says Janssen should "show respect" as royalty strife nears conclusionNewly appointed Zealand Pharma CEO says commercial organization was too expensiveUS audiologists want clarity on OTC hearing aid returns policies Former Novo Nordisk CEO Lars Rebien opened factory in Russia – "I've been too naive"EMA advises clinical trial managers over impact of war in UkraineHead of US audiologist association thinks OTC could increase hearing loss awarenessOrphazyme reveals survival plan: Possible buyers and investors have been contactedOrphazyme confirms delisting in the USOrphazyme's creditors left without real optionsUS House of Representatives passes bill to cap insulin priceHERA calls for participation from life science industry GN Hearing CEO: OTC will increase price transparency on the hearing marketOrphazyme is in dialog with a number of potential suitors in search of rescueHearing Industries Association calls for more OTC regulationTop news from MedWatch this weekOrphazyme down to 20 employees after multiple firing roundsCEO of Novo Holdings: "We have executed the strategy we laid out when I joined"Analyst: Price cap on insulin is unlikely to affect drugmakersDemant has long-term expectations in ChinaGN Hearing CEO: Three reasons why Lively will soon be profitableFormer Novo CEO Lars Rebien appointed executive chair at FerringY-mabs resubmits cancer drug for marketing approval in the USWilliam Demant Invest increased its investment portfolio by USD 3.4bn in 2021The Lundbeck Foundation to focus exclusively on Danish biotechCEO of the Lundbeck Foundation defends share split proposalDemant wants more women in leadership – but won't set targets for its executive managementOlympus spins off scientific solutions divisionWorld's largest public-private antibiotic fund unveils first investmentsAnalyst comments on Novo Nordisk's record-breaking stock priceDeparting head of venture investments at the Lundbeck Foundation considers futureNovo Nordisk loses two senior staff to alternative antibiotics firmAudientes nominates former Microsoft veteran to board Orphazyme names the last day of trading in US Nanovi submits cancer biomarker for marketing approval in the USFDA grants Sanofi's blockbuster priority review in a new indicationZealand Pharma's restructuring plan has led to dismissals in DenmarkOrphazyme reveals new release date for 2021 reportZealand Pharma board re-electedEndoscopy president to leave Boston ScientificNordnet economist: Investors doubt future GN growthOrphazyme creditors approve restructuring planPfizer to acquire Reviral as RSV race continuesPfizer's RSV acquisition target is Novo Ventures portfolio companyGenmab loses royalties case against JanssenDanish Medicines Council considers fast-track schemeJanssen promises full focus on Darzalex after defeating Genmab in courtGenmab value drops by over USD 1.5bn after royalties defeatLundbeck finds new CFOTop news from MedWatch this weekBiontech and Genmab's collaboration goes deeper than previously saidLundbeck reports positive results from head-to-head study of antidepressant England and Wales reject Leo Pharma's eczema drugOrphazyme has dismissed co-founder and chief scientific officerLeo Pharma enters collaboration with Canadian biotech firmLundbeck sues competitor for infringing on patent rightsNovo Nordisk executive joins board of Finnish OrionEli Lilly and Almirall report promising results from phase III atopic eczema study Pharma lobby pledges to launch drugs on EU markets no later than two years after approvalNuheara submits self-fitting hearing aid for FDA approvalUS senators propose bill to force finalization of OTC rulesThe Novo Nordisk Foundation increases health focus in 2030 planBiontech to avoid big acquisitions despite billions on the bottom lineFerring VP steps down as chair of API manufacturerEvaxion co-founder takes step back from management, joins boardMedWatch closed for EasterGSK to buy cancer company for USD 1.9bn Boehringer Ingelheim enters collaboration on hearing loss treatment for up to USD 100mNovo Nordisk target price increased by five institutionsGN Hearing CEO: R&D organization is back on top formGenmab ponders next steps after preliminary cancer candidate resultsBavarian Nordic to start phase III with Covid-19 booster in JuneAmbu expands single-use endoscopy target market with new featureAmbu launches new gastroscope in Japan and EuropeJanssen's sales of Darzalex exceed expectationsLeo Pharma absorbs scrapped innovation hubs to streamline focusAnalyst: Darzalex sales could reach top end of projectionsLeo Pharma brings hair loss cream into phase IIBausch Health investigated by US Department of Justice over misleading marketing Bavarian begins phase III trial of RSV vaccine in older adultsCancer drug hope raises Genmab's spirits after legal defeatDemant lost ground at Veterans Affairs in MarchSnipr Biome brings first candidate to human trialSnipr Biome takes aim at antibiotic resistant bacteria in phase I trialSonion accuses Huawei and Sony of copying technologyUS institution changes share price target for three big Danish drugmakersAbbvie pulls plug on Swedish R&D partnershipNovo Nordisk initiates phase I trial of oral deviceOrifarm expands headquarters following huge acquisition Leo Pharma's climate targets receive science-based stamp of approval FDA rejects schizophrenia drug from TevaWHO recommends Pfizer's corona pillWestern medtech exports to Russia pick up speed againAging French population could boost Danish health exportsDanish Medicines Council makes five recommendations after April meetingAstellas Pharma ends development of dust mite allergy vaccineQufora expects French approval in 2022, trains sights on million-dollar businessTop news from MedWatch this weekEMA approves Novo Nordisk plan to store insulin at room temperature for longerCHMP recommends approval of Novo Nordisk's hemophilia drug for postpartum bleedingFour drugs recommended for approval by CHMP at April meetingAbundance of downgrades may put damper on accounting season, says analystLeo Pharma eczema drug makes Express Scripts preferred product listAnalyst: Increasing inflation will have multimillion-dollar impact on Novo Nordisk Malaria breakthrough hope rekindled by pandemic research after 30 years of stagnation Huge executive reshuffle at Saniona – firm to stop US activitiesNovo Nordisk foundation gives billions back to Denmark to fund developmentLundbeck VP joins board of migraine firmNovartis books multimillion-dollar sales of Genmab-developed drug in Q1Axsome Therapeutics steels itself for FDA rejection of migraine drugDanish life science foundations broke investment records in 2021Otonomy reports positive results with hearing loss candidate Demant to divest hearing implant division to CochlearDanish diabetes patients often prescribed expensive insulin firstAnalyst: Kesimpta sales from Novartis slightly over expectations Demant's hearing implant division struggled with recalls and pandemic pressureCochlear relieves Demant of loss-making implant divisionDemant CEO won't rule out dismissals following divestment of implant divisionBoston Scientific beats Q1 revenue expectations, except for endoscopy salesY-mabs CEO resigns with immediate effectMerck, Novo Nordisk spared from 1,500 suits over diabetes drug blamed for cancerDupixent drives sales advancement in Sanofi's first quarterEstron finds new CEONovo Nordisk to test key hemophilia drug in children in phase III Smith & Nephew books Q1 sales slightly better than projectionsEli Lilly upgrades full-year guidance due to solid growth in Q1Pent-up demand for hearing aids continues to boost sales in USNovo Nordisk upgrades full-year guidanceOrphazyme receives offers, begins negotiations with potential buyerNovo Nordisk reaches primary endpoint in phase III of once-weekly insulinNovo Nordisk subsupplier reinitiates Wegovy productionNovo Nordisk unveils Wegovy salesNovo Nordisk terminates program on innovative insulinNovo Nordisk aims to submit hemophilia drug for approval this yearOne day a month, Genmab employees are free to do as they pleaseTop news from MedWatch this weekNovo Nordisk drug becomes world's top-selling diabetes medicineBiomarin raises Voxzogo sales expectations againProduction limitations put a damper on Novo Nordisk's potential growthEargo enters million-dollar settlement with the United StatesLundbeck veteran reflects as he nears 25-year anniversary: "Don't forget your roots"Novo Nordisk remains coy over Wegovy blockbuster potentialBank says not to expect surprises in Demant's Q1 reportDemant predicts USD 14m impact of war in Ukraine in first ever quarterly reportNovo Nordisk confirms start of phase I robotic pill trial Eli Lilly wants to gain on Novo Nordisk's obesity leadDemant's Q1 results met with neutral response from analystNegative impact on Demant from Russia's war won't get any worse, says CEOInvestors asked Demant for more transparency – now they have itLeo Pharma takes hand eczema treatment into phase III Amplifon narrowly beats analyst consensus in first quarterNovo Nordisk initiates share buyback scheme and acquires shares from owner Analyst predicts favorable market conditions for ColoplastAmbu obtains CE mark for fifth generation single-use bronchoscope Bose to drop hearing aid business, media reportsAnalyst "positively surprised" by Demant's Q1 developmentEU proposes cross-border data space to strengthen health unionAnalyst: Bose hearing aid exit reflects market complexity GN Hearing beats analyst expectations for Q1WS Audiology's revenue grew by 20% in Q2 2021/2022GN Hearing CEO: Bose's exit spotlights complexity of hearing aid marketAnalysts flock to raise Novo Nordisk share price target following upgradeBavarian Nordic data shows booster shot protects against OmicronGN Hearing lets staff go to optimize supply chainWSA maintains guidance despite strong growth – CEO explains whyColoplast downgrades organic growth guidanceAmbu downgrades financial guidanceGN Hearing in talks with VA on new hybrid product categoryColoplast's biggest ever acquisition lands firm USD 40m in two monthsLundbeck poaches Zealand Pharma VPPotential buyers prepared to chase arimoclomol approval, Orphazyme deputy chair saysColoplast will not exit Russia, says CEOAmbu to reign in expectations after seventh downgrade since 2019Analyst will focus on phase III studies and travel vaccines in Bavarian reportTop news from MedWatch this weekColoplast postpones launch of ostomy care platform Bavarian Nordic maintains 2022 guidance Genmab enters agreement on cancer biomarker Bavarian terminates HPV and HBV collaboration with Janssen Denmark has paid out one-third of Bavarian Nordic's Covid-19 vaccine supportColoplast to issue notes for EUR 3.5bnBavarian will market Covid-19 vaccine on its own – but doesn't rule out future partnersEngland and Wales open for potential Leo Pharma recommendationZealand Pharma changes financing agreement Danish demand for ALK adrenaline pen surges, causing supply issuesEuropean innovation initiative puts Novo, Sanofi, and Eli Lilly in the same roomUS Democrats fighting insulin prices might falter as midterms nearAnalyst: Improved market conditions will support Lundbeck's key products in Q1Novo Nordisk enters research collaboration with Flagship PioneeringPfizer to acquire migraine firm for over USD 11bnLundbeck maintains guidance after exceeding expectations in Q1Novo Nordisk appoints new general manager for TurkiyeColoplast inherits possible USD 70m slipup from Atos MedicalLundbeck to delist in USDemant and GN gain ground at Veterans Affairs in AprilAnalyst will focus on royalties defeat and increased costs in Genmab's Q1 reportLundbeck CEO expects migraine market to grow following Pfizer's billion-dollar acquisitionEU migraine drug approval triggers multimillion-dollar bill for LundbeckSanofi reports data reinforcing efficacy of RSV candidateGenmab beats Q1 expectations and narrows full-year guidance rangeALK beats analyst expectations on all parametersGenmab throws in the towel – won't contest royalties rulingGenmab CEO on royalties defeat: "I'm sad and disappointed"Indian generic drugmaker settles lawsuit with Leo PharmaLundbeck to test Vyepti in direct comparison with competitorsALK reaches symbolic milestone as tablets generate half of revenuesZealand Pharma rescue pen books USD 0.6m revenue in Q1MedWatch closed on Friday, May 13Orphazyme sells entire business to US biotech companyZealand Pharma CEO hopes for partnership news in coming months FDA approves Eli Lilly diabetes drugSonion chair retires as replacement takes overEargo gets second warning from Nasdaq for missing reportsNew EU regulation has made the medtech industry turn to the USOrphazyme didn't know buyer before negotiations beganEU to terminate vaccine agreement with ValnevaFuture uncertain for Orphazyme CEO as firm soldLundbeck has initiated phase I trial of acquired candidateSonova sales surpass analyst expectations in annual reportArkansas alleges insulin pricing plot involving Novo Nordisk, Eli Lilly and SanofiAnalyst: Strong Sonova advance indicates improved marketZealand Pharma sells insulin pump to Mannkind CorporationObesity rates increase to "epidemic" level in Europe, WHO warnsOrphazyme delays annual report again after striking deal with KempharmIssues at Novo Nordisk lead to shortage of fast-acting diabetes drugZealand Pharma stock soars after selling insulin pumpUS government exercises option to buy Bavarian smallpox vaccines for USD 119mAnalyst: US vaccine order secures future cash flow for BavarianALK execs rake in profits after exercising share optionsAnalyst predicts slow start for Leo Pharma's Adtralza in UK Almirall enters partnership with Inserm Transfert to research vitiligoIn a world of options, Genmab's CEO chose partnershipsDiabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's OzempicNovo Holdings establishes new firm managed by biotech veteransOrphazyme's creditors to vote on sales agreement at end of MayThousands of collaborative research papers with China pose threat to Europe, authorities worryBavarian lands monkeypox vaccine contract with unnamed European countryAlmirall and Evotec to collaborate on multiple severe skin disease targetsAudientes generates first-ever revenue in Q1Zealand Pharma reports positive phase III results against congenital hyperinsulinismAmbu appoints Britt Meelby Jensen new CEO Novo Nordisk regains Novorapid supply capacityALK CEO sells shares for USD 1.5mAmbu board had started headhunting process long before firing of CEOBritt Meelby Jensen wants to rebuild trust in AmbuAnalysts have great faith in incoming Ambu CEODanish Medicines Council rejects Novartis breast cancer drug Nine new drugs recommended for approval by CHMP at May meetingOutgoing Ambu CEO commends colleaguesTop news from MedWatch this weekSmallpox projects send stocks soaringOrphazyme halves board of directors – chair not up for reelectionBavarian's market value up USD 1bn over three daysALK finds replacement for long-time North America lead Almirall announces Danish launch of MC2 Therapeutics-developed psoriasis creamMonkeypox vaccine attracts interest for Bavarian as virus spreadsJesper Høiland retires as chief commercial officer of Ascendis PharmaFormer Ambu CEO's equity investments end in USD 2m lossesCarb-X secures USD 370m in fight against antibiotic resistanceBavarian Nordic ramps up monkeypox vaccine productionDexcom is in talks to acquire device firm InsuletNew head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"EMA publishes new plan to support antibiotic developmentRumored purchase of GN Group could mean divestment of hearing aid division, says mediaGermany orders 40,000 monkeypox vaccines from Bavarian NordicCHMP to remove 100 generic medicines from marketNovo Nordisk invests additional millions of dollars in new manufacturing facilitiesGN purchase story is very speculative, says analystUS to start using Bavarian vaccine stockpileBavarian Nordic upgrades guidance following vaccine contractLong wait for IVDR implementation is over, putting an end to pandemic "wild west"UK buys 20,000 smallpox vaccines from Bavarian Nordic as demand soarsLeo Pharma looking for pediatric patients for eczema trialBavarian Nordic eyes European monkeypox approval for smallpox vaccineNew CFO wants to shake things up at WSAChinese patent expiration dates draw closer for Novo NordiskRumored GN purchase unlikely but not impossible, say analystsEMA begins analyzing Bavarian Nordic's vaccine against monkeypoxZealand Pharma CEO believes in firm's obesity effortsPfizer granted FDA fast-track designation within NASH indicationPancryos strikes deal with Brigham and Women’s Hospital on type 1 diabetes drugAnalyst predicts more Bavarian vaccine orders in Europe in light of monkeypox outbreakRSV caused more than 100,000 child mortalities in 2019Orphazyme's fate sealed as creditors approve Kempharm saleBavarian Nordic upgrades guidance for second time in five daysGeneric drugmaker Orifarm considers lawsuit against scandalized Indian CROGN price spikes might be an overreaction, says bankDanish Medicines Agency to launch second reimbursement risk-sharing programWS Audiology and fashion expert hid advertisement on Danish national TVAnalyst spots more monkeypox opportunities for BavarianOrphazyme is now officially in American handsPincer Biotech appoints CEO, cementing goal to combat antibiotic resistanceEargo weathers the storm – stays listed on US exchangeDenmark reassesses rejection of Novartis cancer combination to include more exceptionsEMA appoints Steffen Thirstrup as chief medical officerSobi receives FDA breakthrough designation for hemophilia drug Additional data demands delay Biomarin's hemophilia drug submission in USSnipr Biome hopes to raise up to USD 80m this yearOrphazyme CEO on sale: "It’s sad, but we tried everything"Zealand Pharma issues almost USD 40m in sharesNew chief medical officer will help shape the EMA's public imageSnipr Biome fights to regain five US patents Coloplast chair joins Danish gender equality think tankZealand Pharma promotes medical advisor to chief medical officerLeo Pharma consolidates global commercial organization, reducing overall unit count Wegovy celebrates first birthday with subdued cheersArtificial intelligence identified eight in ten skin cancer cases in studyNovo's once-weekly insulin hope on par with daily injections, phase III trials showDanish scientists succeed where Theranos fraudster failedALK's new manager to kickstart tablet sales in UK and Ireland Top news from MedWatch this weekUSA reports 21 confirmed monkeypox cases – global total surpasses 700Canada places USD 56m monkeypox vaccine order at Bavarian NordicZealand Pharma obesity drug continues to phase IIEli Lilly squares up to Novo Nordisk on obesity marketStolen Novartis data up for saleAmbu recalls single-use product one year after launchBavarian Nordic eyes opportunities in huge pox vaccine stockpilesEli Lilly share price boosted by obesity data for diabetes treatmentGeneral Manager of Novo Nordisk in Denmark to move to Japan Danish Supreme Court upholds Spinraza decision, denies compensation claimsFDA expands Dupixent indication, EU application to followOrphazyme reports USD 90m deficit for 2021Lundbeck shareholders approve new equity structureInfluencer collaborations common in hearing aid industryOrphazyme burned through millions of dollars in futile fight for successMC2 Therapeutics chief medical officer to step down, will be replaced by Chief PhysicianProfessor claims Eli Lilly's tirzepatide could essentially eradicate type 2 diabetesLong Covid may cause diabetes and hypertension, South African insurer saysGenmab launches new case against Janssen, demands compensation and royaltiesEmployee perception of leadership harms image at three prominent life science firmsGSK reports positive RSV vaccine dataSydbank analyst: GSK news could help Bavarian Nordic in partner huntBavarian Nordic upgrades guidance for third time in three weeksNew arbitration full of upsides for Genmab, says analystBavarian Nordic may well upgrade again, says Sydbank analystTop news from MedWatch this weekBavarian head of investor relations celebrates competitor's breakthroughNovo Nordisk reports positive weekly growth hormone data Bavarian Nordic says more upgrades could be on the wayGenmab presents full data set for cancer drug Denmark calls for fair treatment of Novo Nordisk as US eyes insulin price capNew Ambu CEO might have to hunt for more capital, says mediaSmall steps for Demant and Sivantos at Veterans Affairs in May – GN, Sonova lose outAnalyst: Genmab cancer data is promising compared to rivalEMA committee recommends market withdrawal of obesity drugDemant acquires remaining 80% of Shengwang, completing acquisitionModerna on general manager hunt in DenmarkEU orders 110,000 monkeypox vaccine doses for member statesBavarian Nordic upgrades for the fourth time in four weeks following EU monkeypox contractData issue put Leo Pharma in the Danish Medicines Agency's crosshairs in 2021Bavarian stock price drops despite guidance upgrade and EU monkeypox vaccine orderVoxzogo demonstrates positive results for infants with dwarfismBavarian Nordic CFO: More monkeypox orders may followBiomedical Alliance Europe warns of potential medical device shortageOlympus R&D and manufacturing sites in Japan run on renewable energyAlmirall aims to improve psoriasis patients' mental well-being with digital solutionLundbeck head of R&D: "We have cleared the way for opportunity"New share split beefs up acquisition power, says Lundbeck EVPAmbu's stock hits lowest price in five yearsModerna on booster race: May the best data winThe Lancet publishes Lundbeck Vyepti study Drugmakers aim to curb release of antibiotic waste into the environmentInteracoustics lands another record resultBavarian Nordic updates phase III booster study plans, sets launch for AugustAnalyst: Bavarian's new study design ensures smooth processLeo Pharma partners with Vipergen on dermatology drug discovery Novo Nordisk reshuffles global general managersBavarian wants a more reliable, less cumbersome booster studyRoche Diagnostics and Nordic Bioscience strengthen biomarker partnershipBavarian Nordic’s monkeypox shot is making it a hot stock againLundbeck lawyer says pharma is fighting over legal talentTop news from MedWatch this weekGenmab to buy back 370,000 sharesMSD eyeing Seagen acquisition, media reportsNHS launches antibiotic subscription scheme to fight superbugsQufora lifts long-term goals despite supply challengesPfizer invests in Valneva, updates agreement on Lyme disease vaccineNovo Nordisk joins top ten of most profitable pharma firms worldwideOrphazyme ADS holders given July deadlineDanish committee does not recommend reimbursement for Novo Nordisk's WegovyCEO describes global biotech downswing as Category 5 hurricaneEU opens antitrust investigation into Vifor Pharma for trashing rival PharmacosmosSonion wins copycat case against Sony and HuaweiFormer Vifor Pharma CEO had no knowledge of alleged Pharmacosmos smear campaignVifor Pharma denies having spread false information about PharmacosmosZealand Pharma enters AI partnership with Iktos The future of hearing consultations could be digital, pilot program suggests"We have suffered a significant financial loss as a consequence of Vifor's conduct," says PharmacosmosUK to widen vaccine offer to help control monkeypox spreadAnalyst: New UK monkeypox strategy might boost Bavarian Nordic ordersNovo Nordisk and Echosens partner up to develop diagnostics for "silent disease" Drug sales outweighed pandemic impact on Janssen Denmark's 2021 report Epidemiologist calls Pfizer's corona pill a "game changer"Pfizer makes good on promise to donate Russian profits to UkraineUS Senators introduce bill to cap insulin prices Hearing aid sales beat pre-pandemic levels in 2021GSK to invest USD 1.2bn in infectious disease battleWHO considers emergency classification for monkeypoxTakeda Pharma denied general conditional reimbursement in DenmarkCDC wants children to have access to monkeypox vaccineEvaxion Biotech's lung cancer candidate ready for clinicNovavax vaccine recommended for approval for EU teenagersBiontech wants to save the world by developing drugs without clear commercial potentialNovo Nordisk starts recruitment for combination trial of semaglutide and Astrazeneca tabletCHMP has approved nine medications during June Lundbeck to prepare FDA filing based on promising Alzheimer's dataLundbeck to utilize fast-track status in Alzheimer's drug dialog with FDANovo Nordisk and Leo Pharma seek permission to use oilBavarian Nordic was late to the vaccine party – but don't count them out just yetALK to start phase I trial of peanut allergy tablet vaccineWHO decides against calling monkeypox a global health emergencyLundbeck still looking for acquisitions despite positive Alzheimer's dataNovo Nordisk drags competitor to court over Saxenda copiesALK expects to have approved peanut allergy vaccine in 2030EMA awards priority status to Bavarian Nordic's RSV vaccine for the over-60sAudientes applies to switch exchangesBavarian Nordic CEO shows no mercy to competitors as firm continues partner hunt: "If they fail, the value of our program increases"Leo Pharma appoints experienced Swedish national to boardEMA starts assessment of Bavarian Nordic's monkeypox vaccineStallergenes slapped with injunction US authorities expand monkeypox vaccine plan Eargo raises USD 100m from investment firmFruergaard leveraging experience from Danish partnerships in key roles in BrusselsOverview: Pharma giants and Bavarian Nordic fight over billion-dollar vaccine marketLeo Pharma eczema treatment recommended in two UK countriesJanssen awarded breakthrough therapy designation for Genmab bone marrow cancer drugSanofi reduces US insulin prices for the uninsuredFujifilm invests USD 1.5bn in Danish factoryLundbeck Foundation brings in experienced player to implement investment strategyLife science firms are planning USD 6.3bn construction spree in DenmarkNovo Holdings portfolio company sold to US buyerBavarian Nordic is working with EMA on monkeypox vaccine label expansionGenmab to submit cancer candidate epcoritamab to the FDA before year-endNovo Nordisk denied general conditional reimbursement for Wegovy in Denmark – againEvaxion picks gonorrhea as second target for vaccine candidateColoplast's climate goals approved by international initiativeNovo Nordisk Foundation establishes Danish Diabetes and Endocrine AcademyTop news from MedWatch this weekBavarian Nordic to supply US with additional 2.5 million monkeypox vaccinesCovid vaccine race lights fire under GSK boss as RSV battle intensifiesOrifarm reports progress on top lineFertin Pharma's bottom line suffers as bonuses and postponed product launches biteRegulators agree on Covid-19 vaccination adaptation planSanofi launches nonprofit brandDemant lands loan agreement with investment bankFormer Bioporto CEO to lead board of medtech firmNovo Nordisk will pay abortion-related travel costs for US employeesAstrazeneca acquires biotech firm for up to USD 1.3bnFDA gives new Biogen Alzheimer's treatment priority statusLeo Pharma to withdraw from a quarter of its marketsLundbeck Foundation makes hire for new investment departmentBeijing rolls out China’s first ever Covid vaccine mandateMSD getting closer to USD 40bn acquisition of Seagen, media reportsPharma industry keeps wary eye on huge EU policy revisionRoche awarded priority review status for Genmab drug rivalLundbeck and WSA follow Novo Nordisk's lead – will pay abortion-related travel costs for US employeesOrphazyme co-founder becomes board chair at biotech startupNovavax triumphs on US stock exchange despite lack of FDA approvalBeijing scraps China’s first vaccine mandate in abrupt reversalMedtech firm to test whether hospital textiles can be reusedEllab continues acquisition spree with Dutch targetTop news from MedWatch this weekCalifornia's insulin initiative is an ill-conceived idea, says analystNovo CEO spies new pricing model in EUÖssur brings in new Teva veteran as CFO Novo Nordisk to test diabetes tablet against Eli Lilly drug Novo Nordisk's hemophilia drug shows potential as once-monthly treatmentLeo Pharma pulls the plug on Leo Innovation LabDanish life science firms boosted by currency tailwindFather hands over Pharmacosmos reins to sonDiamyd Medical meets study goal with diabetes vaccineOrexo starts clinical study of nasal rescue medication – challenging established market Chemometec CEO's wife convicted of insider tradingThink tank predicts life science sector role to grow as EU struggles to stay innovativeOrion enters partnership with MSD, upgrades guidanceAnalyst forecasts potential Novo Nordisk upgrade in strong second quarter outlook European Dermatology Forum recommends Leo Pharma drug in line with other biologicsY-mabs enters clinic with new cancer candidateNovavax’s Covid-19 vaccine gets US nod as latest pandemic weaponNovo Nordisk Korea faces potential strike as employees protest failed salary talksNovo Nordisk's Wegovy earns B+ from US nonprofit research organizationInfosys inks EUR 110m deal to acquire Base life science WHO to reconsider monkeypox outbreak as global health emergency Novavax takes a beating on the stock exchange after FDA approval Pharmacosmos leadership passed down to third generation: "It's been in the cards"Rhovac CEO quits after failed studyMorgan Stanley raises Novo Nordisk stock rating to "overweight"Top news from MedWatch this weekIndustry association says Sweden ought to capitalize more on life science innovationNew US monkeypox vaccine order prompts Bavarian Nordic upgradeDemant, Sonova gain ground at Veterans Affairs in June – GN and Sivantos lag behindBavarian Nordic upgrades again following new batch of monkeypox contractsPila Pharma's drug hope receives special FDA statusVertex doubles down on diabetes – acquires firm and resumes stem cell studyAbbvie to submit Genmab-developed cancer drug for EMA approvalNovartis beats sales expectations for Genmab-developed KesimptaBavarian Nordic gets new order for 1.5 million monkeypox vaccine dosesLeo Pharma on leaving 22 markets: Freeing up resources enables us to invest in unmet drug needs Boehringer Ingelheim makes million-euro investment in fight against antibiotic resistanceJohnson & Johnson's Darzalex Q2 sales surpass projections Analyst sees limited potential for Genmab stock despite strong Darzalex performanceCowen lifts Bavarian Nordic to "outperform" after recent monkeypox vaccine orders Biomarin’s hemophilia gene therapy nears European market after US setbackWild week sends Bavarian Nordic's market value up millions of dollarsNovavax's Covid-19 vaccine backed by CDC expertsAudientes halves 2022 revenue goalWellington owns less than 5% of Genmab sharesRoche reports continued strong demand across portfolio in H1 2022Valneva plunges after Europe slashes Covid-19 vaccine orderRoche to reshuffle management and boardNestlé Health Science partners with Enterome to treat food allergies and bowel inflammationÖssur acknowledges difficult quarterCHMP officially recommends Bavarian Nordic's vaccine for monkeypox in EuropeAmazon to acquire One Medical in USD 3.5bn dealAudientes to launch new product in Q4LEGO owner invests USD 40m in skin treatments from fish skinBavarian Nordic expects imminent European monkeypox green lightCHMP gives Eli Lilly diabetes drug the nodTop news from MedWatch this weekCHMP approves 11 drugs at July meetingBavarian Nordic granted European approval of monkeypox vaccineNeedham lifts Bavarian Nordic's target stock price 13%WHO declares monkeypox global health emergencyAlmirall notes "good traction in Europe" for psoriasis cream WynzoraAnalyst: Bavarian Nordic continues hot streakBavarian Nordic considers 24-Hour emergency production of monkeypox shotFDA clears Ambu's new bronchoscope generationNeuromod launches device to help Danes living with tinnitusEMA appoints new chair of pediatric committeeDiabetes firm brings in additional USD 10m for phase III trialZealand Pharma hires head of regulatory affairsJanssen nears goal of moving patients to new version of Genmab's DarzalexGSK upgrades guidance Teva enters billion-dollar settlement in US opioid caseIndia in talks for monkeypox vaccine as global outbreak spreadsBoston Scientific exceeds most expectations in Q2BMS beats analysts' Q2 projections Bavarian Nordic vaccine filling facility approved by US and EUBiden administration is mulling over monkeypox budget as high as USD 7bnSanofi lifts forecast as blockbuster eczema drug gainsBavarian Nordic continues trading high for 12th consecutive day, value spikes USD 1.4bn Coloplast is phasing out natural gasTakeda's profit shrank in Q1GN head of media set to join Novo NordiskSmith & Nephew exits tough half yearAmplifon sales slightly disappoint in Q2 Organon enters partnerships with Danish upstart on non-hormonal contraceptionLeo Pharma will support abortion-related travel for US employeesAstrazeneca boosted as Covid-19 therapies offset vaccine dropEU to investigate container rates – expects results by New Year'sPfizer drops phase II-ready NASH candidateOlympus Innovation Fund's first investment is in endoscopy firmNovo Nordisk has twin successes with once-weekly insulinTop news from MedWatch this weekCosmo struggles to find EU partners for promising acne drugAGC Biologics intensifies hunt for new staff with launch of recruitment teamAlnylam plans to make potential obesity debut by targeting specific geneNovo Nordisk reels in Danish Medicines Agency department headCorona vaccine production makes for record year at AGC Biologics in DenmarkBavarian Nordic stock up 68% since mid-JulyAmbu's new bronchoscope opens the door to particularly demanding proceduresAnalyst ahead of H1 report: Strong momentum looks set to continue for Novo NordiskAmgen to fight USD 10bn tax bill Subcutaneous version of Roche's blockbuster cancer drug meets study goalsRSV candidate ready for phase I in success for Boston Children's Hospital and Danish researchersWellington owns almost 5% of Genmab sharesOrganon backing satisfies Danish startup's funding needs for a new non-hormonal contraceptiveDenmark to reconsider monkeypox vaccination strategy as case numbers riseWard 24/7 raises USD 2.5m despite capital market pressureAlnylam says heart disease drug meets goal in late-stage trialBavarian Nordic wins yet another monkeypox order from undisclosed countryModerna exceeds revenue expectations by over USD 700m Novo Nordisk upgrades despite sales and bottom line disappointments in Q2Ambu downgrades, will cut costsNovo Nordisk's obesity business doubles in size but still doesn't measure up to estimatesRybelsus sales disappoint while Ozempic surpasses expectations at Novo NordiskInvestors' speedy study hopes quashed as Novo Nordisk continues cardiovascular trialNovo Nordisk EVP still believes in cardiovascular benefits of WegovyWS Audiology establishes business unit for the AmericasEli Lilly downgrades after underwhelming report, though diabetes business advances ALK raises financial expectations one week before Q2 report drops Layoffs alleviate Ambu's need for more capitalNovo Nordisk CEO retains faith in obesity businessState of Illinois is investigating pricing of Novo Nordisk's diabetes productsMonkeypox is declared a US health emergency, freeing up fundingLundbeck CFO begins workNovo Nordisk can mitigate production consequences from potential gas stopAmbu layoffs will be spread across several countriesNovo Nordisk feels pressure of international conflictsAnalyst: Ambu's unsightly downgrade is tied to unmet growth expectationsGenmab and Biontech expand their partnership Lundbeck and partner present "slam-dunk" data for new Alzheimer's drugAnalyst: Eli Lilly's planned study comparing obesity effects with Novo Nordisk will grow the marketAmbu dampens hopes for proclaimed growth driverUnion Therapeutics begins phase IIb trial of eczema tabletSnipr secures important US patentPost-pandemic employee air travel clouds Novo Nordisk's climate reportGenmab upgrades 2022 guidanceZealand Pharma to delist in US Analyst: Genmab trading will be neutral despite strong growthOlympus continues to grow endoscope businessLundbeck's head of R&D to join board of e-health firm Brain+Eargo's sales plummet in troubled quarterFour new products will help Novo Nordisk division grow Lundbeck raises 2022 guidanceMSD diabetes drug found to contain possible carcinogenAmbu CEO wants to avoid further downgrades: "I've communicated what I'm confident we can deliver this year" New monkeypox shot technique to get emergency US approval to extend supplyY-mabs reports second quarter sales increase for cancer drugFormer CEO left Y-mabs with USD 10.7m in severance payZealand Pharma fined by Danish financial supervisory authorityGenmab beats expectations across the boardALK releases surprisingly strong quarterly figuresOrganizational expansion sends Genmab costs soaringAbbvie withdraws from cancer candidate collaboration with Genmab Novo turns to new factories to boost supply of obesity drugEurope will have to wait for Ascendis Pharma's weekly growth hormoneGN, Sonova advance with Veterans Affairs in July – Demant, WSA retreatALK fears politicians will force pharma industry to foot pandemic billAnalyst: Upgraded ALK sales guidance could still be beatenZealand Pharma's deficit grows in quarter with product divestmentGenmab says new arbitration builds on a straightforward questionGenmab to measure growth hope against bestsellerALK to exit Turkish market: "It's bad business if all we get is peanuts"Genmab postpones crucial cancer candidate decision following Abbvie exitUS biotech firm ramps up collaboration with Genmab after dropping drug candidateALK's tablet trial in Ukraine set to continueTop news from MedWatch this weekGenmab CEO: "We can do things in a smarter way than pharma companies"Denmark buys additional 10,000 monkeypox doses from Bavarian NordicAnalyst: Genmab's Darzalex income coming in faster than expectedGenmab CEO strives to maintain company culture as staff count grows to 1,500 Analyst identifies difficult growth conditions for Demant ahead of Q2 reportPfizer's new acquisition generates billions of dollars from migraine drugCutting monkeypox vaccine dosage is no easy fix, officials sayNovo Holdings silent on insider trading caseDemant downgrades after revenue disappointsSonova downgrades, blames high costs and weak results from key marketsAnalyst: Discouraging announcement from Sonova puts spotlight on GNAnalyst identifies some positive elements in Demant report despite downgradeGN Hearing launches new product platformGN Hearing to utilize pandemic experiences in new product launchUS downswing reflects shift in underlying demand, says Demant CEOAnalyst to hone in on Vyepti rollout and patient uptake in imminent Lundbeck reportDemant CEO highlights strong performance from Diagnostics, acknowledges Communications letdownDemant rejects criticisms of lobbying efforts against OTC channel: "That’s how America works"Key products generate strong Q2 result for LundbeckHearing aids to reach millions with FDA over-the-counter approvalNew GN product to solve challenges for hearing aid users, says CEODemant's divested hearing implant business was unprofitable in H1Eargo stock surged following OTC rules reveal
Vyepti study misfire makes for learning experience for LundbeckColoplast presents strong Q3 figuresTurbulent markets won't prevent Sonova's grand platform launchInvestors react to Lundbeck's failed Vyepti study, analyst says uncertainty has increasedBavarian Nordic pivots operations to focus on monkeypox vaccine productionGN Hearing downgrades organic growth forecastGN seeks OTC approval for flagship product Lundbeck sued in the US – againBavarian Nordic finds US partner for monkeypox vaccine productionDemant plans to increase investments in China GN Hearing wants to outperform restrained US market in H2GN downgrade "unsurprising" says analystColoplast has inflation concerns Novo Nordisk diabetes drug hit by supply issuesLeo Pharma appoints new CFOUS will start making Bavarian Nordic's monkeypox shotLundbeck gears up as Alzheimer's agitation approval looks attainable Coloplast's important growth market still curbed by the pandemicSonova acquires Chinese hearing clinics chainManufacturers mull over OTC options as Best Buy announces new hearing aid lineCochlear expects net profit advance for next yearGN Hearing predicts slow start for OTC marketTop news from MedWatch this weekGN Hearing, Sonova raise pricesLundbeck counts on continued strong growth for depression drugColoplast struggles to meet demand due to silicone shortagePharmacosmos gets nod to use natural gas alternativesColoplast raises prices to offset energy cost spikesChina's hard line on Covid-19 won't hinder GN Hearing – workers can isolate in factoriesEurope recommends cutting monkeypox vaccine dosage as cases riseSSI Diagnostica buys US-based diagnostics firmNovo Nordisk's combination drug for obesity and diabetes shows positive results, heads to phase IIISonova launches new product platformBioinnovation Institute provides million-euro loans to three start-upsUS contract manufacturer's Covid-19 vaccine success and facility expansion wooed Bavarian Nordic Novo Nordisk aims to learn more about obesity risk through new collaboration Curious pandemic effect spoiled ALK's late stage asthma study with childrenMonkeypox news will draw attention from upcoming Bavarian Nordic Q2 figures, says analystAnalyst: WS Audiology will weather storm better than competitors New Novo Nordisk treatment targets 25% weight loss Bavarian Nordic's reports revenue growth but books deficitBoard member leaves Bavarian Nordic due to potential conflict of interestBavarian Nordic's overlooked travel vaccines surprised positively in Q2, says analystPharma partner waiting game makes RSV candidate more valuable, says Bavarian CFOBavarian enters monkeypox supply deal with Latin America and the CaribbeanBavarian Nordic's RSV production takes a back seat to monkeypox shot: ”This is the responsibility we must shoulder"The hearing aid industry struggles but life science thrives WS Audiology's top line grows 11% in challenging quarter – guidance maintainedAmbu confirms preliminary figures for Q3 – operating profit drops below expectationsAmbu's Q3 endoscope sales went up 4%Leo Pharma drags atopic eczema tablet through another phase I studyNovo Nordisk disavows off-label use of blockbuster after supply shortage Ambu CEO: Strong US dollar revenue boost will continueAmbu fires 50 employees in DenmarkWS Audiology restructures to make big break in AmericasPfizer to submit RSV vaccine for FDA approval in fallALK CEO sells over 130,000 sharesWSA holds off on new product platform – still sees potential in existing lineNew Bavarian Nordic cancer vaccine hints at bright futureAnalyst: New Bavarian Nordic initiatives reflect soaring monkeypox vaccine demandOrphazyme buyer intends to resubmit failed drug candidate for FDA approvalBavarian Nordic: "We are ready to buy more vaccines"Audientes books first-ever revenue in H1 but is still far off full-year expectation Moderna says it’s suing Pfizer, Biontech over Covid-19 shotsTop news from MedWatch this weekWSA is not yet committed to OTC – but has FDA-approved device readyMerck loses interest in SeagenThe US has enough monkeypox vaccines to administer two doses to high-risk groupAmbu CEO: "That is why we are market leaders"Olympus divests optics division for USD 3bnAlgeria criticizes Novo Nordisk over insulin supplies and slow collaborationAngry investors sue Enochian Biosciences and ownerAmbu CEO buys over 40,000 company sharesNovo Nordisk exits licensing agreement for Aeterna Zenataris productBavarian Nordic's CDMO receives USD 11m in state financingNovo Holdings invests USD 50m in South Asian genome companyGN has yet to feel impact of new Chinese lockdownsUSA prepared to provide USD 680m for monkeypox drugFDA speeds up assessment of Sobi-Sanofi hemophilia drug Teva initiates phase III trial of long-acting schizophrenia injection Delayed phase III study caused Novo Nordisk to exit hormone test contract Astrazeneca CEO questions more booster shots for young peopleLeo Pharma appoints new board member Novo Nordisk to start human trial of new diabetes drugIsrael approves Y-mabs cancer drug Bavarian Nordic concerned over monkeypox dose splitting: "There is very, very limited data"Coloplast advances its long-term strategy despite challenges on many frontsAscendis Pharma submits candidate for US market approvalColoplast's next acquisition will likely target a product or technology, CEO saysNovo Nordisk enters USD 6.3m legal settlement in USColoplast has contingency plans for difficult business environmentDenmark's largest pension fund divests all Lundbeck sharesChina growth levels are the thorn in Coloplast's side, CEO revealsNovo Nordisk to acquire Forma Therapeutics in USD 1.1bn dealNovo rare disease lead hails acquired candidate as "significant addition" to portfolioStudy of Bavarian Nordic's monkeypox vaccine raises questions about protectionATP says Lundbeck share split was "a step in the wrong direction" following divestmentNovo Nordisk believes sickle cell anemia market will double in value by decade endColoplast to take quantum leap in core markets with new high-tech productsLundbeck leads list of highest paid CEOs in DenmarkTop news from MedWatch this weekBavarian Nordic has initiated phase III of Covid-19 boosterAmbu CEO wants more women in leadershipDenmark passes on four new medicines, recommends twoMC2 Therapeutics breakthrough unleashes new skin treatment potentialWS Audiology closes factory, lets 189 employees goY-mabs schedules FDA meeting on delayed cancer drug for OctoberDemant establishes innovation unit in Kuala LumpurLeo Pharma's energy contingency plan approvedBoehringer Ingelheim enters dermatology marketEvaxion approaches crossroads in gonorrhea vaccine developmentDanish company developing skin cancer detection app secures fundingEU blocks Illumina acquisition of GrailGSK wins WHO seal of approval for malaria vaccineNovo Nordisk licenses hypoglycemia drug from Zealand PharmaColoplast has a cost problem, says EVP of global operationsBavarian Nordic raises expectations after another EU monkeypox vaccine orderAnalyst: Zegalogue launch should be "plug and play" for Novo NordiskZealand CEO: Novo Nordisk is "the perfect partner" to market rescue penDanish Crown nominates Novo Nordisk exec as vice chairZealand Pharma intensifies partner hunt for other drug candidatesNine startups and two Novo Nordisk projects join Bioinnovation Institute programLeo Pharma CEO: "The strategy has started to crystalize and yield a return"Coloplast veteran appointed CEO of Neuspera MedicalLeo Pharma leaves the door open for acquisitionsNew Danish hospital tender includes sustainable packaging requirement Researchers suggest Covid-19 boosters could become obsoleteModerna sees annual US market for Covid-19 shots ranging up to USD 13bnBank lowers Lundbeck's predicted chance of success in Alzheimer's agitation indicationNovo Nordisk exec joins board of ArgenxNovo Nordisk to launch cheaper version of long-acting insulin in USColoplast's new factories in Costa Rica will increase salary savings and reduce climate footprintDenmark must play role in EU reference lab endgame, says chamber of commerceTop news from MedWatch this weekFormer Ambu employee stands trial for alleged insider trading Novo's insulin pen return system launched successfullyA promotion leaves Biogen to hunt for new general manager in DenmarkGN Group's staggering debt concerns investorsColoplast leads Danish life science industry on ESG reportingTeva presents positive migraine drug resultsNovo Nordisk and Microsoft to collaborate on drug development using AIBristol Myers Squibb's plaque psoriasis drug receives FDA approvalEU watchdog criticizes European vaccine procurement, urges stronger negotiations in futureWSA and Sony enter OTC partnershipJefferies raises Genmab price target as faith in cancer candidate growsNovo Nordisk says Microsoft partnership does more than cut costsBarclays analysis leaves Demant and GN Hearing out in the coldAnalyst sees logic in WSA and Sony partnership, but lacks faith in OTC market Novo Nordisk brings forward salary regulations for 50,000 employees due to increasing inflationWS Audiology wants to benefit from Sony's brand and consumer trustAnalysts: Novo Nordisk's Wegovy relaunch must go smoothly MC2 Therapeutics turns back on eye treatment to focus on skinSonova wins big with Veterans Affairs in August, as Danish manufacturers all dropJohnson & Johnson announces USD 5bn share buybackPfizer initiates phase III of influenza vaccine candidateGlobal pharma firms waver on Japan due to drug pricing and regulationNovo Nordisk Pharmatech wants option to switch away from natural gasEmployment researcher: Novo Nordisk salary advances are part of retention strategyTop US business group warns of Congress failure on R&D tax perkAltimmune meets NASH goal in phase I Sensorion initiates study of hearing loss therapy candidateNovo Nordisk says US Inflation Reduction Act will hurt innovationCredit Suisse: Lundbeck stock is cheaper than the pharmaceutical industry averageEli Lilly boasts of high demand for new diabetes drugMonkeypox on decline in USSanofi-Astrazeneca preventive RSV drug recommended for approval by CHMP Advanced Bionics Denmark increases bottom line almost tenfoldCHMP supports label extension of Leo Pharma's atopic eczema treatmentCHMP recommends approval of 12 drugs at September meetingTop news from MedWatch this weekNew Boehringer Ingelheim general manager in Denmark wants to draw on experiences from ChinaSecond half of Zealand Pharma's congenital hyperinsulinism study data revealed at conferenceEMA backs standard approval of two Covid-19 vaccinesWHO advises against Regeneron and GSK Covid-19 treatmentsGN Group stock is under pressure, says analystZealand Pharma sued over misusing trade secretsAmbu will be well positioned under potential Chinese ban on foreign medical equipmentFormer Ambu employee fined for "negligent insider trading"Audientes has first day of trading on Spotlight exchangeLundbeck ties bank loans to sustainability targetsBavarian Nordic wins decade-long contract with CanadaOrphazyme falls back into old habits – delays reportAnalyst predicts more monkeypox orders as Bavarian Nordic enjoys trading surgeNovo Nordisk faces potential impact of new US legislationBavarian Nordic appoints board observer intended to take chairmanship MedWatch gets new Norwegian sister media Bavarian Nordic mulls over expanding monkeypox vaccine production with partners FDA warns of insulin pump hacking risk CHMP insists that generic drugs be market removed after fake trialsPharmacosmos drug beats competition as EU investigation into alleged slanderer Vifor continuesZealand Pharma will have crucial data ready in few weeksNovo Nordisk hopes to begin approval process of once-weekly insulin in H1 2023Clock is ticking on post-Brexit UK medical equipment lawsBavarian Nordic's Covid-19 vaccine data has been delayedAlmirall starts human trials of skin treatmentThe future of migraine treatments belongs to CGRP drugs, says professorNovo Nordisk expects phase III data for diabetes app imminentlyBavarian Nordic's Covid-19 vaccine has difficult journey aheadEli Lilly's Mounjaro could become one of the world's biggest drugs ever FDA halts DBV's peanut allergy trialCovid-19 infection linked to more type 1 diabetes in kids and teensNovartis eyes double blockbuster potential for Genmab-developed drugColoplast lacks overview of suppliers' gas dependenceTop news from MedWatch this weekEnochian chair on co-founder's murder for hire charge: "It is deeply shocking"Pfizer resumes hemophilia study after nearly yearlong pausePharmacosmos expects massive growth in four yearsThe Lundbeck Foundation, ATP, LEGO asset manager join forces on secretive projectWS Audiology brings in head of EMEA region from ColoplastDupixent could dominate pediatric eczema market for up to a decade, analysis findsFDA advisors support approval for Ferring's intestinal infection medicineLundbeck foundation, LEGO family office and ATP project revealed as trio acquire Ferrosan Medical Devices Danish life science is turning down the heat – literallyNMD Pharma gets FDA orphan drug designation Ferrosan's financials could have motivated Lundbeck and partners' new investmentContera Pharma enters partnership with Vernalis Research on undisclosed diseaseGenmab-partner Seagen strikes deal on Chinese rights for TivdakY-mabs partner seeks launch of cancer drug in BrazilAlzheimer’s progression slowed by drug in major trialAmericans on Medicare to pay lower premiums after spending overestimatedDenmark rejects Sobi's blood disease medicine due to "unreasonably high" priceBiogen and Eisai to seek regulatory approval for Alzheimer's medicineDenmark proposes 6 initiatives to lower drug prices – met with skepticism by industry associationInvestors lose faith in GN Group, send stock price plummetingNovo Nordisk and Novartis will participate in large Danish project on decentralized clinical trialsNovo Nordisk Foundation becomes bigger sponsor of state researchEisai and Biogen's Alzheimer's success leaves many questions still unansweredBill & Melinda Gates Foundation grants USD 128m to Pfizer for RSV and GBS vaccinesRussian employees at Novo Nordisk and Coloplast have not been drafted for warNovo Nordisk inks multimillion-dollar deal with Ventus TherapeuticsAlmirall enters deal with Simcere on candidate ready for clinicBavarian Nordic's vaccine against smallpox and monkeypox appears to be workingIndigo Diabetes sends diabetes device to clinicLarge block of Genmab shares up for sale in USNovo advances third business leg with Ventus deal, says analystAllergy Therapeutics secures funding for clinical testing of peanut and grass allergies vaccinesOctagon Therapeutics graduates from pilot project to research alliance with Novo NordiskBiomarin resubmits rejected hemophilia medicine in USTop news from MedWatch this weekThe Lundbeck Foundation eyes Ferrosan IPO in 5 years Bavarian signs more monkeypox vaccine deals in Latin AmericaNew Lundbeck Foundation investment is first taste of changed strategyAnalysts predict Zealand Pharma's future holds a partnership – or perhaps even an acquisitionNovo Nordisk's Rybelsus hasn't lived up to expectations, say analysts Bank hails Zealand Pharma's data as "home run"Novo Nordisk nails another phase III study of once-weekly insulin Genmab enters antibody commercialization agreement with Oxford BiotherapeuticsInvestors fear share emission from debt-heavy GN Eli Lilly and Biograil join forces in easy-to-swallow partnershipEFPIA calls for US-like voucher system to boost European antibiotic researchDenmark gives four cancer drugs the thumbs-downIndustry veteran assumes chief commercial officer role at Novo Nordisk PharmatechAnalyst deems Novo Nordisk once-weekly insulin has blockbuster potentialNordic venture capital firms expand to listed biotechs in hunt for bargainsGoogle to utilize Cloud potential to strengthen AI diagnosesZealand Pharma sells shares for over USD 100mZealand Pharma CEO: Share sale arms us for partnership negotiationsAudientes builds on Q2 momentum, maintains guidanceThree scientists share chemistry Nobel for cancer improvement technology breakthroughComplete company divestment is not part of Zealand Pharma's strategyDexcom rolls out new glucose monitor in EuropeJefferies spots weaknesses in GNMultimillion-dollar prices for gene therapies are fair, Vertex CEO saysLife science CEOs' paychecks decrease as markets declineFujifilm doubles bottom line in annual reportFDA fast-tracks Eli Lilly's obesity candidateBavarian initiates new arm of phase III Covid-19 vaccine trialNovo Nordisk Foundation donation to send Danish STEM students to Silicon ValleyColoplast launches pelvic organ prolapse productEMA re-elects chair of pediatric research committeeWin-win or naivete? – Snipr Biome to spill its secretsGenmab has a worthy successor to Darzalex, bank saysBank of America prefers Sonova to GN and DemantTop news from MedWatch this weekFerring moves into new Danish headquartersAmbu's endoscope business would have worked out without Invendo acquisition, CEO saysFujifilm loses contract partner NovavaxBiomarin axes 4% of global workforceEnochian believes in victory in former CFO's wrongful termination lawsuit Ambu wants to tighten focus under renewed strategyDupixent might halt "the atopic march," research findsFrench Biocorp enters smart pen partnership with MerckSonova eyes bright future despite gloomy marketsSonova CEO had hoped for a "less dynamic" post-pandemic periodSeventure Partners invests EUR 10m in Clinical Microbiomics EU Commission accuses Teva of breaking antitrust lawsFilm star's foundation grants Muna Therapeutics USD 4.9mNovo Nordisk targets combined launch of insulin app and once-weekly insulinPfizer denies texting missteps in negotiating Covid-19 contracts with EUConsumers have not pivoted to cheaper alternatives, Sonova CEO saysSonova is testing new model for raising listing prices Sonova in talks about rechargeability issues with large customerOlder diabetes drugs linked to reduced dementia risk in studyInternational hearing conference to focus on new products in troubling timesSonova remains unconvinced about OTC viabilityGN Hearing has launched new product platform in some European countriesStarkey appoints three operational leadership positionsAmbu begins production in new Mexico plant WS Audiology boss: Strong brand and good prices are a good framework for OTCDemant on the sidelines until OTC proves its worthSony and WSA launch their first OTC hearing aidsGSK boasts 83% efficacy for RSV vaccine candidateDemant's top-line growth in line with outlook, Jefferies assessesGN Hearing is ready to launch OTC hybrid hearing deviceDemant takes the temperature of the hearing aid marketGN Hearing CEO: Worldwide hearing market is steady or slightly decliningGN Hearing CEO: Confidence is affected when you don't perform as expectedGN Hearing "satisfied" with brand presence at Costco, sees benefits of rumored new supplier openingGN Hearing has an OTC head start, CEO saysGN Hearing's new product platform in line with predecessor, Jefferies assesses Read MedWatch's coverage of the EUHA conference Bank needs to see improved GN Group cash flow in fourth quarterWSA CEO: Consumers are taking longer to decide – but there is no crisisCHMP recommends approval of 10 drugs at October meetingTop news from MedWatch this weekBavarian Nordic receives Swiss order for 100,000 monkeypox dosesNovo Nordisk completes Forma Therapeutics acquisitionGenetically modified humanized minipigs could be used in therapeutic antibody testingBavarian Nordic's Covid-19 booster excels in six-month follow-up studyEU prosecutor’s office opens investigation into Union's vaccine procurement Bavarian's booster shot ticks off crucial competition criterion, says analystNovo Nordisk and Danish university make insulin discoveryFDA delays decision on Biogen ALS drugRoche disappoints with sales below expectationsJefferies concerned over Lundbeck share saleRoche CEO cautious on Alzheimer’s trial despite Eisai’s successNew Lundbeck study of depression drug meets endpointCredit Suisse gives GN thumbs-up, Demant thumbs-downNovo Nordisk expands phase III program of obesity tablet treatmentJ&J third-quarter Darzalex sales exceed expectationsEli Lilly to acquire developer of hearing loss gene therapy for up to USD 610mALK expands Danish headquartersEmbark Biotech receives grant, bringing new obesity candidate closer to human trialsLundbeck CEO has no current capital raising plans Report criticizes insulin giants for unequal access to medicinesHearing manufacturers react to Eli Lilly's hearing therapy forayDanish manufacturer will help make lickable diabetes testNovo Nordisk and Eli Lilly struggle to supply sought-after drugsNovavax Covid-19 booster wins US emergency authorizationNovo, Sanofi, Merck and Novartis sign animal welfare declaration Lundbeck CEO acknowledges investor frustration over share splitAmgen hails cost-saving effect of biosimilarsFDA concludes study of Coloplast's transvaginal mesh, upholds banChina’s monkeypox shot will target the actual virusLeo Pharma's label extension wish granted Leo Pharma lets several US employees goBill & Melinda Gates Foundation and Bayer to develop non-hormonal contraceptionAbbvie acquires DJS Antibodies Boost Pharma receives another FDA special designationOlympus names next CEOTop news from MedWatch this weekPfizer to quadruple Covid-19 vaccine price in USNovo Nordisk to warm Danish homes with excess heat from factoriesGSK takes step toward RSV approval in JapanDragonfly Therapeutics exits DenmarkCoegin Pharma establishes new cancer company in Norway, appoints CEONasdaq warns Enochian over missing annual reportTakeda signs licensing agreement on celiac candidate US pharma firms have ramped up lobbying in 2022Investors fleeing indebted GN Group, media saysGenmab-developed drug nears blockbuster win as Novartis sees 172% sales boostBavarian Nordic's Covid-19 booster candidate to be tested on 3,000 volunteersMedtronic to spin off patient-monitoring, lung-treatment unitsBiogen upgrades financial expectations due to solid third quarterRoche to close Danish research center with 60 workersFDA approves another drug from the Janssen-Genmab partnershipInsulin pen company raises EUR 2.5mNovo Nordisk supplier gets another FDA warningSwedish diabetes research to be launched into spaceAnalyst: New Genmab-developed cancer drug has blockbuster potentialAmplifon beats expectations in Q3Boston Scientific's bottom line halved in Q3 Novo Nordisk expands smart pen partnership with Biocorp, prepares launch in Japan Genmab secures global rights to Scancell antibodyBank spots risk for slower Novo Nordisk restoration of Wegovy supplyFujifilm Diosynth Biotechnologies to produce Argenx antibodyGN can handle debts in 2023, says bankTakeda raises sales expectations for Lundbeck antidepressant MSD upgrades after Q3 sales fared better than expectedEli Lilly's sales of new diabetes drug off to good startFDA raises questions about Y-Mabs's children's cancer candidateDanish life science reacts to closure of Roche research center – lost out to worthy competitorYear-to date Dupixent sales surpass all of 2021Almirall has great European expectations for eczema candidateDenmark approves wider use of Dupixent for severe asthma in childrenGenmab and Abbvie submit new cancer drug for FDA and EMA approvalTop news from MedWatch this weekPfizer investigated for billion-dollar tax fraudLundbeck CEO calls for permanent R&D tax deduction and better access to skilled laborY-mabs suffers 16-0 defeat at FDA voteAscendis Pharma to start phase IIb trial of dwarfism candidateCanada approves indication expansion for Novo Nordisk hemophilia drug Nuheara and HP collaboration hearing aid approved for OTC channelEU politicians summon Pfizer CEO again after no-showFDA sets deadline for Ascendis Pharma drug decisionNovo Nordisk's best-selling diabetes drug expected to have soared in Q3Swedish bank raises expectations for Novo NordiskALK to take short-term blows from price squeezing and potential recession, says bankEli Lilly downgrades earnings per share and revenue expectations Pfizer’s experimental vaccine for mothers prevents severe RSV in infants in trialEli Lilly surprises with Mounjaro Q3 salesAnalyst on Lilly's diabetes hope: "An extremely strong start"Eli Lilly eyes unprecedented demand for MounjaroDemant downgrades guidance and prepares to fire staffNovo Nordisk upgrades guidance after sales increaseNovo Nordisk's year-to-date obesity drug sales exceed 2021 levelsAnalyst highlights strong top-line growth and Wegovy update in Novo ReportNovo Nordisk on track to secure Wegovy dosesNovo Nordisk's rare disease segment boosted by hemophilia treatments in Q3Potential obesity candidate dropped by Novo despite phase I successNovo Nordisk CEO: lessons have been learned from problem-plagued launch Ozempic is in short supply on most markets, says Novo NordiskFDA to review Novo Nordisk drug for rare metabolic diseaseDemant's cost-cutting efforts reflect cautious approach to 2023Demant misjudged resilience of US hearing aid market during crisisGN Hearing reports zero growth in Q3GSK's RSV vaccine candidate wins FDA priority review statusDemant's divestment of implant business drags outNovo Nordisk testing weekly diabetes tablet in phase IDemant owner increases GN stakeNovo Holdings acquires US-based home infusion therapy firmNovo Nordisk shot helps teens lose weight, new study findsGN Hearing has a long way to go to reach guidance Genmab upgrades guidanceNovo Nordisk and six peers make joint emission reduction pledgeDemant owner continues buying GN stock, now owns 10% Ambu seeking to nominate founder's heir for board seatAnalyst spots strong figures behind Genmab upgradeAnalyst: "Important to distinguish between William Demant Invest and Demant"Coloplast's guidance for next year features prominently in analyst's expectationsDemant owner's GN investment could draw attention of competition authority, says law professorTop news from MedWatch this weekMigraine firm enters clinic on back of million-dollar investmentNovo Nordisk stresses importance of keeping production going during an energy crisisNovo Nordisk shelved obesity treatment candidate due to inadequate dataBoehringer Ingelheim presents late-stage data for chronic kidney disease treatmentEuropean Research Council elects two new vice presidentsBiogen and Eisai's Alzheimer's success strengthens Novo's belief in approachColoplast expects 28–30% operating margin in 2022/2023Coloplast enters new market through distribution dealColoplast playing it safe with new guidance due to inflationJyske Bank: Coloplast's 2022/2023 prognosis is rather weakGN rebrands US acquisition Coloplast CEO says no sign of recovery in ChinaIs William Demant Invest seeking hostile takeover of GN? Three scenarios in playLundbeck upgrades annual guidanceLundbeck's key products exceed expectationsBavarian Nordic's Q3 revenue exceeds DKK 1bnDeborah Dunsire after upgrade of guidance: Lundbeck has efficiently returnedNouveau riche Bavarian Nordic to grow "slightly thin" pipeline Bavarian Nordic hopes to break even this yearBritt Meelby Jensen: Ambu must adjust itselfGenmab cancer drug incomes surpass USD 400m in Q3Genmab has two potential blockbusters up its sleeveGenmab CFO: Q3 results are impressive given investments made Bavarian Nordic CFO: 15-20% of RSV market would be "very attractive"ALK raises minimum full-year sales guidance after Q3Genmab expects important comparison study data next yearPfizer expands EU supply dealsNovo Nordisk and Abbott launch digital integration service for smart insulin pensALK CEO denies tablet business is in crisis despite lowered expectationsGN maintains expectations, reports of warm welcome for new platformZealand Pharma CEO has high hopes for obesity candidateColoplast to establish solar farm to cover firm's electricity needs in DenmarkGN doesn't think Demant wants a seat at board tableStrong reception of new platform puts GN Hearing on track to meet guidanceGN chair would be unable to block a potential acquisitionCHMP recommends approval of four drugs at November meetingTop news from MedWatch this weekSonova downgrades to lower end of guidance after difficult quarterRoche says Alzheimer’s trials failed in disappointment for fieldGN Hearing CEO denies debt challengesCostco contract unlikely to be renewed, Sonova hintsGN chair welcomes William Demant InvestPhony pharma tweet unleashes chaos – Eli Lilly, Novo Nordisk, and Sanofi stocks take hitsEMA holds its ground – certain obesity drugs must be removed from market Analyst will look for strategic measures and new outlook in Ambu's annual reportAmbu plans transformation, targets 5–8% growth in 2022/2023Novo Nordisk suspends Twitter advertisingSonova keeps options open for potential Costco contractAudientes facing headwinds, lowers sales outlook Coloplast stocks up on supplies for potential gas crisisAmbu eyes return to double-digit growth with fewer launchesFormer Ambu CEO received millions of kroner in severance payAscendis Pharma submits drug candidate for European market approvalAmbu CEO heralds transition year after "too optimistic" past predictionsAnalyst sees positive elements in new Ambu strategy, though guidance disappointsGN chairman unsure about his board futureFerring Pharmaceuticals and Gubra to collaborate on inflammatory bowel diseaseAmbu maintains investment level for R&D despite narrower focus US Inflation Reduction Act makes pharma market less attractive, says Novo CEOColoplast finds new president for Interventional Urology in own ranksNovo Nordisk potentially facing tough competition from Amgen's obesity candidateAmbu halves pipeline to put quality over quantityFDA emergency authorizes Roche's monkeypox testNew long-term ambitions will be defined at later date, says Ambu CEO Vtv Therapeutics to start crucial trial of oral diabetes treatment in 2023US pharma industry urges official action against antimicrobial resistanceGenmab COO appointed to board of influential biotech associationBavarian Nordic predicts vaccine sales will double in 2023Lundbeck loses head of US organizationGE Healthcare invests USD 80m in expanding Norwegian facilityAbena in sustainability drive to make up for single-use productsColoplast testing preventative silicone bedsore dressingsDrug-resistant infections kill 35,000 people a year in EuropeBavarian Nordic enters EU joint procurement deal for monkeypox dosesBank identifies rising costs for Lundbeck, lowers share price targetWHO drafts pandemic accord including compulsory transparency in pharma contractsFDA approves former Eli Lilly candidate that delays type 1 diabetes onset Novo Nordisk initiates trial of new candidate against fatty liver diseaseTop news from MedWatch this weekSobi taps founder for chairman positionColoplast launches new catheter in US Future multibillion-dollar obesity market will be dominated by Novo and Lilly, bank predictsEli Lilly CEO admits insulin could be cheaper after Twitter chaosAnalyst: Multibillion-dollar obesity market estimate could boost Novo tradingAllergy Therapeutics appoints interim CFOTeva CEO steps down, replacement foundFDA awards priority review to Genmab and Abbvie's cancer candidateGN Hearing's Veterans Affairs market share drops to eight-year low – failed launch to blameNovo Nordisk invests over USD 740m in Danish facility New chairman candidate says Sobi will be revitalizedCarnegie slashes Bavarian Nordic share targetAudientes reaches out to market for help in rights issue Novo's Danish facility expansion will free up production capacityNew GN product will win Veterans Affairs market shares, bank assessesSonova pulls out of CostcoEli Lilly to double Mounjaro productionEMA establishes new quality innovation expert groupScandinavian life science cluster praises "significant" Novo decision to invest in DenmarkLundbeck counts on employee growth despite economic turmoilDenmark to pass verdict on Lundbeck's migraine drugWorld’s most expensive drug approved to treat hemophilia at USD 3.5m a doseTeva denies outgoing CEO board roleStrained Danish job market poses challenge for Novo's newest expansionGN Hearing CFO finds new job Genmab's chief development officer sells shares in USAnalyst spots a future for Sonova at CostoAnalysts agree: Kåre Schultz was the right man for Teva – for a timeFujifilm to build USD 188m manufacturing facility in USWSA and Philips raise prices after discount ends at CostcoDenmark recommends Lundbeck migraine treatmentAmbu retires main argument for single-use endoscopesBavarian Nordic chair sells shares for USD 100,000Central Norwegian bank's stake in GN Group drops below 5%Denmark rejects Gilead and Eisai cancer drugsAmbu exits Russia Danish reimbursement committee submits diabetes reassessment proposal for feedbackTop news from MedWatch this weekWS Audiology lives up to topline growth expectations – sees challenges aheadBavarian Nordic grants all employees an extra four days offBank believes in cancer approval for GenmabFDA green-lights Diamyd Medical's paused diabetes vaccine studyWSA CEO says Kirkland Signature absence at Costco has helpedWS Audiology CEO expects market slowdown to continue in coming monthsWS Audiology cautious about new hires – but has no layoff plansEisai and Biogen plunge after report of second death in groundbreaking Alzheimer’s drug trialAmbu raises prices, drops discounts, and hopes for customer understandingChina approves Vifor's iron deficiency IV infusionBank counts on double-digit growth for Novo Nordisk in 2023Axsome races for Alzheimer's agitation approvalFDA response to Novo supplier eliminates some Wegovy supply concernsNovo Nordisk moves digital unit, appoints new headEisai and Biogen's Alzheimer’s drug sparks hot debate over benefits as risks like brain bleeding emergeHorizon confirms buyer interest from Amgen, Janssen, SanofiRetention, retention, retention – Danish life science firms shower employees in extra benefitsPatient Square Capital becomes majority owner of EargoUK authority warns of Dupixent adverse effectsPharmacosmos tight-lipped on competitor's Chinese market nodPotential Demant divestment raises competition concernsALK CFO to step downNovo Nordisk to test best-selling substance in stroke indicationFormer US head of Leo Pharma gets board seat at KempharmAnalyst proposes four solutions as GN battles with ghosts of debts pastAnalyst spies alternative buyers in the wings as Cochlear's potential Oticon acquisition raises eyebrowsFDA approves Ferring microbiotica-based treatmentNovo reaches share milestone, analyst credits WegovyFDA confirms rejection of Y-mabs cancer drug Coloplast conducts catheter study to highlight single-use benefitsAcquisitions to help Coloplast attain growth goalExtra data boosts Lundbeck's agitation caseTop news from MedWatch this weekSonova completes Hysound Group acquisition, strengthens presence in ChinaAmbu, Coloplast and GN helped by relaxation of China's covid policyUS prepares to drop public health emergency status for mpoxCompanies must avoid pitfalls of new patent system, advisors warnJanssen withdraws from Horizon Therapeutics bidding war without making offerDanske Bank predicts Novo Nordisk will lead USD 100bn obesity marketNovo Nordisk Foundation issues grant to support RNA vaccine development in DenmarkUK competition authorities also concerned by proposed Oticon Medical saleFDA introduces stricter requirements for special status candidatesLeo Pharma reaches endpoints in phase III hand eczema trialAmplifon starts US consolidation driveUS won’t back 2022 patent waivers for Covid tests and treatmentsBiogen and Sage complete FDA rolling submission of depression drugUSD 1.6bn investment to ensure supplies of sought-after Novo Nordisk drugColoplast deputy chair spends USD 7m on shares in firmFederal court throws out cancer cases against GSK, Sanofi and PfizerFDA ruling to trigger royalty payments for Novo NordiskForward Pharma's last hope in protracted Biogen battle extinguishedNobel Prize winner: "Good research is driven by curiosity"More countries back EU Commission investigation into potential Oticon Medical saleFDA awards Pfizer's RSV vaccine candidate priority review statusNew majority owner makes several board appointments at hearing firmEli Lilly and Boehringer Ingelheim drug proves effective in children with type 2 diabetesEU Commission proposes staggered transition to new medtech requirements after industry warnings Full house for Ambu – all products live up to new EU requirementsFDA approves new sensor for insulin pensDanish agency joins competition authority chorus in criticizing Oticon Medical saleFDA approves Covid-19 jabs as boosters for infantsCEO gets "taste of own medicine" by participating in vaccine trialChina approves Y-mabs drugEllab slapped with customs fine over US importsBoard chair at Coloplast and Lundbeck warns against large pay risesAmbu credits MDR milestone to fastidiousnessEnochian Biosciences sues co-founder for fraudTop news from MedWatch this weekGenmab presents promising new data for cancer hope in USAmgen is said to agree to buy Horizon at USD 26bn valuationNovo Nordisk to launch sought-after obesity drug in DenmarkNo reimbursement makes Wegovy an option for few Danes, says professorHealth ministers back EU Commission's staggered approach to new medtech requirementsAmgen to buy Horizon Therapeutics in USD 27.8bn dealJanssen presents first data from combination trial featuring two Genmab drugsEli Lilly increases dividendsNovo Nordisk to test app and heart disease antibody in phase III trialObesity drug Wegovy's European rollout delayed after US setbacksGN Group's science-based climate goals gain approvalEli Lilly expects 2023 revenue to pass USD 30bn markThe world's biggest sovereign wealth fund keeps buying and selling GN stock – but won't say whyModerna and MSD publicize promising study of cancer vaccine Christmas strike puts British nurses on medtech companies' naughty listsGSK to move headquarters to central London in 2024Founder heir puts Ambu first – exits chair position at cancer firm UK watchdog to probe antibiotic prices amid strep A outbreakNew Danish government to extend a hand to life science companies Pfizer predicts billion-dollar RSV salesChemometec CEO to step downGenmab CEO profits USD 5m from share saleAmbu chair rejects shareholders association's suggested ownership changeCDC expands BMI charts for children to include those with severe obesityNew funding fuels Minervax's hope to win strep B vaccine race despite huge competitionEargo enters OTC partnership with US benefit managerNMD Pharma gets green light to proceed with neuromuscular targetInfluencers charged with stock manipulation – one tweet featuring OrphazymeNovo Nordisk and Lundbeck reprimanded for breaching UK marketing lawsChina is the big unknown in Coloplast guidance, assesses JefferiesCostco lowers prices of GN Hearing productNovo Nordisk acknowledges UK marketing violationDenmark ends the year with two new drug recommendations and one rejectionCHMP rounds off 2022 with five recommendationsTop news from MedWatch this weekCHMP rejects Y-mabs cancer drugGN and Sivantos win Veterans Affairs market shares in NovemberFDA warns of shortage of Eli Lilly's diabetes drugsRoche opens Novo Nordisk career path for laid-off employeesSecondary industry to spring from Novo Nordisk's Danish Wegovy launchLundbeck CEO looks to a near future undisturbed by patent expiration11 stock notifications later – GN investigates Norges Bank investmentGenmab CEO spots potential in Amgen's billion-dollar Horizon acquisitionFerring gets cancer nod from FDANovo Nordisk expands partnership with Amalgam RxDanish Health Authority: Wegovy should play a "smaller role" in obesity treatmentSwedish antibiotic research center bulks up collaborationAmbu chair dispels power shift concerns after founder heir joins board Pfizer gets hands on another RSV candidate through existing dealOlympus to acquire AI endoscopy startupALK loses R&D exec, finds Novo Nordisk replacementBritish nurse strike spreads to more healthcare workersLeo Pharma single-handedly unearthed promising Japanese eczema candidate Hearing firm goes out of businessUK competition authority escalates investigation of Oticon Medical saleR&D head retires after 19 years at ALK: "We created the modern ALK"Genmab and Abbvie file for cancer drug approval in JapanEU gets rolling on decentralized clinical trials with new guidelinesA TikTok trend sold out Ozempic, leaving people with diabetes dizzy, scaredGN Group CFO quits – replacement found at ALKColoplast chair profits millions of kroner from share optionsNovo Nordisk buys access to try out long-acting injection technologyBavarian Nordic meets recruitment target for RSV studyAudientes completes rights issue, secures fundsLeo Pharma wins Japanese approval to launch and manufacture main assetBavarian Nordic enters agreement with US defense department Lundbeck CEO reflects on share split criticism, rejects power shiftBiontech enters clinic with mRNA-based malaria vaccine MedWatch wishes you happy holidaysNovo Nordisk ends 2022 triumphantly – and next year is looking even betterTop news from MedWatch this weekAnalyst: New Bavarian Nordic deal is a sign of governments' watchful eye on virus threatsCEO Jan van de Winkel: New cancer drug is Genmab's most important milestone next yearJanssen nears market with yet another projected blockbuster from Genmab collaborationDespite new diabetes treatments, Novo Nordisk predicts long-term success for insulinJapanese pharma firms join forces to reduce industry's environmental footprintNovo Nordisk overtakes giants in market valueColoplast agrees to million-dollar settlement in the USVaccine pioneer sees mRNA technology’s limits in treating cancerBavarian CFO eyes breakeven chance in this year's decisive final daysDanish Medicines Council delays review of Leo Pharma's eczema treatment Bavarian Nordic CFO: Share price turbulence likely tied to biotech element Novo Nordisk tops list over most popular shares among new investorsGN shorting was almost halved in DecemberInvestigation questions FDA approval of AduhelmPfizer hemophilia therapy hits goal in final-stage studyGenmab gets new MS market rival after fresh FDA approval Genmab CEO won't rule out acquisitions and strategic partnerships from next year's prognosisOperating costs and development in China key focal points for Coloplast in 2023Three Genmab cancer drugs close in on big milestones in 2023Novo Holdings invests in newly merged blood disease company All Wegovy dose strengths are back on US marketEyes have been opened to the Genmab-Biontech collaboration, says CEONorwegian researchers make breakthrough cancer diagnosis discoveryESG compliance makes companies more attractiveColoplast's products generating 80% of revenue have been MDR approved Denmark acted coordinator in EU Commission's work on decentralized clinical trialsNovo Nordisk named one of JPMorgan's preferred pharma stocks in 2023Janssen submits Genmab-developed drug for European approvalTakeda elected 2022's best place to work in EuropeNovo Nordisk continues rollout of popular obesity drug with Norway launchJPMorgan spots challenging first quarter for European medtech firmsNovo Nordisk to test anti-obesity molecule in triple the highest approved dosePandemic made Mexico plant more desirable, says Ambu CEO Analyst: Better conditions in China to ease Coloplast's cost pressureValneva's market success hopes dwindle after disappointing Covid-19 booster dataSonova launches competing product to GN's hybrid hearing deviceMinervax completes phase II enrollment, wins FDA fast-track statusGN's high expectations deadlocking stock priceEmbattled Y-mabs tightens pipeline focus, reduces staff by 35%First protective RSV option one step closer to marketFormer Leo Pharma EVP tapped to lead Oncopeptides through difficult timesNovo Holdings invests in Danish medtech firmNorthsea: NASH candidate data coming soonInflation has medtech industry in tight squeezeEMA accepts Biomarin application for label extension of dwarfism drugEargo launches new OTC deviceTop news from MedWatch this weekEnsoma acquires Danish CRISPR university spin-offAlzheimer’s drug from Eisai, Biogen gets FDA accelerated approvalPrivate investors believe in GN Group stock comebackLundbeck and Otsuka win FDA priority review of Alzheimer's agitation drugEU Commission to give more time for MDR transitionAnalyst: Priority review for Lundbeck-Otsuka Alzheimer's agitation drug signals unmet need Bionic pancreas system nears commercial launchAnalysis firm names two Novo Nordisk drugs in 2023 top sales growth predictionAscendis Pharma to enter new disease area with eye disorder candidateNovo Nordisk declared world's best place to work in 2022Novo Holdings invests in US-based gene-editing companyNovo Holdings invests in biotech company for third timeNovo Nordisk enters agreement with Fujifilm Cellular DynamicsBiogen partner Eisai shares jump after FDA approves Alzheimer’s drug LeqembiUnion Therapeutics presents topline results for psoriasis drugLundbeck: Alzheimer's agitation drug can make a real differenceBiogen and Eisai submit Alzheimer's drug for European approvalFDA fast-tracks Union Therapeutics drug for rare skin diseaseUS fails to pass Netflix-style model for new antibiotics – "a huge disappointment"Renewed optimism could be behind Ambu trading surge, says analystDNB Markets recommends to sell Genmab stockPharmaceutical firm calls special meeting after investor demands Per Wold-Olsen's removalOrifarm brings in communications lead from Leo PharmaWS Audiology's climate goals receive science-based stamp of approvalHemab doses first patient with candidate for rare blood disease Eli Lilly predicts possible launch of obesity drug in 2023Extensive layoffs at Leo Pharma – 300 jobs lostLeo Pharma to source new drug candidates externally following layoffsNovo Nordisk, Eli Lilly, Sanofi sued by California over pricesAscendis Pharma CEO tight-lipped on potential assault on Novo Nordisk's mother lodeLundbeck hires new head in USNovo Nordisk and Lundbeck prepare to help laid-off Leo employeesFDA approves Novo Nordisk's Rybelsus as first-line treatment optionNew US lawsuit over insulin prices will have minimal impact on Novo Nordisk, says analystOramed's oral insulin candidate fails in late-stage trialTop news from MedWatch this weekObesity treatments catch drugmakers’ eyes as sales seen soaringUkraine to force pharmaceutical firms to discontinue Russian activitiesWelcome to the new MedWatchBavarian Nordic breaks even in preliminary financial updateDanish medtech firm partners with German giant to eliminate needles in blood sugar testingAnalyst: Bavarian has even better year ahead after breakeven 2022Bavarian CFO predicts another record-breaking year aheadGN could be potential acquisition target, says bank Novo Nordisk renounces orphan drug title for potential blockbusterSales of Novo Nordisk's Wegovy are off to a good start in 2023Bavarian Nordic ditches debt refinancing: "We don’t need the money right now"Ambu silent on Russian exit issuesBank raises expectations for Bavarian Nordic's 2023 outlookGlobalData predicts huge diabetes market growth, names Novo Nordisk drugs as driversGubra could go public before summer, says media Leo Pharma to initiate early-stage trial in inflammatory diseasesModerna gains as RSV shot prevents most cases in older peopleMerck is set to remove cancer-causing chemical from top diabetes drugsLeo Pharma spokesperson on layoffs of 300 employees: "It came as a shock"Gates foundation grants USD 10m to tuberculosis vaccine researchAnalyst: New Moderna RSV data bodes well for Bavarian NordicColoplast is the world's most sustainable medtech firm in new analysisSonion moves production out of Philippines, fires 1,200 employeesPharma companies say new US drug price law leaves them in limboAstellas Pharma's emissions reduction targets for 2030 approved by SBTiSpokesperson: Laid-off Leo employees have leg-up in job hunt at Novo and LundbeckNorway denies Novo Nordisk reimbursement for obesity drugModerna on RSV vaccine candidate: "We know it's very safe, and now we see it's effective, too"Lilly’s donanemab fails to get early FDA approval for Alzheimer’sEvaxion wins FDA fast-track statusNovo Nordisk to invest EUR 130m in French factoryDigital healthcare firm says first German deal is within sightAnalyst: Wegovy prescriptions in US signal strong start to 2023Top news from MedWatch this weekEMA expects antibiotics shortage to improve in coming monthsTwo researchers praised Novo Nordisk's obesity drug but didn't disclose paymentsFDA starts review of potentially first NASH treatmentPharmacosmos wins Chinese reimbursement dealNovo Nordisk denies sponsoring 60 Minutes segmentDenmark recommends three drugs Citigroup is worried about Lundbeck's futurePharma lobby wielded "inordinate amount of influence" over EU during pandemicEli Lilly seeking chronic kidney disease approval with JardianceAnother bank impressed by early 2023 Wegovy prescriptions Pharmacosmos to invest in Chinese organization following reimbursement winModerna's chief medical officer on 3-in-1 vaccine: "Great news for global public health"Janssen's books disappointing sales of Genmab-developed DarzalexEli Lilly to support production of diabetes drugs with USD 450m investmentEU launches imaging initiative to support cancer diagnosis and treatmentPharma association denies pandemic lobbying: "Interest protection was on standby"Asensus Surgical wins CE Mark for intelligent surgical unit under MDR rulesPatient groups urge EMA to tackle antibiotic shortagesNew batch of hearing firm recommendations moves GN up, Demant and Sonova downFDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccineBiontech inks deal with UK on sped-up cancer trials Bavarian Nordic featured on Cowen list of 2023 biotech favorites FDA approves ALK's house dust mite tablet for teens Atrogi doses first patient in diabetes studyMC2 Therapeutics CEO steps down as board memberGN's veteran chairman to retireUS medtech group expands production in DenmarkPer Wold-Olsen's retirement is "a great loss for GN"AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes Analyst: Chairman exit increases chance of GN-Demant mergerEMA says antibiotic shortage situation isn't "major event"Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connectionCHMP recommends expanded approval of DupixentNew ALK head of communications to draw in new hiresDenmark rejects Janssen and Genmab drug twice in JanuaryCHMP recommends four drugs in JanuaryTop news from MedWatch this weekJPMorgan: Novo Nordisk to accelerate growth this yearAnalyst: Wegovy prescriptions continue upward trend in USLeo Pharma layoffs have no effect on listing plansUS senator calls for increased scrutiny of Big Pharma acquisitionsBank expects strong 2022 conclusion from Novo NordiskFDA panel could shatter Bavarian Nordic's Covid-19 vaccine dreamLeo Pharma to reuse model from failed acquisitionAlzheimer's drug wins priority review in JapanNovo Nordisk wins case in US appeals court Orphazyme trio founds new firm focused on neurology and rare diseasesAnalysts await Novo Nordisk's 2023 guidance with high expectationsNordea cuts Lundbeck share target week before annual reportMedtrace wins US patent on new heart imaging methodAmgen takes on Abbvie blockbuster Humira with unusual price planPfizer hopes Covid-19 sales will increase in the long runNovo Nordisk predicts wide range for 2023 sales growthNovo Nordisk doubles obesity sales in 2022Novo Nordisk meets upgraded guidance, sets new revenue recordRare Disease business comes in slightly below expectations for Novo NordiskStudies of Wegovy in higher-than-approved doses beginAnalyst: Strong Novo Nordisk outlook should satisfy investorsNovartis beats Kesimpta sales expectations in Q4Novo Nordisk sues Viatris over copycat Wegovy Potential blockbuster submitted by Novo Nordisk for European approvalGN, Sivantos, Sonova lose Veterans Affairs market shares in December Supply issues to continue in 2023, reports Novo Nordisk Nordea spots increased chance of GN being acquiredNovo Nordisk CEO rakes in cash in record yearNovo Nordisk CEO says obesity is "obviously a big market"Boston Scientific's endoscope sales beat predictionsBank lowers Demant share target week before annual reportAnalyst: China headwinds will dampen Coloplast's first quarterEli Lilly raises 2023 expectationsEurope pharma sector risks lagging the world, say drug chiefsColoplast's bottom line disappoints in otherwise strong reportNovo Nordisk hopes to retain employees with share giftColoplast launches male catheter featuring new technologyUnilabs and Siemens Healthineers enter million-euro strategic partnershipALK forecasts lower growth in 2023 than strong 2022 resultDupixent becomes ninefold blockbusterAnother hurdle overcome in delaying MDR deadlineChina accepts regulatory filing for ALK allergy tabletColoplast to set new treatment standard with Luja – but keeps sales goal under wrapsTop news from MedWatch this weekAnalyst: Wegovy prescriptions keep pace in week 4Danaher takes interest in CatalentGN chair's exit rekindles acquisition plans, says mediaA sluggish start turned sprint – Novo's diabetes tablet Rybelsus catching up with bestsellerAmbu's core business will drive organic growth in Q1 ALK CEO's pay package stays unchanged despite record yearNew product to help Demant in continued difficult marketALK refuses to abandon US despite tablet opposition: "Winners aren’t quitters"Ambu beats analysts' predictions on all accountsDemant exceeds topline expectations, but operating profit lags behindWS Audiology maintains expectations after Q1Demant announces imminent launch of new flagship hearing aidDemant foresees acquisition year, raises debt gearing expectationDemant expecting to close divestment of Oticon Medical in Q2FDA clears new generation of Ambu bronchoscopesNo stock buybacks in 2023, reports Demant Lundbeck's key products disappoint on performance driven by weak Brintellix salesDemant sees reason in consolidating the hearing aid manufacturing industryWS Audiology finds no negative impact on traditional hearing aids from OTC launchEisai says US launch of Alzheimer’s drug "ahead of expectations"Novo Nordisk CEO: Wegovy will be launched on big European markets in 2023Lundbeck to launch key product in Ukraine in 2023Demant CEO takes pay cut following bottom-line drop in 2022Opinion: Set the bar high in the revision of the EU’s pharmaceutical legislationLundbeck CEO's pay package halved after dull stock yearLundbeck's new long-term goals reflect growth confidenceGN's annual report awaited with bated breathGN Hearing reports huge Q4 growth, meets full-year targetGN to raise USD 1bn in rights offeringGN Hearing expects to beat market growth in 2023Ambu holds back new launchesATP bought Demant stock for millions of dollars in 2022 Reopened Chinese hearing aid market is difficult to predict, says Demant CEOLundbeck CEO remains optimistic despite flagship product's Q4 setback GN Hearing CEO: "I don't see a need for consolidating the market"Demant sets new powered-by-renewables goal Curbing pharma pollution is key to superbug fight, report saysWilliam Demant Invest has yet to form opinion on GN rights issueGN benefitting from Sonova's exit from Costco ALK hires new CFO with long Novo Nordisk backgroundLeo Pharma gets positive topline data in yet another phase III trial targeting hand eczemaNovo Nordisk and partner dose first patient in clinical heart failure studyMedia: FDA to probe accusations of paid weight-loss add in guise of news Novo Nordisk donates millions to help victims of earthquakeGlobal head of R&D leaves SanofiGN chief gains huge wage increase following strong Q4Ambu undertakes major reshuffle, leading to dismissals and departuresGN declared winner of major tender in AustraliaMedia: Novo Nordisk to launch weight-loss drug in UK this springFrequency pivots after failed trial for hearing loss drug candidateFormer head of research at Sanofi moves to J&JUnion Therapeutics awaiting new data before pursuing partnerEnsoma completes purchase of Danish CRISPR firmUS newspaper sues EU over Pfizer textsColoplast contests Italian payback requirementsBavarian Nordic to acquire travel vaccine portfolio from EmergentBavarian Nordic projecting multimillion-dollar operating profit in 2023Another delay hits Bavarian Nordic's booster studyUnion Therapeutics welcomes competitor's strong dataAnalyst: Bavarian Nordic's newly acquired travel vaccines fit portfolioCochlear maintains full-year expectations despite half-year setbackEconomically challenged Emergent reached out to Bavarian Nordic in travel vaccine talksBavarian Nordic gains 280 employees, increases US presence via vaccine dealExisting partnership has to adapt following Bavarian's vaccine buyEMA forming group to monitor medical device shortagesNovo Nordisk and Lundbeck to remain in PhRMA despite news to the contraryDrugmakers to earn less under accelerated approval in US test schemeAmgen kicks off jumbo dollar bond deal to finance Horizon acquisitionEU officially adopts extended MDR transitionEmbattled Audientes broaches subject of company divestmentBavarian Nordic hires bureaus in US to find unboosted older people for clinical studyJanssen exits NASH collaborationColoplast counting on hockey stick production curve in Costa RicaAudientes expands distribution network in NepalAscendis Pharma books EUR 583m loss in 2022GN, WSA recede at Veterans Affairs in January – Demant and Sonova win outAscendis drug celebrates first anniversary in US while Europe still awaits accessTop news from MedWatch this weekDanish pharmaceutical firms to be repaid millions of dollars due to typoMC2 Therapeutics-developed skin drug wins market share in EuropeAmbu opens up about stalled Russian exitDenmark reports two more multiresistant bacteria cases from DicillinBavarian Nordic completes discounted directed issueHemab raises USD 135m in Series B financingAnalyst: Bavarian Nordic's 5% directed issue discount is "within the norm"Smith & Nephew's 2022 performance weighed down by inflation and currency headwindsHemab tight-lipped on deals with Novo Nordisk and GenmabAnalyst expects cautious 2023 outlook from GenmabGN’s rights issue could be less than announcedNovo Nordisk stock sets closing price recordEli Lilly says shortage is over for diabetes drug that drew weight-loss interestLundbeck proposes Falck CEO and Novo Nordisk veteran as new board memberJ&J is rejected by US supreme court over USD 302m vaginal-mesh awardDenmark rejects reimbursement for migraine drug AimovigEuropean CMO is behind contaminated antibioticName change to connect Orphazyme buyer Kempharm with rare disease areaGenmab's conservative outlook predicts duller growth in 2023Genmab's costs increased in 2022 – trend to continue in 2023Genmab to say more about new disease area this yearGenmab still has an appetite for acquisitionsFormer Novo Nordisk vice chair to step downApple makes major progress on no-prick blood glucose tracking for its watchScientists discover flaw in insulin absorption assumptionProfessor rebuts Ambu's explanation for slow Russia exitNovartis enters partnership on app for chronic patients with Dawn Health Genmab keeps recruitment pace upFDA approves hemophilia drug from Sobi and SanofiData analysis and AI to ensure expedient launch of Genmab's new cancer hopeGenmab CEO's pay increased 9.4% in 2022Analyst predicts Genmab's new goal will be autoimmune diseasesCHMP recommends eight drugs in February – rejects Covid-19 pillNovo Nordisk's Wegovy sales in US still rising – albeit at slower paceTop news from MedWatch this weekLeo Pharma prepared for layoffs "respecting the person on the other side of the table"Genmab CEO on BioNTech co-candidates: "We have to present good data – and that takes time"Genmab expands bonus initiatives for management and employeesColoplast saving up for new acquisitions despite still being debt-loaded from Atos Medical buyPfizer to acquire Seagen, says media SEB assesses "very likely" Novo Nordisk upgrade aheadJesper Høiland tapped for ALK board positionInvestor rebukes Genmab's proposal to pay leadership even moreAI Act could force innovation to flee EuropeBiogen and Eisai's Alzheimer's candidate wins priority review in ChinaJefferies raises GN share price targetBioMarin's dwarfism drug going through growth spurtAudientes explains missing Q4 sales citing unexpected Indian marketColoplast voluntarily recalls number of inflatable penile prosthesesPfizer’s RSV vaccine wins US panel’s backing for safety in older peopleBiotech exec describes close colleague running for US president – "A winner"Hemab co-founder to start over in cancer companyTen companies join Bioinnovation Institute program Eli Lilly to lower insulin prices by 70% in USAmplifon reports "solid revenue growth" in first months of the yearGSK’s RSV shot gets FDA advisers’ backing on safety for older peopleInvestors were informed of Hemab co-founder's exit before Series BAnalyst: Eli Lilly's insulin price drop is politically motivatedNovo Nordisk to expand R&D presence in BostonBavarian Nordic confirms 2023 outlook Zealand Pharma eyeing strategic partnerships for late-stage candidate EQT seeks up to EUR 3bn from Galderma IPOZealand Pharma soon to submit rescue pen for European approvalBavarian Nordic's vaccine acquisition expecting to close within three monthsNovo Nordisk sells off cancer candidate from acquisitionGlobal obesity costs expected to double to USD 4.27trn by 2035Bavarian Nordic confident after FDA panel backs GSK, Pfizer RSV vaccines despite safety concernsBernie Sanders urges Novo Nordisk and Sanofi to follow Eli Lilly's example: Drop insulin pricesTop news from MedWatch this weekNovo Nordisk increasingly uses monkeys for animal testingDemand for Novo Nordisk's Wegovy acceleratingBoehringer Ingelheim in phase III study talks about Zealand Pharma obesity drugAnalysts raise expectations for Demant following annual reportNICE recommends Lundbeck migraine drugNovo Nordisk CEO on EU pharma reform: "A lose, lose, lose"New diabetes drugs changing treatment in the USDNB Markets: Ambu is a classic "turnaround case"Cochlear partners with Norwegian startup on "hearing aid" glassesAlmirall expanding in the Nordics – ramps up hiringModerna eyes testing mpox, bird flu vaccines in humans this yearFDA extends review of BioMarin's hemophilia A gene therapy Novo Nordisk executive resignsEuropean Council formally adopts extended MDR transitionBiden proposes tax hike on income over USD 400,000 to fund MedicareDanish hourly employees at Novo Nordisk secure 4% wage increase in 2023EMA complains about prospect of getting new sex-working neighborsObesity treatment awareness boosts interest in Zealand Pharma's pipelineAnalyst sees no signs of acquisition bids for GN GroupBlockbuster weight-loss drug Wegovy to be available on NHSWomen's health company Organon gives day off on International Women's DayDNB: GN has million-dollar wiggle room in rights issueLeo Pharma books multimillion-dollar loss in 2022Eli Lilly Alzheimer’s drug fails to prevent disease in trialEli Lilly, Boehringer Ingelheim seek diabetes pill clearance for childrenLeo Pharma exercises option to acquire partner's drug candidateYearlong losses have almost emptied out Leo Pharma's coffersPfizer and GSK posed for RSV vaccine launches this yearBernie Sanders introduces bill to cap insulin prices at USD 20The Dicillin scandal grows – two more Danes infected with multiresistant bacteriaSandoz fights to keep name secret of CMO behind contaminated antibioticJefferies raises peak sales estimate for Zealand Pharma obesity drug candidateNovo Nordisk buys 104 acres in North CarolinaLeo Pharma enters partnership with Irish CROTop news from MedWatch this weekNew book reveals former CEO almost moved Novo Nordisk to SwitzerlandSanofi to acquire Provention Bio and type 1 diabetes drugZevra to finish what Orphazyme started: "We have set ourselves up for success"Pfizer's migraine nasal spray gets FDA nodLeo Pharma awaiting final decision on antibody after phase II defeatWegovy exponents did not disclose payments from Novo NordiskPfizer to acquire Seagen for USD 43bnZealand pharma expects to recover all its SVB depositsEuropean Medicines Agency warns of diabetics’ risk amid Ozempic shortageGlobalData: Mutation-prone RSV could hinder vaccine developmentWegovy would cost US government USD 27bn – even with limited uptakeNovo Nordisk: Life science power in EU industrial policy revision has been dimmed by Brexit US Veterans Affairs will pay for some to get new Biogen-Eisai Alzheimer’s drugGN, Sivantos VA market shares decrease in February – Demant and Starkey gainLeo Pharma cleaves R&D organization, hires veteran dermatologist to lead early developmentNovo Nordisk to reduce insulin prices by up to 75% in the USGN retracts proposal to raise capitalJoe Biden applauds Novo Nordisk for insulin price reductionsDeparting GN chair: An organizational split would be unwiseShareholders' association to GN: ”Reach out to Willian Demant Invest"New GN chair wants to find debt solution – but can't say whenSandoz finds multiresistant bacteria in six Dicillin batches as concerns growInsulin price cuts could end up making money for US drugmakersEU weighs plan to incentivize drugmakers to fight superbugsAnalyst: Novo Nordisk's price reductions challenge complex healthcare systemUK pharma group suspends Novo Nordisk for two yearsDenmark predicts new EU requirements following Dicillin scandalWilliam Demant Invest has nothing to say on scrapped GN capital raiseBritain’s a long way from becoming a science superpowerSanofi follows Lilly, Novo in cutting insulin pricesNew US Medicare guidelines could affect Novo Nordisk's WegovyFive companies advance in BioInnovation Institute's acceleration programPharmacosmos launches iron deficiency drug in JapanNovo Nordisk reacts to suspension: "We take the decision very seriously" Activist fund denies rumors – does not own GN stockGN's scrapped capital raise: Norges Bank voted no, William Demant Invest abstainedTop news from MedWatch this weekSix-month Ozempic shortage mostly over after weight-loss craze drained supplyDNB surprised by GN's lack of backup planWegovy prescriptions in the US grow for another weekTakeda’s USD 4bn psoriasis pill helped clear skin in mid-stage studyAdolescent patients' eczema improved in Leo Pharma's late-stage testingLeo Pharma presents positive data in hand eczema phase III trialCompetition sharpens on active ingredient production – EU weighs measuresWilliam Demant Invest report reveals GN Group stakeAmbu mulling over capital raiseColoplast updates inflatable penile implant production after recallsNovo Nordisk CEO: Future obesity market size is difficult to assessCryptic message about future of Leo Pharma's R&D chief left unexplained Unrealistic expectations for duodenoscope fuelled Ambu's overuse of fundsNordea finds new Ambu targets encouraging and trustworthyAscendis Pharma initiates long-term study of SkytrofaAmbu CEO: Technology, scalability and partnerships will ensure growth New hearing company 14 years in the making – "We expect to rise to the top"Roche and Eli Lilly to collaborate on early Alzheimer's detection testAnother UK authority looking into Novo Nordisk's marketing violationGN board member steps down due to family health issuesNovo Nordisk enters multimillion-dollar partnership to slow insulin resistance Novo Nordisk could lose private insurance reimbursement for obesity drug on home market Ambu ruled out raising capital in August – now it's "due diligence"Patient group did not disclose Novo Nordisk ties in obesity treatment campaignFDA issues warning letter to OlympusAdvanced Clinical opens office in Copenhagen Novo Nordisk board discussed supply issues at every meeting in 2022Ambu share offering complete at 4.7% discountNovo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usageLess than one in five Novo Nordisk execs is a woman – chairman expects change over timeNordnet sees reason in Ambu's speedy capital raise Novo Holdings could earn big on acquisition bid for SynlabTop news from MedWatch this weekEU delays new drug law proposalNovo Nordisk reaches primary endpoint in phase III study of oral semaglutide Production at contaminated CMO continues – authorities deny further risksObesity drug hit makes Novo Nordisk more valuable than NestleIndian generic drugmaker to launch Leo Pharma copycat drug in USCalifornia moves forward with making biosimilar insulinNovo Nordisk enters collaboration with AI-driven drug discovery companyNovo Nordisk chair boasts competitive production advantageAmbu wins European approval of two fifth-generation bronchoscopes Genmab promotes senior VP for strategy to executive managementAnalyst: New Novo Nordisk data sets the bar high for diabetes pills Denmark: Violation of good manufacturing practice is source of contaminated antibioticZealand Pharma presents positive early-stage results for weight-loss candidateSandoz severs ties with European CMO – Dicillin permanently withdrawn from marketOwners inject EUR 100m into WS AudiologyDanish pension fund argues for capping Genmab CEO's payFerring closes research institute, fires staffAmericans prevented from buying Ozempic in British ColumbiaAstraZeneca retires diabetes drug in the NordicsLundbeck and ALK boost the Lundbeck Foundation's operating resultJPMorgan says GN prognosis is too "conservative"J&J drops RSV vaccine after two competitors get closer to approvalWatchdog looking into Novo Nordisk sponsorship of patient groupWHO mulls over labeling obesity drugs as essential medicinesBluebird Bio expects delay on FDA sickle cell drug applicationDanish health minister to answer questions about Novo Nordisk sponsorship of patient groupNew study says AstraZeneca drug rarely leads to RSV mutationsNovo Nordisk helps Canada resolve Ozempic issueFormer GN chair says there have been no acquisition signs from Demant ownerFormer Bavarian Nordic chairman sees opportunities in Johnson & Johnson's RSV exitColoplast challenges its biggest catheter competitor in clinical contestCHMP recommends nine drugs in March Top news from MedWatch this weekAnalysts: GN risks paying 10% interest rates on massive debtWegovy's prescription success continues another week in the US Analyst: Coloplast study attests to Luja as premium product Former Ambu CEO to spearhead Swiss biotech companyNovo Nordisk to halt Ozempic sales in Russia, says drug authorityFDA points out shortcomings in Ascendis applicationNovo Nordisk is financing weight-loss programs in EnglandATP wants Bavarian Nordic to cool use of warrants in reward schemesBad news from FDA slashes market value of AscendisInvestor predicts huge Wegovy potential in USEli Lilly's Mounjaro could overtake Wegovy, says professorAdcendo dreams big after extended Series A financing roundColoplast testing silicone dressing against standard careBioInnovation Institute companies have raised over DKK 3bn Denmark indulges Sandoz, keeps CMO behind contaminated Dicillin under wrapsHappy Easter Break from MedWatchNovo Nordisk could see multimillion-dollar boost from winning strife over discountsAmbu relaunches formerly recalled productBillionaire family pledges USD 200m for Alzheimer’s drug researchColoplast's newest business area could become its biggestAmbu competitor takes the lead in US and UKShareholders displeased with Bavarian Nordic's stock dilution Novo Nordisk listed fourth on Danish ranking of companies fetching Russian workersEvotec hit by cyberattackBavarian Nordic reaches required RSV cases in phase III trial of vaccine Bank expects more mpox vaccine contracts for Bavarian NordicMexico plant weighs down Ambu's climate accountNovo Holdings sees worst result in 11 years – loses DKK 6bn on life science investmentsNew guidelines can dampen sales of Covid-19 vaccinesNovo Nordisk enters agreement on developing cell therapies for obesity and diabetesUS biotech company initiates phase II clinical trial of treatment for atopic dermatitisAstraZeneca gives up RSV antibody rights in US, Sobi streamlines dealZealand Pharma taps Centerview to explore partnership dealsBritish malaria vaccine approved for children in GhanaNovo Holdings CEO hopes weak annual report is an isolated occurrence Novo Nordisk announces big upgrade after increased expectations for key productsNovo Holdings invests in Swiss biotech company, enters boardAnalyst spots more likely outcome than Zealand Pharma sale as rumors boost stock Hempel brings in new chief financial officer from GN GroupWeightWatchers enters weight loss drug market with acquisitionFDA rejects Eli Lilly's inflammatory bowel disease drug citing production plansNovo Nordisk sets new record as market value soars to USD 370bnNovo Nordisk's crazy growth impresses analyst: "My estimates have been exceeded"Sonova gives up market shares to competitors on veterans market in MarchLundbeck and Otsuka await important exam results on Friday for potential Alzheimer's drugTop news from MedWatch this weekFDA advisory committee vote in favor of Lundbeck and Otsuka's Alzheimer's agitation drug RexultiGenmab enters multiyear antibody partnership with ArgenxNovo Holdings CEO still believes in "a golden era in biotech innovation"Weight-loss telehealth startup Calibrate Health cuts 18% of jobsJefferies: Lundbeck and Otsuka have potential blockbuster candidate within reachOrphazyme nears settlement in US class action lawsuit Novo Nordisk to optimize organizational use of artificial intelligenceDemant raises financial guidance for 2023 ALK grows first-quarter top line, maintains full-year expectationsDanaher shelves its takeover pursuit of CatalentAnalyst says early Demant upgrade is a good signDNB lowers recommendation and share price target for ALKDanske Bank reviews ALK's preliminary Q1 figures: "Weaker than expected"Genmab partner's Darzalex sales almost reach analyst estimatesALK lost billions of kroner in market value after announcing disappointing tablet salesBavarian Nordic's Covid-19 vaccine hanging by a thin threadBioInnovation Institute expands women's health focus with FerringAround half of Leo Pharma's laid off workers have found new employmentNovo Nordisk Foundation cuts off funding for protein center, likely shutting it down The research will live on, says dean on protein research center's closing downLundbeck reports positive phase II proof-of-concept results for migraine drugUK competition authority flags Demant divestment of Oticon as problematic Analyst: Lundbeck migraine study is "exciting" newsBoehringer Ingelheim to start talks on late-stage study of Zealand Pharma's obesity candidate this summerLundbeck R&D chief encouraged by migraine results, paving the way for more to followDemant CEO says first quarter was driven by strong hearing aid sales Hearing Industries Association says OTC still marred by aspects of uncertaintyDemant almost finished adjusting its retail network in USGenmab's new arbitration against Janssen denied in courtAstraZeneca executive calls on UK, EU to do more to attract investmentDemant seeking to increase popularity with US veteransNovo Nordisk to make sustainable plastic from methanol productionManufacturers' post-pandemic relationship with Veterans Affairs has improved, says Oticon chief Analyst: Genmab's arbitration defeat could disappoint some in the marketOticon president says hearing aid market is unfazed by years of uncertaintyTop news from MedWatch this weekOver-the-counter hearing aids didn't disrupt the market – but raised awareness of hearing lossEli Lilly to initiate head-to-head study against Novo Nordisk's WegovyProduct launches have helped market growth, says Oticon presidentGenmab appeals arbitration defeat against JanssenCiti: Wegovy on track to sell for USD 6bn annuallyHearing aids sold over the counter off to sluggish start, says GN HearingPatient backlog has opened veterans market for GN HearingColoplast improves pulmonary health in recent studyKesimpta sales exceed first-quarter expectationsAnalysts predict growth for Novo Nordisk thanks to WegovyBluebird reaches FDA’s doorstep with sickle cell therapy as application filedAbacus to speed up new business leg leveraging upcoming EU drug lawFounders of bankrupt hearing retailer says Sonova showed acquisition interestNovo Nordisk takes responsibility as producer of obesity drugNovo Nordisk and Eli Lilly lobby US Congress for Medicare coverage of obesity drugs Novo Nordisk teams up with rivals to recycle injection pens in DenmarkNovo Nordisk runs TV ads in US for multimillion-dollar sumDenmark to reassess reimbursement for allergy medicinesDanish Medicines Agency assesses Dicillin scandal: "Few deviations" from GMP not grounds for non-complianceEU's massive pharma reform targets drug assessments within 180 days at mostAnalyst hopes for news about GN's capital structure in first-quarter report GN Hearing raises outlook for the year Unhealthy work culture – Demant president and two leading employees fired GN to present new debt financing plan – including asset divestments Novo Nordisk CEO on EU pharma reform: "The stupidest thing I’ve heard"Pharma industry taking to the barricades after presented extensive EU pharma reformCHMP recommends nine drugs in April – first RSV vaccine nears finish line Eli Lilly to submit obesity candidate for US approval within weeks Demant exec says goodbye without revealing termination causeGenmab-developed drug reaches first-quarter expectations in US GN will have debt financing plan ready by August Resound Omnia among GN Hearing's best launches everGN Hearing CEO: R&D won't suffer under new debt financing planLundbeck and Otsuka win FDA approval for schizophrenia drugLeo Pharma signs animal welfare declarationAscendis Pharma's growth hormone almost double sales in first quarterTop news from MedWatch this weekLayoffs dent Leo Pharma's reputation among life science employeesEU Commission expects agreement on AI this yearPfizer RSV vaccine rollout could be impeded in low-income countries Ambu finds new COO at biotech firmDenmark recommends Leo Pharma's eczema drug as first-line treatmentOver-the-counter hearing aids behind 1% of first-quarter sales in USAnalyst on Eli Lilly's new obesity data: Definitely an attractive product FDA rejects Ascendis Pharma drug Analyst sees Ambu endoscope sales as driving growthFiring of Demant executive raises more questions than answers, says communications advisor CRO becomes co-owner of Danish biotech company developing a Parkinson's treatmentGN brings Hearing and Audio closer as speculations about division separation lingerAmplifon exceeds expectations in first quarterFactors behind Demant upgrade to attract attention in imminent first-quarter reportDemant confirms grand growth in wholesale segment after recent upgradeAmbu's revenues and earnings disappoint despite top-line growth Wegovy's sales ceiling piques interest in prelude to Novo Nordisk's second-quarter reportAnalyst: Ambu disappoints on key figures despite positive top lineDemant could easily reach its highest expectations, assesses analystDemant CEO: Prognosis held back by uncertainty about momentum's durationDemant stays mute on leadership layoffs: "We have issues and we’re dealing with it"Eli Lilly drug slows Alzheimer’s disease, study findsAscendis Pharma hires new chief commercial officerKey products continue to grow in Novo Nordisk's first quarterHigh demand makes Novo Nordisk hit the brakes on Wegovy Novo Nordisk's Rare disease segment disappoints due to growth hormone drugFDA approves Novo Nordisk's once-weekly growth hormone for childrenFirst RSV vaccine caps 60-year search to stem pervasive lung illnessNovo Nordisk expects Wegovy limits to last "some months"Novo submits new weekly insulin for marketing clearanceNovo Nordisk CEO says EU pharma reform will give Europeans fewer new drugsWeight-loss drugs are a golden ticket for health-linked stocksSpokesperson for Leo Pharma employees: They believe in the transformationNovo Nordisk's fastest launch ever was too fast to scale, CFO reflects on facing obstacles Blackstone is using AI to control diabetes and slash spending on drugsTop news from MedWatch this weekFDA wants more data about Novo Nordisk's potential blockbusterKåre Schultz lands first chairmanship following Teva exitEU nations call for "more drastic measures" to prevent medicine shortagesDemant sees multiple scenarios for divesting surgical divisionPreclinical hemophilia drug triggers USD 15m milestone payment from Novo NordiskColoplast to compare new single-use catheter with competing productLundbeck sells rights to three development programsRecord quarter in sight for Bavarian Nordic, predicts analystWSA raises full-year expectations Bavarian Nordic's increases sales and bottom-line result in Q1ALK confirms top-line growth – bottom line remains unchangedAlmirall's first-quarter Wynzora sales exceed EUR 3m Drug contractor Catalent plunges after annual guidance cut, results delayedBavarian Nordic has secured approvals ahead of closing travel vaccine acquisitionBavarian Nordic must match the bar set by RSV competition, says CFOAnalyst expects continued growth for Lundbeck's key productsBavarian Nordic faces headwinds, maintains Danish Covid-19 vaccine was "the right decision"WS Audiology CEO doesn't feel bested by competitors despite lower growth ALK CEO urges calm after taking a beating from investorsLundbeck raises operating profit expectation after booking its highest quarterly revenueAnalyst: Restricted hospital access in China to dampen Coloplast's quarterly growthFuture quarters will compensate for wanting mpox sales, says Bavarian Nordic CFOCitigroup: Strong GLP-1 prescription growth is promising for Novo NordiskBoehringer Ingelheim and Zealand Pharma's obesity drug candidate achieves 15% weight reduction in phase IIStrong phase II results could increase pace of Lundbeck's new migraine candidatePresident of Demant subsidiary Interacoustics resignsLundbeck ready with plan for important launch: FDA will decide WednesdayFDA approves Lundbeck and Otsuka's agitation treatment for Alzheimer's patientsColoplast grows according to plan, adjusts expectations slightlyGenmab adds 35% to revenue – bottom line drops below guidanceGreater priorities elsewhere prompt Lundbeck to outsource three clinical programsLundbeck CEO: Great pleasure bagging crucial approvalEli Lilly’s CEO promises not to raise insulin pricesNew Genmab cancer treatment could launch in matter of weeksGenmab CEO hopes for new decision in arbitration case this yearSonova beats back, regains veterans market shares in AprilChinese problems halt growth – but optimism is spreading at ColoplastEU report recommends healthcare investments based on experiences from Covid-19Skin patch helps ease peanut allergy symptoms in toddlersMpox is no longer a global health threat but Bavarian Nordic vaccine will stay aroundColoplast wants data on new ostomy product before deciding market viability Olympus reports double-digit growth in several endoscope areasPfizer CEO says negotiating prices with US is like having "a gun to your head"Obesity drugs aren't the easy solution to "globesity": WHOTop news from MedWatch this weekEU Parliament picks chief negotiator for upcoming pharma revisionDifficult company exits from Russia confirm Coloplast's choice to stayGLP-1 drugs show signs of effect in cancer-killing cellsParkinson's drug candidate to prove its worth in phase I – and lure big pharma to the tableLundbeck board member buys shares for DKK 2mBavarian Nordic closes vaccine portfolio acquisition Europe's AI Act could take more than a year to adoptSonova forecasts growth next fiscal year despite short-term uncertaintiesNorwegian investor to increase rate of vaccine productionWHO moves health office from Moscow to CopenhagenAmgen acquisition of Horizon could be thwarted by US competition authoritySonova held back due to loss of Costco contractAnalyst: Subdued prognosis from Sonova after non-renewal of contractWHO warns against overusing AI in healthcareAstraZeneca exits PhRMA Obesity candidate from Gubra and Boehringer Ingelheim passes phase I testingAmgen "disappointed" by resistance to Horizon acquisition Zealand Pharma CEO still has faith in obesity candidate from Boehringer Ingelheim collaborationAnalysts turn up hopes for GN Hearing following first quarterObesity alone didn’t pose biggest heart risk in London studyBavarian Nordic holds off advancing preclinical candidates due to acquisitionDrug companies are minting billions on unproven treatments with FDA shortcutALK expands digital allergy universe to more marketsHearing industry supplier delivers its best financial result citing pent-up pandemic demandOrphazyme's board steps down – new major shareholders take overFDA panel backs Pfizer's maternal RSV vaccineDecisive deadline approaches for Genmab: Seventh drug examined at FDAWHO: Covid has cost millions of years of lifeNovo Nordisk Foundation taps Demant's legal chiefTop news from MedWatch this weekFDA approves cancer drug Epkinly from Genmab and AbbvieBeta Bionics granted FDA approval for bionic pancreasAnalyst estimates USD 3.5bn peak sales for new Genmab drugDoctors find heart risk dips after a year on obesity drug WegovyAnalysts raise expectations for Demant significantly after guidance upgradeModerna to take next step with vaccine candidate against rare disease Catalent launches big changes to the executive teamNew study: Two doses of Bavarian Nordic's mpox vaccine provide strong protectionNovo Nordisk to submit obesity tablet for approval this yearAnalyst: Oral semaglutide shows weight-loss effect similar to WegovyJefferies: Semaglutide data is "reassuring"Pfizer's weight-loss pill could be as effective as Novo Nordisk's OzempicDrugmakers eye USD 23bn biotech Argenx ahead of key dataNovo Holdings participates in divestment of VectivBioDrugmakers behind older obesity drugs aim to leverage Novo Nordisk's supply issuesCitigroup sours on Bavarian Nordic's Covid-19 vaccine, is skeptical of RSV candidateGenmab sees big potential in epcoritamab – expects EU approval this yearWHO starts global network to analyze genetic code of virusesNovo Nordisk enters gene-editing therapy collaboration with US biotech Life Edit TherapeuticsBrazil market clears Y-mAbs cancer drug for childrenEli Lilly has reduced carbon emissions by 20% over two yearsGalecto doses last patient in lung disease trial UK AMR fund injects GBP 39m into antibiotic researchNovo Nordisk doesn't expect home run with new gene-editing therapy collaborationGN completes DKK 2.7bn capital raiseAnalyst: Share sale doesn't solve all of GN's debt problemsNew GN capital plan removes some stock risks, assesses bankGN CEO on new capital plan: "You should always have a plan B"Cochlear sees no other suitors for Demant's implants businessResearchers fear falling from favor with Novo Nordisk FoundationNovo Nordisk's semaglutide shows potential against addictionNovo Nordisk wins EU recommendation for label extension of long-acting growth hormoneAlmirall to collaborate with Spanish research center on skin cancer treatmentGN considers Covid-19 situation far less critical than six months agoDemant proposes partial Oticon Medical divestment to ease competition concernsCHMP recommends two drugs in May Top news from MedWatch this weekHeartseed raises USD 14m for stem-cell therapy developmentA weight loss startup touting mindfulness, Noom is now prescribing drugsAmbu blames hospital staff shortage for European setbackUS officials probe a new layer in opaque drug pricing, supply systemNew production plant sparks hopes of profit at antibiotics makerZealand Pharma CEO predicts complex future for obesity treatmentsEU: Pharma manufacturers should help clean up drugs from wastewaterWegovy prescriptions in US drop in first this year, increase in DenmarkChief negotiator for EU pharma revision dropped by political party following investigationEMA to revoke market approval for Novartis' sickle cell drugFerring partner presents positive phase III result of lumbar disc herniation treatmentSacked EU candidate mulls over futurePfizer presents positive late-stage data for new hemophilia drugDNB: GN could hit long-term debt-gearing target in 2025EU amends vaccine contract with Pfizer, BioNTechCEO leaves OrphazymeSnipr Biome shows proof of principle in phase I trial of lead assetUBS skeptical of Novo Nordisk's sky-high market valuationGenmab CEO sells shares for over USD 8mFDA warns against compounded versions of semaglutideEU and US seek guidelines for artificial intelligenceObesity shot frenzy makes Eli Lilly world’s most valuable drugmakerPfizer’s RSV shot wins US approval following GSK’s to marketNykode expands collaboration with Roche on cervical cancer vaccine Novo Nordisk launches another phase III study of Genmab-developed hemophilia drugUnified EU patent system coming into force Eli Lilly enters multimillion-dollar settlement on US insulin pricesNovo Nordisk wins age discrimination case in US district courtALK pushed out of leading European indexNICE approves migraine wafer from PfizerMulti-cancer blood test spots two in three cases in UK studyNovo Nordisk maintains its defense in case of high-priced insulin – competitor enters settlementTop news from MedWatch this weekNovo Nordisk to buy French developer of digital injection pen add-on Pfizer presents promising phase III data for new antibiotic treatmentNanexa preparing for phase I trial of Novo Nordisk drug in slow-release injectionOlympus ramps up digital ambitions after AI endoscopy acquisitionSobi partners with ViroGates on Covid-19 combination treatment for US marketDenmark warns of Novo Nordisk diabetes drug shortageGPT AI has arrived in the doctor's officeEisai hit by ransomware attackAnalyst: GN Hearing divestment could still be in the cards after new capital planGenmab approval marks the era of bispecific antibodies in blood cancer treatment, says expertUS contract manufacturer acquires Danish consultancy firm Zealand Pharma reprimanded by Danish watchdog following sale of rescue pen to Novo NordiskAnalyst predicts golden future for GLP-1 as drugmakers rush to join inMerck sues US, calling move to cut drug prices "extortion"Takeda, Eli Lilly must defend racketeering suit over diabetes drug, judge rulesDenmark warns against overtreatment with OzempicUK looks to expand obesity-drug access with pilot programSnipr Biome adjusts its strategy - shifts focus towards gene therapyEU Commission approves first RSV vaccine for people over 60Takeda hit with hefty tax bill after drawn-out tax strifeModerna-Merck combination cancer treatment granted speedy review in US and EUEU puts mental health on par with physical health Supply problems pile up on Novo Nordisk as another Ozempic dose faces shortage in DenmarkEisai and Biogen’s Alzheimer’s drug moves closer to full US approvalFDA and Medicare discuss obesity drug coverageFDA to take new steps to modernize clinical trialsFDA panel back RSV vaccine for children from AstraZeneca, SanofiALK finds success with study of house dust mite tablet in childrenALK eyes big potential in indication expansion of house dust mite tabletNovo Nordisk CSO: The foundation for future growth has been laid100-year-old ALK has to dare to fail: "A true pioneer leads the way"Top news from MedWatch this weekLeo Pharma appoints new general manager for UK and IrelandNovo Nordisk plans USD 2.3bn manufacturing expansion in DenmarkEisai, Biogen clinch FDA advisers’ support for Alzheimer’s drugALK sees no approval obstacles for children's tablet following "surprisingly good" dataAnalyst points to potential explanations for Bavarian Nordic stock gainsEU grants million-euro funding to Danish-Swedish fertility researchFurious patients demand action against SandozValneva’s experimental chikungunya vaccine shows immune responseDanish expansion makes Novo Nordisk "a bigger and broader company"Almirall raises EUR 200m in share offeringTakeda and private equity firms struggled for years about who would pay tax billLundbeck to test migraine treatment in 315 children and teensAuthorities report shortage of TBE vaccines from Bavarian Nordic and PfizerDemant jumps on US veterans market in May on new flagship product launchNovo Nordisk tests semaglutide against Alzheimer's in phase III trial Merck's potential Novo Nordisk challenger doesn't impress analystAstraZeneca’s CEO focused on obesity drug that lasts even after treatment endsPfizer sees US antibiotic supply running out as shortage worsensEU Council approves new fee structure for European Medicines AgencyLow birth weight is a risk factor in developing type 2 diabetesXellia Pharmaceuticals changes out CEOs after 15 yearsSmith & Nephew receives share recommendation upgrade from CitiFrance to give healthcare apps one-year early access to reimbursement Amgen and Horizon clap back at US watchdog: "Speculation on speculation” Islandic pharma logistics company proposes former Maersk CEO as board memberSanofi launches AI venture with new appXellia chair on CEO switch: "We need other competencies"If Novo Nordisk can't cure diabetes, someone else might – "that would be pretty embarrassing"Novo Nordisk CEO lauds UK anti-obesity initiative Bavarian Nordic's Covid-19 candidate works best against early Wuhan variantDespite Phase III study involving one-third of asthmatic children, ALK cannot pursue new indication Bavarian Nordic maintains phase III plans despite vaccine worriesSandoz seeks to increase global biosimilar usage with initial focus on USTop news from MedWatch this weekNovo Nordisk reaches shareholder agreement, acquires majority of BiocorpALK CEO to step down, replacement found at Fertin PharmaWeight-loss frenzy leaves Eli Lilly’s diabetes drug Mounjaro in short supply againNovo Nordisk CEO is open to negotiate cheaper obesity drugsEli Lilly fails to beat Pfizer's migraine drug in head-to-head clinical trialALK board took initiative for CEO change as means to future-proof companyCarsten Hellmann can look back on yearlong growth at ALKDNB: Timing of ALK's CEO change spikes uncertaintyReport: Mounjaro will overtake Novo Nordisk's diabetes and obesity drug in short timeBMS sues US government over drug price negotiationsSonova launches OTC product under the Sennheiser brandBavarian Nordic presents positive late-stage data from newly acquired vaccine candidateBerenberg predicts an obesity market of USD 85bn by 2030Bavarian could surpass competitor due to strong phase III data, says analystNovo Nordisk lowers European launching pace of Wegovy in face of huge demandChief Development Officer leaves Leo Pharma – internal replacement in placeNovo Holdings acquires EllabNovo Nordisk wants to curb urge in brain to gain weightCheap Wegovy knock-offs hawked by med spas draw Novo legal actionAstraZeneca scraps another GLP-1 candidate against type 2 diabetesMigraine treatment company receives million-dollar infusion from EU GSK’s shot against RSV protects for two seasonsLeading Leo Pharma employee slammed in UK for actions bringing discredit on pharma industryDiabetes drug Jardiance wins label expansion to include childrenLife science chiefs blast pharma law revision: "We’re falling behind to a level Europe has never seen before”Pfizer, GSK shots for RSV get backing for older adultsBritish authority partially blocks Demant's Oticon Medical divestment Novo Nordisk's obesity and diabetes drugs to be investigated for cancer risksColoplast's main shareholder and foundation to establish shared holding companyMusical chairs on the Ferring board: Founder's grandson takes over Lars Rebien's chairmanshipEllab to continue acquisition spree under Novo HoldingsDifficult sales process has cost Demant dearly in legal and consultancy feesOver 1.3 billion globally will have diabetes by 2050, study findsGenmab's epcoritamab added to cancer guidelinesNovo Nordisk's obesity and diabetes drugs to be investigated for psychological side effectsEMA committee recommends new eczema injection from Leo PharmaTop news from MedWatch this weekCHMP recommends two drugs in JuneDeborah Dunsire steps down as CEO of LundbeckZealand Pharma and Boehringer Ingelheim present promising obesity drug dataZealand Pharma presents phase I data from weight-loss drugLilly’s Mounjaro gives positive results in obese diabetic peopleZealand Pharma submits rescue pen for European approvalEli Lilly boasts big weight-loss in study of GLP-1 tabletFurther phase III data confirms Novo Nordisk's weekly insulin Lundbeck chair confirms: Deborah Dunsire was dismissedDeborah Dunsire leaves Lundbeck after five years with one launch and a more padded pipelineBavarian Nordic to supply smallpox vaccines to EU strategic reservePfizer scraps development of obesity drugJefferies: Eli Lilly shows "noteworthy" weight reduction with next-generation obesity drugLundbeck chair points to incoming CEO's biggest challenge: patent expirationLundbeck board denies debated bonus scheme for incoming CEOBavarian Nordic: Covid vaccine unlikely to be approved based on primary endpointsSanofi presents positive mid-stage data for eczema drug Genmab and AbbVie present positive topline data from cancer drug trial in new indicationVertex delivers positive data from stem cell treatment for diabetes Analyst: Epcoritamab topline data is quite impressiveNovo Holdings on Ellab acquisition: The starting point for ownership is a time span of around five yearsNICE rejects diabetes drug from Eli LillyGN inks divestment agreement in PortugalNovo Nordisk sees no link between Wegovy and cancerCompetition council forces Coloplast to adjust prices in DenmarkFujifilm Diosynth Biotechnologies appoints COO as CEOGubra acquires contract research company and adds mini pigs to repertoireEli Lilly to acquire diabetes-focused biotech companyInsulife has signed agreements for production and analysis in NorwayPharmacosmos is booming: Has doubled in two yearsEuropean alliance sounds alarm on critical shortage of medical devices Novo Nordisk to focus more on the US: Europe is already ten years behind Top news from MedWatch this weekFDA approves first ever cellular therapy for the treatment of type 1 diabetesCost reduction plan costs CEO job at US-based EargoZealand Pharma submits dasiglucagon for review in the USLeo Pharma appoints new General CounselAGC Biologics continues making headway in DenmarkAdditional data supports Zealand Pharma's alternative to GLP-1 as weight-loss drugAbbVie finds new General Manager for Scandinavia internallyNovo Nordisk and Norwegian Medicines Agency in talks of Wegovy reimbursementNovo Nordisk adjusts its purposeModerna continues to make inroads in the Nordics: Has hired medical director in NorwayAmgen and Horizon files counterclaim against US trade regulatorsPresident of Radiometer resigns - replacement in placeChinese doctor who edited babies’ genes wants to fix Alzheimer’sNew trial to determine optimal treatment with Leo Pharma's eczema-suppressing antibodyAnalysts see low probability of GN-Demant merger in the short termChina official meets with foreign drugmakers to boost confidenceAstraZeneca invests USD 400m in reforestation Insulife has received positive signals from the FDA Evotec secures deal worth up to USD 74m for smallpox vaccine developmentModerna seeks approval in Europe and the US for RSV vaccineSonova gets seal of approval for climate goals – will reduce CO2 emissions by 78 percentAnalysts predict upwards adjustment of Novo NordiskNovo Nordisk sues US pharmacy to block knock-offSecretive company receives DKK 30m from Novo Holdings FDA greenlights Biogen's treatment for Alzheimer's diseaseColoplast acquires Kerecis and raises growth expectationsBiotech company recovers from failed phase II trial – shows efficacy in cochlear implantationColoplast CEO: Developments in financial markets led us to billion-dollar acquisitionTop news from MedWatch this weekColoplast acquisition doubles in value in just one yearNovo Nordisk has an appetite for more acquisitionsInteracoustics breaks own records againRadiometer has disappeared from the mediascape – at the potential cost of talented employeesNestlé to sell its peanut allergy drug to Swiss healthcare groupNovo Nordisk's obesity and diabetes drugs under EU suicide risk assessmentAfter new billion-dollar acquisition: Coloplast CEO rules out more acquisitions for two yearsAmbu raises earnings expectationsDespite supply issues: Novo Nordisk to launch sought-after obesity drug in GermanyNovartis loses patent protection on blockbuster drug, appeals Analyst: Conservative forecast may be behind Ambu share price drop – doesn't exclude new upgradeUK approves RSV vaccine from GSKAmbu CEO: Upgrade driven by good momentum – not yet at the finish lineMost Wegovy patients stop treatment within a year, analysis showsNovo, Lilly fall after EU probe into weight-loss drugs widensAmbu begins European launch of new product after CE markingADC Therapeutics hits the brakes on phase II study after seven patient deathsTop-selling diabetes drug continues to struggle: Novo Nordisk reports intermittent backorders worldwideGN wins VA market shares for third month in a rowGoogle’s AI for medicine shows clinical answers more than 90% accurateMyopax receives special FDA status for potential treatment of rare congenital diseaseModerna files two new lawsuits against Pfizer and BioNTechUnion Therapeutics raises DKK 100m: Widex holding company surpasses 5% againSenator slams Eisai and Biogen's pricing of new Alzheimer's treatmentNew Alzheimer’s drug is first to show it slows disease – but it’s facing a rocky rolloutNovo Holdings invests in oversubscribed biotech fundTop news from MedWatch this weekLilly to pay up to USD 2bn for obesity startup VersanisNovo Nordisk urges German doctors to prescribe Wegovy "responsibly"Go-Pen is looking for commercial partners: "We already have some lined up"Pfizer’s USD 43bn Seagen takeover faces EU investigationEli Lilly's insulin costs up to 13 times more for uninsured AmericansSanofi and AstraZeneca win US approval for RSV vaccine for infantsLilly applies for Alzheimer’s drug’s US approval after trial successNovartis increased Kesimpta sales by 105%.MC2 Therapeutics borrows money to make it to 2024: Lost more than USD 15m in 2022Novartis raises outlook after strong quarterFDA will not act on European study of GLP-1 drugsEU authorities see sufficient supply of essential antibiotics for coming winterSaniona and AstronauTx partner to discover new treatments of Alzheimer's diseaseNorway to end reimbursement for OzempicModerna is the world's sixth most innovative company according to Boston Consulting GroupAmplifon lends up to USD 393m for innovation and digitalizationFTC says settlement talks to resolve blocked Amgen-Horizon deal have endedWeight loss drug shortage now includes SaxendaSeasoned audio professionals raise USD 1.5m to prepare for production of new hearing aid J&J's Darzelex sales disappoint slightlyAlmirall gets a thumbs up for climate goalsNorlase to continue investments: New product and production expansion in the pipelineAbbvie and Genmab takes big step towards EU launch of cancer drug: CHMP recommends epcoritamabNovo Nordisk is again struggling with lack of diabetes medicine in DenmarkCHMP rejects one product and approves 14 at July meetingTop news from MedWatch this weekBavarian Nordic discontinues RSV vaccineInvestment bank: Failed RSV program is significant setback for Bavarian NordicRSV loss is a setback – but Bavarian Nordic is in a different place than before, says head of IRGlobal pharmaceutical companies are betting big on ChinaRoche signs USD 2.8bn Alnylam deal for hypertension drugIO Biotech brings in new chief medical director from NovartisDanish pension fund defends Bavarian Nordic investment following project failureDanish Medicines Agency was refused participation in inspection of Dicillin manufacturerÖssur books increasing sales: ”We are firmly on track"Investors say Bavarian Nordic should shelve research effortsBavarian Nordic CEO says R&D efforts won't be discontinuedBiogen to cut 1000 jobsNovo Nordisk launches its own version of ChatGPTEli Lilly’s diabetes drug faces more shortages as demand kicks upTornado destroys Pfizer's main US warehouse – delivery of 30 drugs may be affectedFrench optical chain to enter hearing aid market with Israeli acquisitionAnalyst says market reaction to new hearing glasses is "tempest in a teapot"Several US states are exploring the possibility of providing cheaper obesity medicationNovo Nordisk obesity drugs probed by UK regulator over suicidal thoughtsAmbu receives FDA clearance for new generation of endoscopy screensTakeda delivers beyond expectationsEli Lilly's obesity candidate shows 26% weight loss in additional phase III studiesGenmab raises guidance for 2023 after strong Darzalex salesAmplifon sees strong growth continue into third quarterMedia: Wegovy delivery issues due to repeated safety violationsFDA is monitoring international probes into Novo, Lilly obesity drugsTop news from MedWatch this weekNovo Nordisk has started selling Wegovy in GermanyBiogen to buy Reata for USD 7.3bn in rare-disease dealCovid-19 vaccine market is fading – but Bavarian Nordic retains its candidate while others don'tGSK believes in vaccine battle against Pfizer – now shipping first Arexvy doseSwearing, shouting and spitting: Lundbeck and Otsuka market new Rexulti indication in adBioNTech completes acquisition and enters AI marketBritish billionaire charged with insider trading in biotech companies Bank cuts Bavarian Nordic's price target 30% after shelved RSV vaccineGenmab moves headquartersMerck upgrades after strong quarterPfizer downgrades after declining sales of Covid-19 pillBoard members leave ISD Immunotech one after the other: "We have decided to shake things up"Convatec upgrades after strong quarter in wound businessFrench investor secures Evaxion's future, commits USD 20m in fundingUK competition authority approves principles of amputated Demant deal with CochlearBavarian Nordic upgrades after large smallpox vaccine order from the USEisai eyes Japan, China for Alzheimer’s drug after US approvalNovo Nordisk sued in US for inadequate warning about risk of gastroparesis from OzempicAnalyst awaits news about Genmab's new cancer drug in quarterly announcementAbena and Linak support ban on Koran burningsUS employers limit employee weight loss drug coverageGenmab's revenue reaches DKK 7bn in first half of 2023Genmab CEO awaits key test of strength between Darzalex and new candidate in 2024Genmab CEO ready for European launch: Partner must prove its worthJapanese expectations for Lundbeck drug exceed Danish analysts' estimatesTop news from MedWatch this weekBavarian Nordic to submit chikungunya vaccine for approval in 2024 after more good resultsEMA launches investigation into Indian CRO after serious concerns about data qualityGenmab's employee growth continues, reaches 2000 employeesRising use of weight-loss and diabetes drugs boosts profits for CignaAstraZeneca, Sanofi RSV drug wins backing from CDC panelBavarian Nordic's CFO puts faith in market research on multimillion-dollar chikungunya marketHow Demant will reach its climate goals: Electric cars, green power and supporting suppliersGenmab invests heavily in artificial intelligenceGrowing demand for 30-year-old Ferring product prompts subsidiary to increase productionNovo Nordisk taps board members to join newly acquired BiocorpFormer Leo Pharma profile leaves Swedish biotech company after seven months as CEOFive major US health systems welcome new Alzheimer's drugNovo Nordisk enters clinic with lipid-lowering treatmentNovo Nordisk wants cardiovascular benefits of Wegovy approvedEli Lilly continues upward trend on pre-market after strong Mounjaro salesJefferies: Cardiovascular study may increase pressure on authorities to reimburse Wegovy Bavarian Nordic CEO says short-term focus is on growth of vaccine businessNovo Nordisk enters into AI collaboration with US universityNovo Nordisk nears LVMH as Europe’s biggest firm by market valueAnalysts expect minor upgrade in Novo Nordisk's upcoming reportSnipr Biome and Novo Nordisk extend collaborationUniversities continue fellowship program after million-dollar grant from Novo Nordisk Foundation ALK reached out to main supplier after cases of safety and control breachesNovo Nordisk books DKK 24bn operating profit and upgradesNovo Nordisk acquires Canadian biotech company for up to USD 1.1bnNovo Nordisk's Rare Disease department sold for less than expected in second quarterWegovy constraints are maintained by Novo NordiskAnalyst on Novo Nordisk financial results: Strong growth but not quite living up to expectationsNovo Nordisk CEO: "We are very confident that we can continue to increase production capacity"AstraZeneca signs renewable energy agreement in SwedenCardiovascular study strengthens Novo Nordisk against Eli Lilly, says development chiefDiabetes fusion tablet and potential obesity drug dropped by Novo NordiskJ&J gets cancer drug approved in US – royalties coming to GenmabMore lawsuits increase Novo Nordisk's costs for legal undertakingsNovo Nordisk chief: Inversago Pharma acquisition is "a great addition to our pipeline"German authorities warn BioNTech after secret deal with social mediaAmbu receives US approval for two smaller bronchoscopesFormer employee accuses Pfizer of wrongful termination after corruption revelationsFormer Oticon veterans want to separate noise from conversation – now they're seeking capital to growTop news from MedWatch this weekDemant slightly increased market share with US veterans in July – GN lost slightlyNovo Nordisk’s growth camouflages weak spots in Danish economyGenmab CEO hires in droves but wants to preserve the cultureNovartis completes acquisition of biotech company for USD 3.2bnAstraZeneca in mRNA collaboration with Chinese companyColoplast wins US appeal case over delayAGC Biologics expands contract manufacturing in ItalyNovo Nordisk ramps up lobbying efforts for US obesity drug reimbursementFormer EMA deputy director has diedEli Lilly acquires obesity-focused biotech companyEli Lilly completes acquisition of development partner within diabetesZevra is again delaying submitting Orphazyme asset to FDA for reviewLundbeck's key products under the microscope in CEO's upcoming and last financial reportFDA delays decision on chikungunya vaccine from ValnevaUS authorities launch investigation into Illumina-Grail dealEargo loses momentum in second quarter and lands multimillion-dollar lossAnalyst expects Demant to remain in high gearPfizer challenges Johnson & Johnson on bone marrow cancer marketDemant raises expectationsLundbeck upgrades after 13% sales growth in first half yearDemant's growth continues to surge – operations disappoint slightlyExpensive purchased inventory hits gross margin at DemantHearing aid market has finally fully normalized, says Demant CEODemant considers resuming share buybacks in second half of year Analyst: Lundbeck looks strong in terms of earningsDemant sees great potential in new area of diagnostics businessDeborah Dunsire: Rexulti in agitation could potentially outperform blockbuster salesExpectations before the financial report are that GN Hearing will keep on marchingAnalyst predicts Coloplast growth driven by increased activity in ChinaGN Hearing raises sales expectationsColoplast maintains expectations – sales have picked up in ChinaGubra CEO after first outlook upgrade: "The business is just doing far better than we could have imagined"Proud Deborah Dunsire passes the baton – but one decision she still has doubts aboutNovo Nordisk exec lands board member position at PharmacosmosNovo Nordisk CEO stresses goal to expand chronic disease treatment globally during China visitNew challenges loom in China for Coloplast: Considers lowering pricesGN scales back divestment efforts after improving cash flowColoplast CEO: No more acquisitions here and nowBank remains concerned about ALK's tablet sales in EuropeNovo Holdings bought Ellab at huge discount, media saysGN Hearing has cut 100 jobsBoehringer Ingelheim plans phase III studies with obesity candidate from Zealand PharmaColoplast expects to grow Icelandic acquisition manifold in a few yearsLeo Pharma has submitted drug hope for EMA reviewDemant and GN: AI will be the new battleground for hearing aids Top news from MedWatch this weekHead of people and communication leaves LundbeckLucrative Novo Nordisk business segment suffers headwindColoplast's main shareholders implement new ownership structureJefferies sees great potential in obesity candidates from Zealand PharmaCochlear bags unprecedented revenues, guides for even better 2024Resignation leaves Lundbeck without women in group managementLeo Pharma acquires US biotech Timber PharmaceuticalsAnalysts expect a discussion on Bavarian Nordic's future direction to ensueColoplast closes book on lengthy lawsuit: "It has cost way, way too much money"US wholesalers struggle with costly logistics for GLP-1 productsFinancial services firms deem Lundbeck guidance too conservativeRoche’s fast-growing eye drug set to expand in top EU marketsLeo Pharma to send USD millions in royalties to former drug candidate owners1.9 million Zealand shares sold at a discountSmallpox vaccine smashes expectations and almost triples Bavarian Nordic's revenue in the first half-yaerLundbeck calls for 91-day patent extension on PTSD drugGN's online US store is booming - but still losing millionsSobi rights issuance is meant to finance loanBavarian Nordic bats its eye at travel vaccines on RSV flopEMA suspends Spanish contract manufacturer after 60+ GMP violationsTablet sales come under scrutiny in ALK accountsMedia: Novo Nordisk hires Thermo Fisher as new Wegovy manufacturerNew ALK CEO takes over on November 1stALK shows widespread progress despite European tablet sales declineColoplast launches first laser product to grind kidney stones to dustBayer scraps collaboration with Danish biotech company GubraNovo Nordisk can't keep up with German Wegovy demandALK CEO Carsten Hellmann on resignation: ALK is more important than meFerring sells US royalties rights to Royalty PharmaLundbeck executive dismisses stark criticism of growth hopeBavarian Nordic to test long-term safety of new booster vaccineProblems at Swedish CMO prompts ALK to revise guidanceNovo Nordisk's billion-dollar dividend weakens the Danish kroneNovo Nordisk's Wegovy performs well in phase 3 trial in people with heart failureTop news from MedWatch this weekColoplast expects results from new catheter in 2024Valneva presents positive data from study of chikungunya vaccine in adolescentsDenmark rubber stamps Sanofi blockbuster for infantsThe FTC open to settle the case of Amgen's billion-dollar acquisition of HorizonDiabetes treatment shows potential as an adjunct therapy for Parkinson's diseaseReuters: Novo Nordisk expands Catalent supply agreementHR exec leaves Leo Pharma, successor poached from German rare disease specialistWS Audiology profits take a 36% leap in Q3US advisors: Wegovy costs are untenableEMA warns of continental shortage of Eli Lilly diabetes drugDemant opens technology hub in Kuala LumpurWS Audiology announces new product platform "coming soon"WSA chief exec no longer fears OTC cannibalization Novo Nordisk products subject to new US price negotiationsFDA awards priority review to Zealand Pharma's dasiglucagon applicationAnalyst: Novo Nordisk's bestseller may face future price negotiationsNovo Nordisk acquires Danish biotech companySeveral suitors lined up for Embark Biotech: "Novo Nordisk made the best offer"Coloplast bags DKK 9.2bn through rights issueDiscontinuation of gaming business leaves 40 Demant employees joblessBerenberg expects further restrictions on the use of obesity drugsEndoscopy business booming at Ambu - sees decline in its other two business areasAnalysts: Here are the tasks of Lundbeck's new CEOPfizer expands investment in Swedish production facilityCleanup of former core business prompts Ambu to exit 40 marketsMC2 Therapeutics sells rights to psoriasis drug in ChinaPer Wold-Olsen on 15 years as chairman of GN: "A very positive, rewarding journey"Bavarian Nordic shelves COVID-19 boosterNovo Nordisk outlines plans to build a new factory in DenmarkAnalyst: Not surprised by Bavarian Nordics decision to end COVID booster vaccine developmentTop news from MedWatch this weekAmgen and Horizon settle lawsuit with FTC, paving the way for mergerNovo Nordisk surpasses LVMH and becomes Europe's most valuable listed companyNew CEO has brought change to AJ Vaccines: There was a distinct lack of communicationDespite shortages, Novo Nordisk starts selling Wegovy in the UKNestle divests peanut-allergy drug on disappointing uptakeMC2 Therapeutics chose a partner in China that can lift more than its main asset WynzoraGitte Aabo leaves GN after merger of Hearing and Audio divisionsWS Audiology launches new platform and top productsGenmab and Seagen reach primary endpoints in Phase III cervical cancer studyWSA: Veterans Affairs market share to rise with launch of new Signia platform GN: Merger of Hearing and Audio divisions will boost innovation Israeli biotech Epitomee delivers positive obesity dataNovo Nordisk to sell Wegovy in the UK at a fraction of the US price Ascendis gets USD 150m in cash from selling synthetic royaltyDeparting CEO on leaving GN: My own decisionChairman praised successful turnaround in GN Hearing despite financial declineGN chairman reassures on company's future on top of management changePharmacosmos initiates PhII trial with acquired
drug candidateAnalysts: Generics could hamper Novo Nordisk's business in ChinaGN merger pipelined long before change of chairmanAscendis to launch weekly growth hormone i first European country this septemberWS Audiology has no plans of merging product platformsLundbeck and Otsuka get mixed PhIII results in PTSDAnalyst: Lundbeck's and Otsuka's PTSD project will be uphill - but it's still alivePresident of North American operations to lead GN Hearing from OctoberALK welcomes competition in treating peanut allergyInvestment bank: Novo Nordisk could reach DKK 230bn in revenue from weight loss products by 2030Novo Nordisk enters into US research alliance to develop drugs for diabetes and heart diseaseLeo Pharma proves long-term efficacy of atopic dermatitis drugUK back in EU’s Horizon science program after Brexit freezeEvaluate Vantage puts Novo Nordisk drug on list of most promising biologicsTop news from MedWatch this weekNovo Holdings withdraws from Convatec's boardNovo Nordisk reaches agreement on insulin price cap with New YorkDiabetes patients in UK to get Eli Lilly drug, rivaling OzempicGubra to focus discontinued Bayer collaboration towards overweight and obesityGN appoints a new General CounselPension fund sees greater value in Bavarian Nordic despite vaccine flopLarge shareholder welcomes the merger in GNNorway to pay more for essential antibioticsLeo Pharma goes hunting with the help of banks and ownersGenmab enters into collaboration with Traverse BiotechFDA: Prospects for full supply of Wegovy in the US are unclearAfter two years of losses Leo Pharma is on track to profitabilitySonova and Demant slightly increased market share with US veterans in AugustNovo Nordisk performs stock splitBavarian Nordic wins another contract to supply smallpox vaccines to the EURobert Langer appointed chair of Danish biotech company's scientific councilNovo Nordisk's own factory builder must leave construction to othersLundbeck adds more data to successful migraine study of new candidateAmbu receives European approval for gastrointestinal endoscope 2seventy narrows focus and lays off 40% of its workforce Novo Nordisk caps insulin prices for the uninsured in the USGN completes divestment of Portuguese business and collects DKK 500mFirst patient has received Ferring's gene therapy for bladder cancerEMA committee recommends drug candidate from Ascendis PharmaSurvey: Few Americans have purchased over-the-counter hearings aidsResearchers take new step towards global HIV cureParallel importer sees market for Novo Nordisk obesity drug in new countriesCHMP recommends nine drugs in SeptemberNovo Nordisk and Eli Lilly will dominate the weight loss drug market, experts sayEMA committee recommends Almirall's psoriasis drugAscendis has launched weekly growth hormone in first European marketNovo Nordisk chairman highlighted as candidate for CEO position at BPNovo Nordisk facility in the US allegedly receives FDA noticeNew study: Older people with migraines are harder to treatSale of royalties marks new approach to funding for AscendisNovo Nordisk is rumored to have hired another US contract manufacturerAmbu expands in Malaysia with new innovation centerRobert Langer to open doors for young biotech company: "But ultimately people need to be convinced by the idea and the data"Danske Bank: Acquisition of Icelandic wound care company will boost sales at ColoplastNovo Nordisk enters new partnership for the production of insulin in South AfricaEli Lilly sues clinics for selling fake diabetes drugNovo in supply deal with Ypsomed for auto-injector pensObesity-drug mania propels top stock fund to beat 94% of peersMedia: This is why the FDA has reprimanded Novo Nordisk following US plant inspectionAmbu receives clearance from US authorities for colonoscopeBoard member appointed as new CEO of OrphazymeJefferies on Novo Nordisk: Little risk of semaglutide patent dispute - but could raise concernsLeo acquisition negotiated with four suitors while struggling to surviveMedia: Issues at Novo Nordisk factory have been known for more than a yearNovo Nordisk and UNICEF extend joint initiative to combat childhood obesityNovo Holdings completes acquisition of US antibiotics company for DKK 3.2bnThird time's the charm: Novo Nordisk makes new bid to get obesity drug reimbursed in Danish home marketJyske Bank questions Demant's continued momentum Kåre Schultz: Former chairman of Novo Nordisk Foundation cost me the job as Novo Nordisk CEOEuropean trade association calls for comprehensive reform of MDR and IVDRInvestment bank sees Eli Lilly dominating the obesity market in the 2030sKåre Schultz in new book: Lundbeck was about to drop major collaborationBank downplays importance of patent dispute and FDA notice to Novo NordiskAnalyst predicts USD 100bn obesity drug market by 2035Radiometer has launched its own version of ChatGPTNovo Nordisk appoints new general counselMC2 Therapeutics secures exclusive option rights to new drug candidateJapanese authorities approve cancer drug by Genmab and AbbvieNovo Nordisk enters billion-dollar partnership with Valo HealthGenmab and Abbvie receives EU clearance to market cancer drug Novo CEO: Unlikely that public reimbursement will cover all Wegovy patientsJefferies: Wegovy sales may disappoint in the third quarterParallel importer Abacus upgrades full-year outlookFormer Xellia CEO becomes chairman of biotech company on capital huntNovo Nordisk to expand pipeline through new acquisitionsNovo Nordisk to limit access to Wegovy in new marketsAscendis CFO sells shares worth DKK millionsMinister: Several countries are against key proposal in controversial EU reformInvestor alliance urges pharmaceutical companies to improve environmental impactEdwards Lifesciences subject to unannounced EU inspection Galecto to lay off 70% of its workforce - announces plans to explore "strategic alternatives"GN secures credit facilities of additional DKK 3.4bnGN launches new product platformEU lags behind the US and China in artificial intelligenceKallyope enters Phase II with obesity and diabetes tabletNew GN platform completes ten years of connectivity workGN sets new management team after merger and launches new divisionNovo Holdings makes another investment in US biotech company Johnson & Johnson shows positive results in lung cancer studyAnalyst: Only natural for new GN CEO to form his own teamGenmab has officially opened its new headquartersNovo Nordisk files lawsuit against US authorities ahead of price negotiationCountry Manager: Indians will have to wait for Wegovy until 2026WS Audiology hires new chief technology officer from car manufacturerVaccine breakthrough behind mRNA shots wins Nobel PrizeFDA to support new orphan drugs through pilot program FDA rejects atopic dermatitis drug lebrikizumabFDA updates Novo Nordisk's Ozempic drug label with side effect alertFDA approves Novo Nordisk drug to treat rare conditionSnack maker keeps an eye on Novo Nordisk's obesity drugFujifilm expands management with former Leo executiveLow share price may knock Galecto off the stock exchangeOlympus appoints new chief medical officerNovo Nordisk's semaglutide to be studied for positive effect on alcoholicsInvestment bank: Novo Nordisk's patent victory is a small win as price negotiations loomEli Lilly makes acquisition in Denmark: Takes over company with 12 employeesDNB expects ALK's tablet sales to recover in 2024Eli Lilly's head of diabetes and obesity retiresZealand Pharma CEO: "We've never been stronger"Pharmaceutical industry to grow 4% annually towards 2030Novo Nordisk suffers Wegovy defeat to Viatris in patent courtSunstone still has faith in gains from investment in failed GalectoFujifilm Diosynth Biotechnologies doubles Danish bottom lineBoehringer Ingelheim initiates three obesity studies in phase III Novo Holdings is ready to increase business investmentsObesity drug sparks food sector concerns at Wall StreetGLP-1 drugs linked to increased incidence of stomach problems in new studyFujifilm CEO appoints another new director for "strategic leadership"Lundbeck creates incubator for budding biotech companiesInvestors: Coloplast passes unnecessary tax burden to shareholdersOrphazyme pays millions in settlement with critical investorsAbbvie takes advantage of option and secures potential treatment for Parkinson'sSobi appoints interim CMO as permanent solutionNew GN CEO to restore investor confidenceLeo Pharma appoints Alexander Egeberg as Head of Global Medical AffairsNovo Holdings' AMR fund breaks investment pause to co-lead Series A roundAmbu lands as expected in preliminary reportNovo Nordisk's lawsuit on unoriginal semaglutide gets dismissedBavarian Nordic eases sales outlookAnalyst sees great long-term potential for GNNew research: Anti-viral medicine slows down type 1 diabetes in childrenDemant gets EU approval for divestiture to CochlearBoston Scientific recalls duodenoscopes after malfunctionAmbu receives EU approval for new cystoscopeAmbu's CFO steps down - replacement has been foundNovo Nordisk stops trials in kidney patients early after efficacy resultsBiotech company closes second major funding round in a yearNovo Nordisk's success takes another victim: German dialysis group falls significantlyMicrobiome companies Clinical Microbiomics and CosmosID merge to create a global leaderALK with positive results from tree pollen allergy treatment trials in childrenGenmab close to breaking news on potential blockbustersPipeline hope shows promise for MC2 Therapeutics Novo Nordisk sees a significant increase in illegal sales of its medicinesAmbu CEO after managerial change: It's my job to look forwardEMA changes rules for publishing clinical trial informationAnalyst: Managerial change at Ambu is a blow to confidencePfizer's migraine pill becomes part of a risk-sharing trialHigh expectations for quantum technology: Could be as big as biotechFDA warns sellers of unapproved versions of Novo's and Lilly's obesity drugsFear of higher capital costs for Coloplast leads bank to lower price targetLeo Pharma has started phase IIb study with antibody treatmentNovo Nordisk significantly upgrades its guidanceNew painkiller from Lundbeck moves into the clinicCHMP recommends seven drugs in OctoberHearing company Estron targets US OTC marketLundbeck strengthens research department with German executiveNovo Nordisk buys phase III drug for billion-dollar sumSanofi ready with phase II data for new eczema drugTop executives see potential disruption from weight loss drugsAmbu selects French IT company as supplierFormer Novo Nordisk project delivers promising data for obesity candidateJ&J's Darzalex sales disappoint slightlyLundbeck moves on from swearing, shouting and spitting: New TV ad for Rexulti takes a softer approachNorwegian Medicines Agency issues major fine to Novo NordiskDemant's market share with US veterans drops in September Hearing aid manufacturers commence industry trade show in normalized marketAfter investing half a billion DKK in promising new antibiotics, Novo Holdings keeps its powder dry to secure funds for follow-up investmentsTeva migraine drug shows reduction in depression symptomsGenmab and Johnson & Johnson disappoint with lung cancer drug dataNovo Nordisk Foundation to build 17,000 sqm headquarters in HellerupViolent conflict affects Demant's business in IsraelDemant CEO: Normalized market growth will continue into 2024Kepler: "The enthusiasm around obesity is a bubble"Demant CEO: Sonova's exit from Costco has strengthened our positionWSA sees positive sales impact from new demo tool for Signia launchY-mabs hires American as new CEODemant launches new qualitative hearing testSonova wants to return to Costco - but probably not with the Phonak brandGN sees competitive advantage in new Bluetooth standard Report: Ozempic exceeds budget estimate in Norway after off-label prescribingLeo Pharma halts development of tablet treatment for atopic eczemaGN: New Bluetooth standard future-proofs Resound NexiaNovo Nordisk joins coalition to improve the health of patients of African descentSonova will wait with new Bluetooth standard: Happy with current solutionHearing aid manufacturers expect more benefits from AI - but see no revolutionWSA CEO: Still plenty of room for growth in US OTC channelInvestment bank: GN stole the show at the EUHA fairMedia: Novo Nordisk and Eli Lilly test diabetes drugs as obesity medication for childrenNovo Holdings funds lobbying for new antibiotic business modelGenmab and Seagen presents positive data from phase III study of cervical cancer drugEU Commission fines pharmaceutical companies millions of euros for price cartelEli Lilly files complaint about unapproved versions of tirzepatide Demant: We lacked scale for the gaming marketDid you miss anything from EUHA 2023?More US investors point their attention towards Novo NordiskNovo Nordisk CEO's total income exceeds half a billion kronerMedia: Eli Lilly hires CDMO as subcontractor for diabetes drugGlobal leader: Genmab reinvests more than competitors in R&DNovo Nordisk and Eli Lilly are eating up the entire obesity drug marketAustrian patients hospitalized after presumably fake diabetes medicineBII supports Belgian researchers in launching new biotech companyEU ready to loosen demands on critical medicinesBarclays sees strong growth potential and lower costs at LundbeckNykode raises more than NOK 500m: "An important step towards a potential US IPO"Novo Nordisk has intensified search for illegal copies of its drugsCDC suggests expanded use of Bavarian Nordic vaccine against mpoxUK approval paves way for wider use of MounjaroEli Lilly pays USD 20m in new partnership with ElektrofiLeo Pharma has created its own version of popular artificial intelligenceNew studies find benefits in early drug treatment of Alzheimer’sEli Lilly will study Mounjaro use for weight loss without associated muscle lossUK issues warning about counterfeit Novo Nordisk medicinesSanofi's focus on development prompts share price dropGalecto shelves cancer candidate with promising data: "Unfortunately, these are the conditions"EU expresses concern toward Edwards Lifesciences after unannounced visitEMA sees no evidence of increased cancer risk with GLP-1 drugsNovo Nordisk wants to expand in the USNovo Nordisk is expected to break past its own obesity target more than a year ahead of timeDanske Bank lowers price target for Coloplast ahead of annual reportLeo Pharma reports positive news in expanded phase III study for hand eczemaAmplifon disappoints with earningsOrifarm appoints new Chief People OfficerInvestment bank cuts price target on GNOzempic mania tests Novo’s supply: EMEA earnings week aheadALK CEO resigns: "We've raised the bar"Novo Nordisk CEO has ditched Twitter in favor of LinkedInLilly to pay Beam up to USD 600m for rights to experimental heart disease treatments French diabetes company raises EUR 33.5 millionNovo Nordisk starts first-in-human trials with Dicerna cancer candidateNovo Holdings leads 225m USD investment in Maplight TherapeuticsGLP sales in focus in Novo's Q3 figures after major guidance upgrade - important data to comeNovo Nordisk blockbuster now has a copy in RussiaNovo’s weight-loss drug demand fuels rise in illegal salesMedia: Orifarm owner to sell stake in the companyNovo Nordisk's key products continue high growth in the third quarterNovo Nordisk exceeds obesity target more than a year ahead of scheduleOrifarm owner confirms: We are exploring the possibility of a co-investorMounjaro co-leads Eli Lilly to significant revenue growthJapan approves new Novo Nordisk hemophilia drug - will launch in 2024Novo Nordisk's biopharma products under pressure from declining growth hormone salesNovo Nordisk expects to follow up on terrific 2023 with double-digit growth next yearNovo Nordisk prepares to launch muscle mass preservation drugTheft prompts Novo Nordisk to increase security across its supply chainNovo Nordisk changes Rybelsus recipe to free up semaglutide for top sellersNovo Holdings makes large investment in US biotech companyEli Lilly to expand production following soaring Mounjaro salesNovo Nordisk CEO sounds alarm on EU reform for cheaper medicinesRani Therapeutics suspends two development programs, closes one and lays off one in four employeesProspects for sales growth but declining bottom line at GenmabAnalyst expects high gear at Demant with a hard slowdown aheadLundbeck and Otsuka reports positive data from phase 3 trial of Alzheimer's drugDemant grows on the top line - but disappoints compared to expectationsSale of Demant's implant business is delayedNovo Nordisk buys own B shares from Novo Holdings for DKK 4886 million.Prelude to Lundbeck financial results: Continued solid growth in sightGenmab clarifies expectations and sees revenue at the high endGenmab's COO on launch of new cancer hope: It's gone better than expectedLundbeck narrows outlook after sales growth for all key products - but one in particular disappointsNew Lundbeck CEO reviews strategy: "It’s important to recognize where our strengths are"Improved outlook at Lundbeck is all about timing costsNovo Nordisk exec bags millions through sale of sharesForecast in focus as Coloplast presents its fiscal report on ThursdayEli Lilly gets its obesity drug approved in the USEli Lilly to compete with Novo Nordisk on the price of obesity treatmentAscendis increases sales of growth hormone by more than 30% - raises outlook for the yearAnalyst on competition in the obesity market: There is room for both Novo Nordisk and Eli LillyAstrazeneca secures oral obesity candidate in potential billion dollar dealColoplast shows weaker than expected financial results with flat bottom line growthColoplast to build $100M factory in Portugal to boost catheter productionNovo Nordisk to bolster API production with multi-billion kroner investment in DenmarkGN sees robust growth with Resound Omnia, tightens full-year forecasts for hearing aid businessColoplast CEO gets a 9% pay raiseGN bids farewell to HQ in leaseback deal, boosts capital plan with DKK 500 MillionNovo Nordisk to phase out long-acting insulin Levemir in U.S.Wegovy study sparks high expectations: Novo Nordisk to reveal findings on cardiovascular benefitsGN to cut 300 jobs globally as part of merger of divisionsCHMP recommends approval of Eli Lilly's obesity drugCHMP recommends eight new medicines in NovemberWegovy reduces the risk of blood clots and serious cardiovascular eventsNovo Nordisk EVP on cardiovascular study: A great tool when negotiating reimbursementLundbeck and Otsuka expect news on PTSD study after New Years Ambu's profit decline amidst revenue riseLeadership shift at Pharmacosmos: Henrik Parker appointed CFOZealand Pharma reaps financial gains in Q3, citing advancements in obesity drug developmentGN's new hearing aid business chief Scott Davis to lead from USNovo Nordisk's Wegovy study hailed as 'heavyweight knockout' by JefferiesAnalyst keeps an eye on tablet sales in ALK's Q3 reportConvatec updates 2023 outlook: Higher organic growth, maintains EBIT margin guidanceFreight costs decline to pre-COVID levels, benefiting companies like AmbuBelgium bans Ozempic prescription for weight loss until summerALK surpasses analyst expectations in Q3 with earnings and revenue growthNovo Nordisk's Lange and Moore offload sharesNMD Pharma's Series B round raises €75 million, fuels clinical trials and expansion effortsAnalysts acknowledge ALK's strong tablet sales and marginThree out of four ALK top executives changed in eight months: "There are probably a few more questions asked now"Bavarian Nordic's Q3 report anticipated to showcase significant revenue growth from vaccine salesBavarian Nordic reports lower-than-expected Q3 financials, suffers loss due to COVID-19 vaccine write-downNykode Therapeutics highlights advances in cervical and head & neck cancer studies, prepares for US Nasdaq listingGilde Healthcare raises maximum amount for new life science fundALK's Jext pen sales drop amidst Recipharm's production problemsNovo Nordisk goes head-to-head with Eli Lilly obesity drug ZepboundAcquisitions remain part of the strategy at Bavarian NordicMedia: Eli Lilly to follow Novo Nordisk with substantial investment in production, eyeing expansion in GermanyIndustri veteran appointed GM of Moderna in the NordicsLeadership transition at Sonova: Gilbert Achermann to take over as chairman in 2025Bavarian Nordic "rightsizes" R&D: 50 positions cutNovo Nordisk nears full capacity for now with latest factory expansionNovo Nordisk rumored to be making a major investment in French factoryGN and Demant gained some ground with US veterans in OctoberEli Lilly ready to break ground on USD 2.5bn German factoryNovo Nordisk rumored to be making a major investment in French factoryAlmirall initiates launch of new eczema treatment in EuropeParallel importer expands group management with new CIOAdvertisers flee anti-Semitic content on X - Novo Nordisk upholds advertising pauseSandoz opens new antibiotics plant and biosimilar development center in EuropeBavarian's sales of travel vaccines impress major bankSonova downgrades following prospects of increased investmentsNovo Nordisk donates millions to Gaza and IsraelAn increasing number of female mid-level managers puts male-dominated executive board under pressure at ColoplastDemant resumes share buyback – expects no acquisitions until next yearMedtronic slightly raises its earnings forecastAstraZeneca to focus on healthcare technology – creates new companyUK pharmaceutical industry and NHS reach five-year agreement on drug pricesEuropean health authorities warn of periodic shortages of Ozempic drug in 2024Novo Nordisk reveals price list for Wegovy in Japan: Will launch in FebruarySonova CEO believes in market share boost and expects strong impact from launchesUS competition authority tightens scrutiny of pharma industry's patent tacticsNovo Nordisk Foundation: We could become the world's largest donorMacron expected to announce EUR 2.1bn Novo Nordisk investment in FranceCould outperform Wegovy and cagrisema: Novo Nordisk starts trial with obesity hopeNovo Nordisk confirms: Investing EUR 2.1bn to expand production in FranceGenmab silent on new investor role in private equity fundNovo and Lilly in race to invest the most in obesity drug production Ambu has raised prices in all markets: Customers are responding positivelyColoplast to pause acquisitions: "There will be no significant acquisitions in the coming years"MC2 to recruit first patients for proof-of-concept clinical trial with new candidateEuropean pharmacovigilance committee launches investigation into possible side effect of COVID-19 vaccinesIntron Health boosts Novo Nordisk share price target, maintains 'buy' ratingGenentech and Nvidia join forces to build AI-driven drug discovery platformChina's leading vaccine maker Zhifei targets diabetes, obesity in Chenan buyoutGenmab and Abbvie's epcoritamab is one step closer to treating a new form of lymphomaBillion-dollar profit boosts Novo Nordisk Foundation's political powerEMA grants accelerated status for French chikungunya vaccine Novo Nordisk's obesity drug loses to Eli Lilly's in large comparative analysisGSK announces positive results from phase III trial of cancer drug competitor to Genmab's DarzalexAnalyst: Novo's production scale will be more important than efficacy in competition with Eli LillyWS Audiology changes management team - brings in new COO Novo Nordisk after Ozempic analysis: There are no real comparative studies within obesityPfizer consolidates Nordic companies and cuts jobsFDA contacts Otsuka over marketing of depression drug co-developed with LundbeckNovo Nordisk considers flexible pricing for WegovyNovo Nordisk discounts on weight loss drugs revealed by US mediaAmbu receives European approval for ureteroscopy products Eli Lilly enters potential billion-dollar collaboration with Japanese biotech companyBloomberg Intelligence sees key patent case protecting Novo Nordisk's USD 98bn Wegovy saleAscendis signs license agreement with Japanese pharma companyLong-time Novo investor cuts stake citing weight-loss drug hypeIndustry veterans Conterno and Sullivan join Zealand Pharma's board as observersGubra advances obesity drug into clinical trials: First patient dosed in gubamy studyXellia Pharmaceuticals gears up Cleveland facility after FDA nodNovo Nordisk sues over impure WegovyLundbeck ventures into rare eye disease treatmentAnalyst sees acquisitions helping Lundbeck's pipeline ahead of Rexulti patent expirationBernie Sanders summons pharma CEOs to senate hearing on high drug prices in USAltimmune reports positive results for its obesity drugConsortium gets EUR 8m to develop vaccine against Nipah virusNovo Nordisk has paid US doctors to promote weight loss drugsPfizer ditches development of obesity pill in its current formPfizer's failure with weight loss drug strengthens competitorsRoche enters obesity drug race via new acquisition Zealand Pharma gets important obesity data in 2024Obesity market expected to double by 2024: Novo Nordisk in the driver's seatWSA is approaching black bottom line figuresNovo Nordisk to provide more information on psychiatric side effectsFujifilm invests USD 200m in new headquarters and CDMO businessAnalysts welcome Lundbeck strategy: "It's important not to bet the farm"No promise of profits at WSA despite improvements on bottom line J&J psoriasis drug sales falter as competition heats upWSA CEO thrilled by high employee satisfaction following mergerSea Cargo Charter opens up for ship owners to join initiativeSanofi strikes USD 140 million drug-research deal with AqemiaEli Lilly obesity drug now available in US pharmaciesWSA CFO: We still have a lot to gain on our marginsOwner behind sold biotech firm: "I can retire if that's what I want"Wegovy being tested in alcoholism - but indication not a priority for big pharmaPatent vouchers prove popular in DenmarkZealand Pharma CEO open to reviving sales departmentGSK top boss: RSV vaccine sales will top GBP 1bn this yearJohnson & Johnson stays out of obesity race due to strong competitionNew study: Patients more likely to stick with Wegovy compared to older weight loss drugsLundbeck and Axxam join forces to find early-stage CNS candidatesEU health data sharing on the horizon despite trade secret concernsPotential EU drug voucher scheme criticized - "a random group of patients will foot the bill" Ambu gets US special status for bronchoscopeNovo Nordisk forms unit to study obesity preventionHigh inflation still a challenge at Coloplast, pension fund warnsBioporto secures crucial FDA clearance for kidney testLife science industry will need to recruit 15,000 more people in Denmark by 2030Pfizer and Biontech drag Orban government to court over missing payment for 3 million vaccinesDemant finds new CEO for subsidiary after predecessor's unclear exitNew trial design paved the way for Bioporto's crucial FDA approvalNovo Holdings increases investment in Asian app company Analysts: Novo Nordisk's stock will underperform in 2024 as hype fadesGenmab reports promising results for elusive lymphoma candidateMC2 has all patients in place for phase II trial of skin disease drugEU reaches agreement on artificial intelligence rulesUS senate hearing coming up: Bernie Sanders criticizes high price of GLP-1 drugsSydbank surprised by investor response to Eli Lilly study with obesity drugColoplast Chairman: Acquisitions will drive growthDanske Bank sees acquisitions as bridge over looming patent gap for LundbeckAstraZeneca to pay up to USD 1.1bn for vaccine developerDanish economists call Wegovy reimbursement "too expensive"GN chief exec buys thousands of company sharesNovo Nordisk bemoans long construction times: "It's actually difficult for us to keep investing in Denmark"Olympus expands endoscope collaboration with SonyAlmirall enters into another AI dermatology partnership Trans-Atlantic women's health firm raises almost USD 40m in Series A round ALK expands partner agreement in Japan with grass allergy tabletGenmab and Abbvie to ramp up Phase III studies of epcoritamabEU designates over 200 medicines as "critical"Ferring lays off 134 employees in the USBoehringer Ingelheim and Gubra deepen partnership with €144 million obesity research dealAscendis Pharma's resubmitted Transcon PTH NDA gains FDA acceptance, decision expected by MayMass layoffs announced at Xellia's Cleveland factoryExpanding cancer fight: Nykode advances vaccine candidate for colorectal cancerAmbu gets a new vice chairmanEU Commission backs expanded Health UnionNovo Nordisk buys production facilities in IrelandNykode expects to start clinical trials with new vaccine candidate in 2025ALK and Torii Pharmaceutical strengthen alliance with new allergy tablet vaccine agreementFractyl Health eyes Nasdaq listing amid booming obesity treatment marketCHMP recommends seven new drugs - approves first crispr treatmentAlmost all of Bavarian Nordic's product portfolio on new 'critical' listAmbu CEO promises more growth in legacy business: "Not prioritized enough"Side effect concerns affect Genmab share priceNovo Nordisk Foundation grants up to USD 260m to new vaccine initiativeNovo Nordisk wins battle against illegal Wegovy advertising Media: EU countries have discarded EUR 4bn worth of Covid vaccinesAnalysts: Difficult for Novo Nordisk to repeat share price performance in 2024Lars Fruergaard Jørgensen is Financial Times' Person of the YearApple to halt sales of latest Apple Watch in the US after patent dispute with medtech companyUniversity reports research breakthrough in fatty liver disease - expects interest from big pharma Boehringer Ingelheim and Saniona extend research collaborationEU politician wants to tighten drug voucher requirementsApple working hard to resolve patent dispute with medtech company and avert sales banNovo Nordisk partners with biotech accelerator in SwitzerlandFDA approves Leo Pharma's eczema drug for adolescentsEli Lilly sells European rights to migraine medication for USD 50mEU revokes marketing authorization for generic versions of Biogen's sclerosis drugCorti fears consequences of new AI law in the EUNovo Nordisk wants US Ozempic lawsuit dismissedSonova, GN and Demant lost market share with US veterans in NovemberNovo Nordisk's head of development highlights need for diverse obesity treatmentsFDA warns against use of counterfeit OzempicNovo Holdings-backed firms strike deal for S. Aureus vaccine developmentZealand Pharma aims high in obesity market with a focus beyond weight lossZealand Pharma gains financial muscle with EUR 90 million EIB loanEli Lilly and Fauna Bio sign obesity dealZealand Pharma files for FDA approval for glepaglutide for short bowel syndromeFDA rejects Zealand Pharma application due to problems at contract manufacturerBrazilian pharma firms gear up for Novo Nordisk generics pushAnalysts predict WS Audiology will bring new investor on boardFormer Novo Nordisk CEO failed to inform FDA of guideline breachGalecto drug shows cancer treatment potential in Phase II trialRoche to receive FDA ruling on food allergy indication soonZealand Pharma CEO: Contract manufacturer has resolved issues behind FDA rejectionNovo Nordisk "selective" about potential obesity acquisitions, says directorZevra Therapeutics resubmits Orphazyme asset to FDANovo Nordisk's popularity declining among portfolio managersGN CEO reflects on turbulent 2023: "We are in a good, stable place now"Xellia Pharmaceuticals and Civica extend collaborationRonica Wang steps down from GN boardNovo Nordisk applies for planning permission near DublinZealand Pharma CEO: Potential partners must contribute to obesity businessAnalyst predicts Eli Lilly will dominate obesity and diabetes next yearZealand CEO on new observers on the board: Will benefit from Eli Lilly veteran's experienceBritish doctor investigated after prescribing Novo's Wegovy to DaneFalling rates may increase appetite for biotech, managing partner saysGN to replenish board at upcoming AGM after resignationMajor banks expect more Novo upgrades in 2024China approves AstraZeneca, Sanofi shot to prevent RSV infectionInsulin manufacturers cut prices in USARussian companies get license to pirate Novo Nordisk's blockbusterNovo Nordisk and Eli Lilly at odds over consolidation of product liability cases in US courtDemant appoints new head of investor relationsBoehringer Ingelheim bets USD 2bn on NASH partnershipNykode hires CTO from BiontechStudy exonerates Ozempic and Wegovy for causing suicidal thoughtsThis is how many new drugs were recommended and approved in 2023Novo Nordisk, Omega Therapeutics, and Cellarity join forces in obesity and MASH researchALK acquires US skin test companyUS biotech firm enjoys Novo stock exchange effect after partnership announcementNovo Nordisk to open AI hub in London Novo Holdings leads million-dollar investment in medtech company focusing on neuropathic painPharmacosmos hires life science veteran as new sales and business directorSobi's chairman resigns due to health reasonsInternal communication reveals identities of fired Demant executivesMSD plans to compete with Novo Nordisk for obesity marketEli Lilly launches online sales of obesity drugHearing aids could help prevent dementia - but are shrouded in tabooHemab appoints Alnylam Chief Innovation Officer to boardAmbu finds Chief Marketing Officer at OlympusZealand Pharma CEO: Significant portion of population will take obesity drugs in 2074ALK's new asset is "diamond in the rough," says EVPNovo Nordisk reports successful phase III study with combination drugZealand Pharma raises over USD 200m through directed share issueAscendis Pharma signs distribution agreement with Singaporean firmPfizer promises aggressive weight loss strategyLundbeck targets EUR 5-6bn war chest for strategic acquisitionsDanish Reimbursement Committee stands firm: Will remove reimbursement for GLP-1 analoguesGenmab and Seagen takes next step towards full approval of cervical cancer drug in the USToxic behavior led to Demant firings, sources revealAmbu's climate goals approvedNovo Nordisk CEO: Our biggest obesity challenge is not competitionMedia: WSA owners seek new co-investorNovo Holdings antibiotic fund makes second investment in US-based AMR firmPfizer completes Nordic management puzzle: Norwegian country manager becomes head of NordicsZealand Pharma CEO identifies focus on obesity as driving force behind million-dollar investmentsRoche still deal hunting within obesity indicationNovo Nordisk joins genomic data allianceNovo Nordisk to test aquired antibody in heart attacksGenmab CEO praises "miracle" drug candidateZealand Pharma is potential acquisition target for Pfizer, investors sayZealand Pharma share price multiples almost fivefold in one yearEisai and Biogen prepare for Chinese launch of Alzheimer's drugSwiss pharma giants who missed boat on obesity fight to stay relevantDNB predicts growth momentum at Ambu and lifts price tagetFDA finds no proof that GLP-1 drugs cause suicidal thougtsSanofi considers entering obesity marketOzempic mania fuels deal optimism across drug industryLilly and Novo bosses agree: There is plenty of room for other obesity playersWhistleblower was pushed to breaking point by Demant DirectorEconomist shoots down rumors that Pfizer could acquire Zealand PharmaAmbu to withdraw from Russia in 2024Bank predicts Novo sales growth of 25% this yearAnalyst expects conservative 2024 guidance from LundbeckCommunication advisors call fired Demant CEO's farewell "provocative"FDA approves indication expansion for MSD blockbusterUniversity of Copenhagen files patent application for potential anti-obesity discoveryAscendis innovations to fly the nest as independent companies Novo Nordisk resumes supply of 1.7 mg Wegovy dose in the US EMA reviews safety of CAR-T cancer treatmentsÖssur acquires German firm in EUR 100m dealEU Commission launches Critical Medicines AllianceZealand Pharma gets substantial price target boost from major US bankFired CEO on "unsafe" work environment at Interacoustics: "There were individual cases"GLP-1-markets to reach USD 150bn in 2030, Jeffries predictsEli Lilly plans new launches of popular obesity drug this yearColoplast retains title of world's most sustainable medtech firmFerring to make gene therapy widely available in USLundbeck monitors 30 potential acquisitions: Aiming for one billion dollar deal per yearZealand Pharma has a new major shareholderGenmab is predicted to spend more on research and development in 2024AJ Vaccines has millions in debt converted – againNovo Holdings leads USD 75m investment in Cleveland DiagnosticsALK completes and expands Phase I trial with peanut allergy tabletDNB sees Genmab's 2024 forecast well below market expectationsDemant and GN took Veterans Affairs market shares from rivals in DecemberNovartis ends Phase III trial of peanut allergy candidateRoche Chairman: Antibiotics must not be seen as a mass market productNovo Nordisk owner will invest Ozempic profits in deals in AsiaMedia: Italy's Amplifon plans to buy franchisee network in US pushALK sees room for more players in the peanut allergy marketCiti has lost faith that Johnson & Johnson will exercise option on next myelomatosis drug developed by GenmabEMA to take a closer look at Wegovy's cardiovascular data this weekGenmab loses arbitration case against JanssenLundbeck launches "Say Yep" campaign for migraine drug in the USZealand Pharma CEO: The obesity race can still be won by others than Novo Nordisk and Eli LillyGenmab's Darzalex sales in line with estimates but slightly below own forecastLeo Pharma completes acquisition of Timber PharmaceuticalsLeo Pharma got a hefty discount on Phase III assetEracal Therapeutics and Novo Nordisk partner to fight obesityFund manager: The obesity competition is getting even more intenseLeo Pharmas Delgocitinib triumphs in Phase III hand eczema trialUCB: Lundbeck study could prove to be a potential game changerNovo Holdings buys chunk of Indias Medi Assist ahead of IPOAkouos shows efficacy with gene therapy for hearing lossFormer head of R&D at Leo Pharma takes the helm at BenevolentAIRising demand causes shortage of Eli Lilly's MounjaroFujifilm completes billion-dollar factory expansion in DenmarkEMA to review ALK's registration application for house dust mite tabletNovo Nordisk about to receive important CHMP decision on Wegovy label extensionMichael J. Fox Foundation awards grant to Vesper BioEli Lilly to launch weight loss drug Zepbound in the UK within weeksUse of counterfeit Ozempic linked to hypoglycemiaEVP of Global Quality at Eli Lilly to retireYet another biotech company shows efficacy with gene therapy for hearing lossEmployees, stability and environment are crucial for Fujifilm's billion-dollar investment in DenmarkCHMP rejects two drugs - three get endorsement Analysts: Ambu could be poised for an upward revisionNorth Carolina stops subsidizing obesity drugs for its employeesLargest shareholder unloads Zealand Pharma sharesNovo Nordisk faces opposition to factory construction in IrelandStrong start to the year and possible upward adjustment ahead for AmbuAmbu CEO wins board awardChina approves Novo Nordisk's RybelsusEU proposes lifeline for medical device industry with extended IVDR deadlineAmbu grows single-use endoscope sales by 25%, maintains full-year outlookInvestment bank DNB raises Demant's price target by 6 %EMA recommends indication expansion for Lundbeck drugEyconis spins out from Ascendis Pharma, eyes breakthroughs with USD 150m backingEMA awarded EUR 10m to establish African Medicines AgencyBritish biotech industry stays strong in face of tough marketAnalysts predict another good year for Novo NordiskAmbu CEO open to acquisitions: "We are looking into it now"Novo Nordisk increases revenue by 31%Novo Nordisk predicts double-digit growth in 2024 but keeps range wideSmaller than expected sales decline in Novo Nordisk's biopharma divisionNovo Nordisk plans further significant investments to solve capacity issuesNovartis reports significant Kesimpta sales growthLundbeck-Genmab partnership drug fails to beat placeboBiogen stops sale and development of controversial Alzheimer's drugGSK records blockbuster RSV vaccine sales after four months on marketColoplast launches new wound care product and invests in US sales forceNovo Nordisk expects price pressure on obesity drugs from "a competitor"Danske Bank predicts bumps ahead for Ambu despite strong start to financial yearNovo Nordisk CEO gets raise in record-breaking yearPfizer lays off 20 employees in DenmarkAscendis markets second commercial product – launching in Germany and AustriaLundbeck is not ready to give up on CNS candidateMajor bank sees positive signals in Lundbeck's MSA study despite missed endpointNovo execs and board members receive shares in remuneration programInvestment bank: Estimates too high ahead of Genmab's annual reportAlmirall and Microsoft launch collaboration to develop dermatology drugsNovo Nordisk's price target raised by major investment banks following annual reportNovo Nordisk maintains factory in Russia: "An ethical dilemma"Orifarm merges business units and changes its group managementEMA initiates assessment of Genmab and Seagen cancer drugFDA extends review time for weekly Novo Nordisk insulinPharma industry to pay up: EU adopts new wastewater directiveGubra ends research agreement with Silence TherapeuticsFormer Lundbeck Foundation profile becomes CCO at Xellia PharmaceuticalsMedia: Private equity firm prepares Galderma IPONovo Holdings to buy Catalent and sell three factories to Novo NordiskWSA launches new product in secondary brandAnalyst thinks Demant's expectations may be too highAnalyst: Novo Nordisk acquisition demonstrates potential for huge market growthDemant presents strong forecast for 2024 – more growth is in sightDemant is about to launch new top productNovo Nordisk's USD 11bn factory purchase breaks firm's own recordDemant explores sales opportunities for part of the businessDemant to buy back shares of more than DKK 2bnNovo Holdings on acquisition of Catalent: "Plenty of value creation in sight"ALK gets stamp of approval for climate targetsALK and Catalent collaboration to continue despite Novo acquisitionLundbeck poaches HR exec from AstrazenecaEli Lilly expects new drugs to drive 18% growth in 2024Divestment of business area would not make Demant more vulnerable, says CEOWSA's major debt is due in two years: "We are in the process of dealing with it"Lundbeck expects double-digit growth at the top of its new guidance rangeNovo Nordisk CEO awarded bonus shares and sells shares worth close to USD 21mDemant CEO granted 31% salary increase in 2023Consumer willingness to pay for weight-loss drugs surprises Novo CEOEli Lilly keeps close eye on Novo Holdings' planned billion-dollar Catalent transactionFired Demant company directors demanded positive responses to well-being surveysFocus on synergies and forecast under new structure in GN's annual reportEli Lilly cries foul over Novo acquisitionLundbeck CEO to encourage growth by switching up sales focusALK and university researchers discover new cell that remembers allergiesGN Hearing predicts it will outdo market in 2024Novo Nordisk CEO eyes "huge opportunity" in unused capacity at CatalentOzempic maker Novo gets calls from ‘scared’ food CEOs for adviceWSA launches new product under the Widex brandLeo Pharma appoints new country manager for Spain and Portugal EMA to investigate potential impact of Novo Nordisk's Catalent factories acquisition Analyst expects sluggish start to the year for ColoplastALK reports significantly improved operating profitColoplast launches new product within its core businessNovo Nordisk executive sells shares for more than DKK 48mFormer GN Hearing CEO received DKK 9.5m in exit packageColoplast lowers expectations for reported growth in Danish kroner due to negative currency effectColoplast to capture last major EU market for new catheterDemant CEO after director layoffs: "Our work to ensure a good and safe working environment continues"New ALK CEO on strategy review: "It's not about changing the goals"Novo Nordisk settles in two cases of counterfeit Ozempic and WegovyCatalent presents disappointing resultsNovo Holdings increases its annual investments by billionsInvestment economist: Unrealistic board or unattractive job may explain Lundbeck CEO's high payLundbeck chair defends CEO's wages: "We are paying the market rate"Jyske Bank predicts Coloplast upgrade later this yearInvestors look for pipeline news in upcoming Genmab reportALK vice president secures DKK 4.9m by exercising optionsNovo Nordisk's expansion plans in North Carolina are well underwayAnalyst: Demant's divestment of Communications makes senseObesity success drives up Novo Nordisk's climate emissionsDemant loses slight foothold among US veterans while GN sees modest increaseOzempic shows promising results in reducing infections after hip replacementManchester City striker Erling Braut Haaland invests in NykodeAnalyst expects more supply difficulties at Novo NordiskDespite promising research: Novo Nordisk will not test semaglutide in hip patientsCEO has big cash incentive to sell Galecto before summerFerring country manager resigns after 21 years with the company, but leaves room for board workGerman life science investor Earlybird Health closes second fundAnalysts expect increased 2024 costs at GenmabGenmab: Revenue may exceed DKK 20bn in 2024Novo Nordisk under fire — captured wild monkeys for animal testingGenmab launches new share buyback programSydbank analyst praises "eye-catching" Genmab share buyback programEli Lilly launches obesity drug in the UKGenmab CEO: Share buyback program "has nothing to do" with price dropMore children in the US are being given weight-loss drugs – including Wegovy Genmab's value increases by almost a billion dollars after share buybackPotential share bonus could boost Genmab CEO's salary Genmab: Newer drugs account for 40% of expected revenue growth this yearCatalent laid off 300 employees during restructuring prior to Novo Holdings acquisitionFDA issues warnings to two sellers of fake semaglutideUnion Therapeutics ready for phase III: "We're in a really good place"Genmab CEO warns of excessive focus on possible successor for DarzalexAlmirall acquires antibody candidate from Novo NordiskOzempic is 75% more expensive in Denmark than NorwaySanofi and Regeneron's multi-blockbuster approved for sixth indicationGN nominates two candidates for board expansionFDA approves Roche food allergy drugSales of psoriasis drug developed by MC2 increase significantly at AlmirallLundbeck Foundation CEO nominated for Ørsted chair roleCapital market days may lead Bavarian Nordic to release key figures ahead of scheduleNovo Nordisk is successful in attracting foreign workers to Danish factoryBioporto and Roche expand kidney collaborationEquity broker lowers GN's price target following annual reportGenmab CEO won't rule out future factory on Danish soil: "But we are not at that point now"New research: Possible to maintain weight loss after quitting anti-obesity medicationBiogen's transitional agreement with Fujifilm on Danish factory has expired: Expects major business leg declineBavarian Nordic releases financial report early, reveals extraordinary growthBavarian Nordic scraps cancer vaccine and drops oncologyOzempic boom leaves room for dialysis, Fresenius Medical saysAmbu welcomes Chinese anti-corruption initiativesVisibility is key, says new CEO of Ferring's Danish branchNovo Nordisk on use of wild monkeys in animal testing: It's been stoppedOzempic to send foodmakers looking for healthier offeringsEli Lilly looking for Nordic public affairs head to lead obesity driveMajor Demant shareholder has "no comment" on toxic workplace claims: "It's really not something I want to share with you"Novo Nordisk's board proposes the same lineup in 2024Bavarian Nordic on leaving oncology: "There’s no point in a half presence in cancer"Ambu CEO spots shipping price timebomb on the horizonÖssur plans to change name to Embla MedicalGN is monitoring Red Sea situation closely: Our logistics team is working day and nightWSA appoints new chairman of the boardBavarian's chikungunya vaccine candidate to get accelerated assessment by EMALundbeck's EVP of commercial operations to leave by March 1 - makes several changes to managementIndia to develop its own versions of Novo Nordisk's obesity drugDiabetes company backed by Novo Nordisk heirs raises million-dollar sumEU regulator set to decide on Wegovy’s heart benefits in AprilEMA recommends ten new medicinesNew drugs on US market were 35% more expensive in 2023Boehringer Ingelheim and Zealand Pharma report "groundbreaking" fatty liver syndrome resultsLundbeck CEO: New management team increases focus on future growthMajor bank: Wegovy use could increase USA's GDPFormer Coloplast CEO to chair three boards at 64: Flexibility is importantZealand Pharma CEO on fatty liver data: "Takes the molecule to a whole new league"Lundbeck hires new chief communications officerInternational biotech investor: Raising capital has become more difficultZealand Pharma triples revenue FDA grants Genmab cancer drug priority review status Novo Nordisk enters collaboration and licensing agreement with US-based NeomorphZealand Pharma nominates two former Eli Lilly profiles to boardBavarian Nordic considers acquisitions — once it has paid its debtsViking Therapeutics poised for major share price increase following new obesity dataNovo Nordisk and Eli Lilly enjoy price target leap at BerenbergBavarian Nordic capital markets day has put investors at ease, says pension fundEQT to focus on healthcare investments after raising record amountZealand Pharma CEO highlights obesity drive as reason for share price boostGubra to increase research focus on obesity candidateBank hopes for sneak peek at Novo's new drug at capital markets dayDemant Board has "full confidence" in management's handling of unsafe work environmentNykode CEO thinks "tough prioritization" necessary for pipelineDemant Vice Chair sells shares for over USD 5mAnalyst: Weight-loss drug from Viking Theraputics is "absolutely competitive"Wife of Coloplast deputy chair buys 20,000 shares in firmZealand Pharma price target increases significantly at two major US banksZealand CEO considers higher operating costs a necessity for further developmentLeo Pharma meets big 2023 goal but substantial deficit remainsLeo Pharma to launch new growth driver in Q4 — will start in GermanyNovo Holdings finally reveals focus of biotech babyMore than one billion people are now obeseZealand Pharma gets highest price target to date after positive analysis by major US bankFujifilm signs power purchase agreement for Danish factoryLeo Pharma CEO on future IPO: 2023 marks an important milestoneArctic Bioscience: All patients dosed in psoriasis studyViking Theraputics to issue new shares for more than half a billion dollarsFormer country manager fought to keep Ferring in DenmarkAbacus quadruples bottom line in record yearNovo Nordisk is working on long-acting GLP-1 agentsEli Lilly ramps up in the Nordics ahead of major launchesFormer Leo Pharma and GN Hearing CEO Gitte Aabo nominated for chairman of Swedish companyAnalyst: Catalent purchase could block copies of Novo Nordisk drugsFDA delays decision on Orphazyme's former crown jewelBoston to be the hub for Novo Nordisk's future medicinesStudy shows semaglutide reduces risk of kidney disease-related eventsSacked Demant executive receives USD 2.6 million golden handshakeLundbeck prepares for Phase III study of MSA drug after encouraging dataJeffries: Results from Novo Nordisk's Flow study in line with expectationsGerman investment bank sees potential in Zealand PharmaEli Lilly is catching up to Novo Nordisk in the obesity treatment marketViking Therapeutics exceeds fundraising goal following successful obesity studyAmerican and Israeli researchers earn The Brain Prize for advances in AI and neuroscienceVaccine makers Bavarian Nordic and Valneva to wind down partnership as competitive tides shiftNordic Bioscience wants a piece of the obesity market: "The first trial data after three months looks exciting"Coloplast's top management realizes million dollar gains from share salesGalderma goes public in SwitzerlandBank: Novo Nordisk's US obesity drug sales are set to quadruple in three yearsNovo Nordisk wants Japan to know it has an obesity problem, tooNew Novo obesity drug provides huge weight-loss effect in just 12 weeksVtv Therapeutics to start PhIII test of diabetes drug in Q2Demant removes upper age limit for board membersOzempic side effects send nauseous, constipated users to TikTok for helpNovo Nordisk expects approval of Wegovy in China this yearCigna aims to broaden obesity drug coverage with financial guaranteesJoe Biden in State of the Union speech: We finally beat Big PharmaPension fund will vote against re-election of Coloplast chairman Novo Nordisk expects to launch new weight-loss tablet by 2030Burglars target Novo bestsellers in pharmacy break-insEli Lilly's Alzheimer's candidate delayed — againCEO confident as Novo Nordisk's record filling factory purchase closely scrutinizedSanofi has positive results with drug candidate for skin diseaseInvestors expect Demant to focus on core business at Capital Markets DayLundbeck investors fret over patent expirationNovo Nordisk shared internal knowledge with selected investorsDemant upgrades medium to long term guidance and expects bigger market share and increased earningsNovo Holdings' total values grew by double digits in 2023Third major Nykode Therapeutics figure buys shares in firmAnalysts give thumbs up to new Lundbeck data and phase III plansWegovy’s newly verified heart benefits under review by MedicareDemant investing heavily in artificial intelligence to develop the hearing aids of the futureMC2 Therapeutics and Hyphens Pharma partner up to bring psoriasis cream Wynzora to Southeast AsiaInjection should match results for new obesity tablet, says Novo Nordisk EVPNovo Nordisk CEO sticks to own obesity market metrics as analyst speculations aboundEli Lilly partners with Amazon to sell more weight-loss drugsGood momentum in Demant's Chinese retail business two years after acquisition, firm reportsBavarian Nordic's pox vaccine approved in SwitzerlandSurge in fake Ozempic reveals dark side of weight-loss frenzyGN expands the board with two new membersAsgard Therapeutics raises EUR 30m to transform cancer cellsEli Lilly's lebrikizumab shows promise for atopic eczema in skin of colorHead of R&D at Lundbeck feels on safe ground ahead of Phase III study with potential growth driverInvestor on ALK: 2023 was a tumultuous yearLundbeck initiates Phase IIb study with first-in-class potentialNovo Holdings scores big in Amolyt exit with Astrazeneca buyoutEU paves way for cross-border health data exchangeGenmab will start a share buyback program of up to DKK 3.5b on MondayLundbeck's two hottest internal drug candidates have good potential, says analystWS Audiology refinances debt and raises new capitalMore people are now starting treatment with Eli Lilly's Zepbound than Wegovy in the USNovo Holdings CEO: Activist investor helped spur record Catalent acquisitionUBS downgrades the rating of SonovaBiden takes steps to increase research into women's diseasesNovo CEO: Weight loss medication may change from lifelong treatmentNovo Nordisk Foundation unveils plans for world-class AI supercomputer to fuel scientific breakthroughsNovo Nordisk CEO sees good fortune in bad luck after supplier failure years agoDemant owner increased stake in GN in 2023Novo Holdings ramps up green investmentsFuture pharmaceutical reform ready for final EU Parliament vote Novo Nordisk expands production againTwo drivers for William Demant Invest's GN stake increase, says Nordnet Novo Holdings to open India officeNykode takes steps towards treating autoimmune diseasesNovo Nordisk subsidiary lands record revenue as GLP-1 adventure pays offZealand Pharma board nominees confirmedNovo Nordisk Q1 figures could disappoint, warns analystZealand Pharma open to being acquiredCiti concerned by possible Genmab data delayCHMP recommends new once-weekly insulin from Novo NordiskNovo Nordisk chairman acknowledges budget concerns in the USBavarian Nordic nominates former Novartis executive for board electionNovo Nordisk's Wegovy to be covered by US Medicare for heart disease patientsChina urges Lilly to boost investing amid US cutoff threatGalderma surges in debut, bolstering Europe IPO recoveryOzempic maker Novo’s workers are too stressed, CEO saysFujifilm and argenx extend agreement for efgartigimod productionNovo Nordisk to acquire Germany's Cardior Pharmaceuticals for EUR 1 billion12 drugs recommended by CHMP in MarchLundbeck voices concern over proposed patent reform in the EU: Could put the industry’s trade secrets at riskAnalysts on Novo Nordisk's new acquisition: Consistent with strategyFujifilm Diosynth CEO nominated as life science executive of the year in his home country DenmarkUK risks critical medicine shortage as EU lures drugmakersSpending on advertising weight-loss drugs has doubledNovo Nordisk set to apply for German health insurance coverage for WegovyNovo Nordisk ready to share Wegovy reimbursement risk EU approves long-acting schizophrenia drug from Lundbeck and OtsukaDenmark and Sweden to establish joint EU reference lab for antibiotic resistanceZepbound patients in panic mode as pharmacies can’t get enoughGN and Demant lost ground with US veterans in February - Sonova and Starkey advancedGenmab expands US headquartersBernie Sanders calls on "greedy" Novo to lower the price of OzempicNovo Nordisk is spending billions on global factory expansion — but two facilities are being kept under wrapsEU prosecutors to probe Pfizer over controversial vaccine caseFujifilm Diosynth Biotechnologies CEO is Danish Life Science Executive of the YearBavarian Nordic starts commercial launch of pox vaccineGenmab acquires privately-owned Profoundbio in USD 1.8 billion dealAnalysts: Genmab’s first major acquisition fits the strategyZepbound patients have a solution for obesity drug shortage: Release the vialsAstellas CCO: Pharmaceutical reform will scare investments away from EuropeGenmab's USD 1.8 billion bet on Profoundbio aims for blockbuster returnsGenmab CEO after acquisition: "We have the capacity for more"Novo Nordisk gained 9,000 full-time employees in 2023EU responds to criticism of patent plans: A "proportionate and tailored initiative"Danske Bank raises doubts about Zealand Pharma's obesity candidate as a monotherapySaturday Night Live pokes fun at Novo Nordisk in Ramadan sketchShortage of Eli Lilly's obesity drug in US becomes officialNovo Holdings participates in USD 160m fundraising roundScientists find new genetic triggers for obesity riskNovo Nordisk after landmark year: "We see our culture evolving"Production problems continue to plague ALKFormer ALK CEO becomes chairman at Irish generics makerNovo Nordisk head of investor relations appointed general manager in TaiwanNovo Nordisk publishes positive Wegovy heart failure data Job boom at Novo Nordisk is not unique among life science companiesLilly and Boehringer's Jardiance fails to beat placebo in cardiovascular studyLeo Pharma chairman parts ways with William Demant Invest boardBank expects subdued Q1 for Novo Nordisk — but prescription stats bode wellFirst stage of Novo's Catalent acquisition drags outAmbu receives FDA approval for gastroscopeLundbeck and Otsuka apply for Rexulti for treatment of PTSDFormer Lundbeck executives reunite in Spanish pharmaceutical companyCiti concludes Lundbeck's PTSD treatment has limited potentialDNB: US approval of new Ambu device was expectedFerring reports more or less stagnant top line in 2023Chinese copycats threaten to undermine Novo's Wegovy rolloutLars Fruergaard Jørgensen joins Danish central bank's board of directorsLilly’s new USD 2.5bn plant to boost obesity drug supplyMedia: Psoriasis and eczema firm Union Therapeutics may be heading for an IPOGeneric weight loss drugs boosted by UK approval for BioconFormer ALK boss was headhunted to Irish pharmaceutical companySmall shifts in March sales of hearing aids for US veteransNovo Nordisk extends collaboration with US biotech firmEU Parliament adopts position on new pharmaceutical reformAmbu raises full-year guidance after the second quarterNovo Nordisk's Wegovy nears three years on market: "We haven't fully seen how much demand there really is"EFPIA criticizes EU Parliament position on pharmaceutical reformRoche awarded priority status for early Alzheimer's detection testReality sets in for Zealand Pharma share Ambu CFO on guidance upgrade after strong quarter: "It is important to rebuild trust"Russian authorities approve development of Wegovy copyEU pharmaceutical reform negotiations not happening anytime soonClosure of factory and normalized customer behavior take big bite out of Estron's profitsEMA concludes there is no link between GLP-1 drugs and suicide attemptsSwedens Hansa Biopharma raises almost EUR 30m through share issueNovo Nordisk to assert obesity market dominance with new and improved version of WegovyFDA expert panel backs new endpoint designed to accelerate approvalsLundbeck CEO: Firms are returning to CNSEli Lilly, Novo euphoria risks disappointing investors, Goldman saysNovo Nordisk jumps five places on list of the world's largest pharma firms by salesAscendis CCO joins the board of directors at MagcathOver 200 websites shut down after selling fake weight loss productsGenmab could benefit from potential new FDA endpoint, say analystsJohnson & Johnson's Darzalex sales just beat expectationsWSA appoints new CEOGubra reveals possible new anti-obesity drugChairman on new WSA CEO: Must boost growth and earnings WSA came far closer to breaking even under outgoing CEO's leadershipBoehringer Ingelheim overtakes Bayer as Germany's largest pharmaceutical groupNovo Nordisk joins collaboration aiming to reduce aircraft CO2 emissionsLexaria Biosciences aims to make Novo Nordisk diabetes drug more effectiveLilly’s Zepbound outage deepens as almost all doses shortLilly’s weight-loss drug improved sleep apnea in studiesFocus on strong market and growing reimbursement at US hearing aid showGerman authorities give Novo Nordisk the go-ahead to acquire CardiorLundbeck Foundation takes a stake in WS AudiologyWSA investment years in the making for Lundbeck ownerJPM: FDA panel’s nod to MRD endpoint could increase J&J’s likelihood to license Genmab's Darzalex successorAmbu to launch new duodenoscope in the US in 24/25Ozempic ‘oops’ babies spark debate about weight-loss shot use as fertility drugsDemant CEO: Rising reimbursement has helped the US market - but not like in EuropePresident of Widex US: New top-of-the-range product breaks the trend with special designNovo Nordisk opens AI hub in LondonSettlement between Eli Lilly and insulin patients breaks downOwner families are now open to an IPO of major hearing aid groupGN is preparing for May 1 launch on Veterans Affairs channel: "We are 100% focused"GN’s US President: We have been talking about One GN for yearsIncreased subsidies are boosting US market, says GN country presidentCSL Vifor proposes solution for Pharmacosmos disputeAmbu learns from past mistakes as it prepares to launch new scope Novo Nordisk on next potential weight-loss drug: We are constantly working to improve our supplyLundbeck exec on upcoming acquisitions: ”I am sure we will succeed”Eli Lilly expands manufacturing network through new factory acquisitionRenovaro investors sued in US for insider trading Africa’s biggest drugmaker can help ease obesity medicine supply crunchNew partnership to speed up production of cell therapy for type 1 diabetesTikTok’s crackdown on Ozempic influencers threatens weight-loss drug hype machinePhysician skepticism hinders uptake of new Alzheimer's drug in the USLundbeck building USD 143m research facility to "keep up with the times"Family-owned Orifarm to find new investor in 2024: Plans to kick-start acquisition huntEU starts investigation into "unfair" medical device competition with ChinaJefferies predicts continued recovery in European tablet sales for ALKLeo Pharma to move production and cut 100 jobs at headquartersLundbeck focusing on two drug groups as possible acquisition targetsStudy finds Medicare subsidies could mean access to millions of Wegovy patientsBernie Sanders scrutinizes Wegovy and Ozempic pricesEU launches Critical Medicines AllianceAudiologist shortage may cause problems in US market, says industry organizationEU Parliament adopts public health data spaceUK regulator approves Ascendis Pharma's Yorvipath Coloplast and wound care sector suffer due to new US reimbursement proposals Boston Scientific's endoscopy business achieves organic growth of almost 10%Hearing aid manufacturers aware of potential audiologist shortage: We are continuously working on itScholz gets another pharma boost with new Merck siteBiotech firm behind FDA-approved antibiotic: "It's been a day to remember"New GN campaign highlights link between hearing loss and cognitive declineCHMP recommends eight drugs in AprilAscendis ponders launch strategy for newly approved drug in the UKNovo Nordisk's once-weekly insulin to be reviewed in the U.S. on May 24Amgen wants to bring Tepezza to the market in EuropeColoplast confident that wound care products meet new reimbursement requirements in the USBavarian Nordic initiates rolling US submission for its Chikungunya vaccine candidateGenmab and Pfizer gain full US approval for cervical cancer drug TivdakBavarian Nordic receives EUR 65m EU order for smallpox vaccinesXellia's US factory exempted from frequent FDA inspections after 11 yearsMounjaro and Zepbound boost Eli Lilly's outlookAnalyst: Eli Lilly's upward revision fuels positive numbers from Novo NordiskNovo Nordisk cuts price of diabetes drug in DenmarkAnalysts won't rule out Novo guidance upgrade on eve of Q1 reportHead of R&D wants to transform Lundbeck from within — new FDA center will helpOzempic maker Novo Nordisk has Denmark’s economy hookedEli Lilly expects sales growth to accelerate in second half of the yearFirst report from united GN coming soon, thriving hearing aid sales expectedNovo Holdings to invest USD 200m in quantum technologiesNovo Nordisk upgrades 2024 guidanceGN had good start to the year as hearing aid division reports 14% organic growthNovo Nordisk's obesity business continues growth trend in first quarter Former Widex CEO to leave WS Audiology boardGN CFO: Positive cash flow in Q1 is a significant improvementAnalyst on Novo's Q1 report: Good overall, but Wegovy disappointedNovo CFO on guidance upgrade: Mainly due to tax rebatesGN CEO on Veterans Affairs sales: "We are not where we want to be"Genmab prepares for key approval for cancer hope in the USALK to cut 125 jobsLeo Pharma upgrades full-year guidanceGenmab exceeds revenue expectations in first months of year - guidance maintainedALK tablet sales in Europe continue positive trendNovo Nordisk cuts ties with Copenhagen PrideAmgen soared as CEO touted experimental obesity drug’s progressNorth America to remain largest growth driver through 2024, says Leo PharmaIn a quarter with difficult comparables, analyst sees continued progress for DemantUS authorities request more information about Novo's Catalent acquisitionPrescriptions for semaglutide drugs skyrocket in US as Novo Nordisk plans capacity increaseDemant reports 3% sales increase in first quarterALK to invest over USD 100m in production over next two years Novo Nordisk Foundation, Gates Foundation and Wellcome Trust team up on global healthDemant still believes in growth in China despite current stagnationAnalyst sees opportunity for upward adjustment from ColoplastWorld's largest hearing aid retailer acquired 150 stores in Q1Here are the obesity drug hopefuls vying to unseat Ozempic and ZepboundColoplast upholds growth guidance despite slightly disappointing revenueDemant secretly acquires long-time distribution partnerGN announces new financial goals at capital markets dayGN achieves record market share of 17%GN CEO thinks debt goals can be met before 2028Bad order timing leads to disappointing ostomy sales at ColoplastNovo Nordisk asks for more time to answer Sanders on Ozempic’s priceColoplast launches catheter version for womenLeo Pharma publishes "inspiring" results for psoriasis treatmentBavarian Nordic's sales of bestseller shrink while travel vaccinations take offNovo Nordisk close to releasing phase III hemophilia dataDocumentation requirements delayed Coloplast launch: "They simply hadn't seen a product like it"Bavarian Nordic becomes "victim of own success" as it struggles to meet travel vaccine demandNovo Nordisk to pay up to USD 600m in latest obesity R&D dealGirl regained hearing after gene therapy treatmentNew weight-loss, diabetes drugs reach one in eight americansDarzalex could become even more dominant in the market for treating multiple myelomaBernie Sanders asks Danes to put pressure on Novo Nordisk over price of GLP-1 drugsLundbeck appoints Maria Alfaiate EVP of commercial and corporate strategyFar fewer type 2 diabetics are dying of cardiovascular diseaseAdvisor on senator's attack on Novo Nordisk: "If that doesn't set off alarm bells, nothing will"Ambu confirms preliminary figures: High growth and better margins in second quarterThe rise and fall of Enochian Biosciences: from a cure for HIV to murder-for-hireBiotech chairman denies knowledge of Chief Scientist's murder-for-hire plotNovo Nordisk reaches endpoints in hemophilia medicine trialSonova predicts product launches will accelerate growthNovo Nordisk Foundation: Bernie Sanders is wrongLundbeck's strategic brands heading towards continued double-digit growthNovo Nordisk's hemophilia drug will be tough competition for Roche's, says CitiLundbeck maintains full-year guidance in Q1 reportLundbeck's key products surprise positively - Rexulti slightly restrained in the USNovo Holdings to become majority owner of Austrian medtech firmNovo Nordisk sells USD 5bn in bonds to fund capacity expansionLundbeck CEO attributes significant growth in key product sales to clear prioritizationNovo Nordisk to test if semaglutide can help people drink less alcoholNovo Nordisk invests USD 291m in wastewater treatment plantWSA reports slightly slower growth in second quarter Roche's obesity candidate achieves significant weight loss in phase I trialGenmab CEO warns West's distrust of China could harm pharma industyNovo Nordisk's head of development sells shares for USD 1.2mNovo’s Wegovy will bankrupt health system, Senator Bernie Sanders saysAlexion wants to return Zealand Pharma candidateFormer Novo Nordisk VP criticizes price of obesity drugs: "The only thing Novo Nordisk doesn't want to hear"Eradication of Lundbeck's net debt "proves underlying strength," says CEOWSA sees OTC hearing aids pushing previous category completely off the tableOutgoing WSA CEO: This could have been betterZealand Pharma hopes for 7-9 percent weight loss in important study - may open up dialoguesBernie Sanders bashes Novo again: "They are exploiting our broken healthcare system"Review of EU Pfizer deal postponedDemant completes divestment of cochlear divisionEli Lilly's supply issues spark new momentum for Novo Nordisk on US obesity marketEU Commission does not accept EMA rejection of Duchenne muscular dystrophy drug TranslarnaChina approves Eli Lilly's blockbuster diabetes drugBavarian Nordic's CMO to leave at end of MayGenmab completes USD 1.8bn acquisition of ProfoundbioNovo Nordisk has no plans to repeat record factory purchaseBavarian Nordic CEO: Search for new chief medical officer will probably take at least six monthsWS Audiology making headway in IPO preparationsNovo Nordisk denies timing factory expansion announcement with US electionEU health union established — expansion already planned Biotech firm raises USD 30m for weight-loss candidateNovo Nordisk building in danger of collapse in second fire in a weekNovo Nordisk to free up capacity by changing injection pen in USLundbeck foundation acquisition provides big clue about WS Audiology's market valueAscendis CCO to leave Danish bacon boardLundbeck CEO assembles dream executive team to "transform" businessFire extinguished at Novo headquarters complex, cause remains unclearGenmab to release important data from lung cancer studyOtsuka drops Alzheimer's agitation candidateMany quit weight-loss drugs too early for benefits, insurer saysCEO of new weight-loss firm: "We have a very real chance of creating the best-in-class solution"Genmab to present a series of data at ASCOZealand Pharma shows 4.3 percent weight loss after 12 weeks in Phase I studyGenmab shares drop on early data from lung cancer studyWeight-loss underdog Viking needs a deal to vie with Lilly and Novo NordiskNew Novo Nordisk insulin not recommended for approval by FDA expert panelEli Lilly to invest USD 5.3bn in obesity drug productionOzempic helps reduce risk of kidney complications, study confirmsSydbank: Lack of recommendation for Novo Nordisk's new insulin "not the end of the world"No signs of criminal intent behind fires at Novo Nordisk facilitiesBarclays survey expects market share gains for GN and DemantIndia left waiting another year for WegovyAsahi Kasei bids over USD 1bn for Swedish Calliditas TherapeuticsNovo Nordisk diabetes drug was third-biggest global seller in 2023Yellow Jersey Therapeutics and atopic dermatitis antibody NM26 acquired by Johnson & JohnsonFerring plans to raise CHF 330 million through a bond issueNovo Nordisk blames US health system after Sanders’ Wegovy criticismWeight-loss drug shortages lead to Wegovy tracker from startupDemant wants to be the world's largest hearing aid manufacturerBavarian Nordic receives support for trial of mpox vaccine for children in AfricaALK has submitted an application for expanded approval of tree pollen vaccine ItulazaxDenmark asks doctors to move Ozempic patients to cheaper drugsMarket share gains in April for Sonova and Starkey in the US veterans' marketNovo Nordisk has filed nine lawsuits in the US after finding counterfeit copies of WegovyJPMorgan: Novo Nordisk's Ozempic may gain even wider adoption following study in kidney patientsEU delays implementation of IVDR againCHMP recommends 14 new medications for approvalEMA recommends European approval for Zealands Pharma pen out-licensed to Novo NordiskBavarian seeks approval of freeze-dried smallpox vaccine in the USGenmab calls results in difficult-to-cure lymphoma promisingNovo Nordisk CFO Karsten Munk Knudsen named Danish CFO of the YearALK's Capital Markets Day is approaching: Analyst sees unchanged ambition for double-digit growthZealand Pharma chief executive calls out study speculationGenmab and Biontech to advance lung cancer drug acasunlimab to Phase IIIALK maintains guidance and launches growth strategyMSD and Eli Lilly CEOs criticize Biden reform: "We’re going to miss the next Keytruda"ALK terminates collaboration on new adrenaline productBiotech CEO had known about researcher's criminal past for years before "shock" revelationGenmab CEO on new data: “Unprecedented”Leo Pharma appoints new head of external innovationBritain poised to offer Eli Lilly’s weight-loss drug to patientsALK "can continue to achieve double-digit growth," says CEOAGC completes Copenhagen campus expansionALK changes approach to US market entry: "We want to see some results before we make more investments"Novo Nordisk Foundation to shift focus to stem-cell therapiesEli Lilly releases "promising" data for tirzepatide in fatty liver indicationALK CEO sees growth opportunities in adrenaline pen marketVP of Leo Pharma makes the switch to Fujifilm Diosynth BiotechnologiesEli Lilly's CFO moves to AlphabetEli Lilly partners with Norwegian fibrosis companyEASL Congress webpage publishes survodutide fatty liver data ahead of schedule by accidentColoplast CEO: 2023/24 will be a year of a comeback and launchesUS bank positive about Zealand's leaked fatty liver dataColoplast needs financial tailwinds to reach upper end of forecastFDA staff proposes narrow approval for Eli Lilly Alzheimer's drug"Relatively large" investment to double tablet production at ALKSandoz loses copycat case concerning blockbuster drugBoehringer Ingelheim releases detailed fatty liver dataBanks predict Novo slowdown once patent expires Generic drugmakers in China are waiting in the wings for Wegovy patent expirationFDA calls meeting about Eli Lilly's Alzheimer's treatmentColoplast chief wants to unfold full potential with upcoming strategyPlans for Copenhagen's Innovation District revealed Ambu COO steps down with immediate effect — replacement foundEli Lilly granted partial approval for Alzheimer's medication Search for new Ambu operations boss took months, says CEO GN lowers expectations for this year's sales growthLundbeck R&D head on Øresund life science collaboration: Sweden is the little brother nowGN CEO: Taking time to consider downscaling was right thing to doAnalyst despite GN share plunge: "In the long term, it should strengthen GN"AGC to produce British immunotherapy at Danish facilityGN to focus on most profitable productsNovo Nordisk Foundation to sponsor first step towards new Copenhagen innovation hubNovo Nordisk's US boss could be called to testify before senate committeeNovo on US senate subpoena vote: "We have repeatedly told them that Lars Fruergaard would be happy to testify"Geopolitical uncertainties lead Coloplast to rethink production strategyEli Lilly’s obesity drug crunch shows signs of easing in JapanGenmab hits four-year low after board member sells sharesNew launches boosted Demant and GN's standing among veterans in MayColoplast CEO: Innovation should drive growthNovo Nordisk partners with US biotech company on diabetesUS authorities struggle with illegal online Ozempic salesFujifilm boss offers Denmark tips on how to attract life science manufacturersEli Lilly has stepped up the pace of development in obesityLeo Pharma gets green light from FDA for Adbry autoinjector Novo Nordisk and Biosplice Therapeutics to collaborate on new cardiometabolic disease drugsDemant reaches record market share at VANovo Nordisk CEO volunteers to testify before Bernie Sanders' Senate committeeNovo Nordisk names new Head of Investor RelationsAGC goes hiring after Danish plant expandsNovo Nordisk launches new weekly insulin product in first countryBavarian Nordic submits vaccine for US approvalFire at Novo Nordisk was started by construction workers without permits, investigation findsNovo Holdings firm makes USD 135m divestmentWSA to open third regional innovation centerMedia reports that Novo Nordisk is close to announcing US factory expansion GN holds on to true wireless research as insurance for the futureYet another fire at Novo Nordisk — loud bang reportedUnion contacts Novo Nordisk after fires and work permit issuesLundbeck to test drug candidate as treatment for Cushing's syndromeJesper Høiland becomes chairman of listed Swedish medtech companyExpansion of Novo factory could create 1000 jobs, reports mediaNo cause determined yet for third Novo fire in just over a monthOzempic frenzy lures rich Indians to brave the gray marketAmplifon targets EUR 3 bn in salesEli Lilly broadens crackdown on fake and compounded ZepboundZealand Pharma reports positive top-line results with weight loss drug petrelintideSix EU countries push to end mandatory stockpiling of medicinesFake Ozempic is circulating in Europe and Americas, WHO warnsAnalysts: Zealand Pharma's obesity data shows 'clear winner'Zealand Pharma CEO on weight loss data: We couldn't have hoped for moreNovo Nordisk drops plans for Irish factory Novo Nordisk tightens security after fire: "Until now it was built on trust" ALK withdraws Chinese application for allergy tablet and raises guidanceNovo Nordisk's hemophilia candidate shows signs of greater efficacy than other agentsZealand Pharma is very open to partnership after promising obesity dataUnderdog obesity drug performs well in Phase II studyPrivacy PolicyServiceJobchangeOtherJobscbpAdvertisingRegulationAboutNewsSubscriptionHearing healthRSSMedWatch.comPharma & biotechTerms and conditionsSubscription TermsContactMedtechArticlearchive
